background
surgic
site
infect
ssi
one
frequent
nosocomi
infect
sinc
nation
coordin
region
network
implement
gather
ssi
incid
data
accord
standardis
method
aim
current
studi
describ
largest
databas
ever
collect
franc
ssi
analys
tempor
trend
method
surgeri
patient
enrol
voluntari
particip
ward
yearli
incid
survey
ward
consecut
surgeri
procedur
includ
patient
follow
day
surgeri
ssi
defin
base
standard
cdc
criteria
patient
risk
factor
collect
day
surgeri
includ
age
asa
score
altemei
wound
class
type
durat
procedur
emergencyelect
videoscopi
surgeri
perform
result
year
studi
includ
oper
oper
patientday
followup
median
postop
followup
day
overal
ssi
incid
rate
organ
space
deep
incision
ssi
account
although
proport
vari
accord
type
surgeri
ssi
incid
rate
increas
patient
patient
ssi
incid
vari
herniorraphi
colon
surgeri
patient
emerg
surgeri
increas
ssi
risk
csection
wherea
videoscopi
surgeri
lower
risk
cholecystectomi
ssi
incid
decreas
oper
patient
rel
differ
accord
procedur
trend
remain
signific
herniorraphi
conclus
databas
provid
thorough
standardis
estim
ssi
incid
accord
variou
surgeri
procedur
impact
nation
polici
ssi
incid
remain
evalu
although
encourag
result
evidenc
specif
surgeri
object
healthcar
associ
infect
hai
incid
rate
deliveri
rang
accord
mode
deliveri
matern
activ
women
risk
factor
data
hai
surveil
matern
unit
lack
mater
sudest
studi
group
hai
continu
surveil
network
matern
unit
locat
south
eastern
franc
report
chang
riskadjust
hai
rate
long
surveil
period
matern
unit
network
method
vagin
deliveri
cesarean
deliveri
includ
surveil
januari
decemb
studi
chang
four
hai
endometr
urinari
tract
infect
uti
vagin
deliveri
surgic
site
infect
ssi
uti
cesarean
deliveri
use
logist
regress
model
estim
riskadjust
hai
rate
year
deliveri
consid
risk
factor
trend
riskadjust
hai
rate
studi
period
studi
linear
regress
yearofdeliveri
odd
ratio
target
hai
result
rate
endometr
uti
vagin
deliveri
respect
studi
period
decreas
endometr
odd
ratio
statist
signific
found
statist
signific
trend
vagin
deliveri
uti
rate
ssi
uti
cesarean
deliveri
respect
studi
period
decreas
ssi
uti
odd
ratio
statist
signific
conclus
find
highlight
posit
effect
particip
surveil
network
infect
control
improv
care
infect
alert
investig
surveil
network
raisin
bordeux
fr
background
nation
surveil
occup
blood
bodi
fluid
exposur
bbfe
franc
conduct
sinc
nosocomi
infect
earli
warn
investig
surveil
network
raisin
collabor
gere
group
detud
sur
le
risqu
dexposit
de
soignant
aux
agent
infectieux
method
particip
healthcar
facil
hcf
voluntari
anonym
bbfe
occur
document
use
standardis
questionnair
document
natur
circumst
mechan
type
devic
infecti
statu
sourc
followup
bbfe
incid
bbfe
report
per
hospitalis
bed
type
personnel
per
full
time
equival
fte
type
materi
per
devic
eccmid
icc
oral
present
result
bbfe
document
particip
hcf
account
hcf
hospitalis
bed
franc
bbfe
overal
incid
per
bed
consid
french
hospit
account
bed
ci
bbfe
could
occur
franc
hcv
hiv
statu
sourc
known
document
bbfe
postexposur
prophylaxi
pep
prescrib
expos
personnel
vs
decreas
may
reflect
impact
april
french
recommend
reduc
pep
indic
first
time
sutur
frequent
caus
bbfe
associ
needl
subcutan
inject
account
bbfe
one
third
occur
among
resid
icu
emerg
room
beyond
surgeri
obstetr
prevent
educ
use
safeti
devic
blunt
sutur
needl
may
thu
prioriti
data
cohort
hcf
particip
also
compar
demonstr
signific
progress
complianc
glove
use
increas
bbfe
incid
among
nurs
assist
fell
per
fte
last
bbfe
incid
fell
per
cathet
per
implant
venou
access
system
conclus
aesraisin
one
biggest
bbfe
surveil
network
result
demonstr
increas
observ
standard
precaut
signific
decreas
incid
type
bbfe
also
point
futur
prioriti
improv
randomis
trial
chlorhexidin
alcohol
compar
povidoneiodin
venipunctur
site
disinfect
effect
blood
cultur
contamin
rate
g
suwanpimolkul
pongkumpai
w
kulwichit
c
suankratay
bangkok
th
background
contamin
blood
cultur
recogn
bothersom
issu
decad
continu
caus
frustrat
clinician
contamin
rate
vari
wide
institut
less
skin
antisept
prevent
contamin
blood
cultur
knowledg
randomis
trial
chlorhexidin
alcohol
venipunctur
site
disinfect
conduct
object
studi
aim
evalu
efficaci
venipunctur
site
disinfect
chlorhexidin
alcohol
compar
povidoneiodin
prevent
blood
cultur
contamin
patient
method
prospect
randomis
investigatorblind
trial
conduct
patient
hospitalis
intern
medicin
ward
attend
emerg
depart
king
chulalongkorn
memori
hospit
bangkok
thailand
august
octob
antecubit
venipunctur
site
randomli
disinfect
either
chlorhexidin
alcohol
povidoneiodin
blood
cultur
drawn
medic
student
resid
blood
cultur
contamin
rate
associ
antisept
determin
result
blood
cultur
collect
studi
contamin
skin
flora
contamin
rate
blood
cultur
chlorhexidin
alcohol
compar
rate
p
povidoneiodin
inpati
ward
contamin
rate
chlorhexidin
alcohol
povidoneiodin
respect
p
emerg
depart
contamin
rate
chlorhexidin
alcohol
povidoneiodin
respect
p
common
contamin
organ
coagulaseneg
staphylococci
conclus
chlorhexidin
alcohol
superior
povidoneiodin
venipunctur
site
disinfect
blood
cultur
sampl
object
inanim
hospit
environ
becom
contamin
nosocomi
pathogen
hydrogen
peroxid
vapour
hpv
decontamin
proven
effect
erad
persist
environment
contamin
rate
recontamin
follow
hpv
decontamin
larg
unknown
investig
extent
methicillinresist
staphylococcu
aureu
mrsa
vancomycinresist
enterococci
vre
gentamicinresist
gramneg
rod
gnr
contamin
ward
sideroom
occupi
patient
histori
mrsa
vre
gnr
infect
colonis
method
fifteen
standardis
site
room
sampl
use
select
broth
enrich
protocol
cultur
mrsa
vre
gnr
sampl
carri
clean
clean
hpv
decontamin
interv
subsequ
day
two
separ
occas
result
environment
contamin
identifi
clean
site
mrsa
gnr
vre
respect
site
clean
figur
one
site
contamin
mrsa
hpv
decontamin
figur
recontamin
vre
identifi
recontamin
mrsa
gnr
identifi
two
day
follow
hpv
decontamin
figur
substanti
recontamin
toward
preclean
level
identifi
day
five
six
hpv
decontamin
mrsa
recontamin
gnr
approxim
postclean
level
note
day
figur
infect
control
infect
control
measur
detect
risk
group
infect
sourc
know
transmiss
way
infect
import
prevent
ni
studi
aim
evalu
knowledg
level
behaviour
model
hospit
clean
staff
ni
set
bed
tertiari
care
educ
hospit
method
questionnair
question
implement
hospit
clean
staff
volunt
enter
studi
questionnair
compos
two
part
first
part
contain
paramet
determin
sociodemograph
properti
second
contain
question
evalu
knowledg
prevent
ni
question
prepar
use
refer
subject
help
execut
clean
staff
firm
statist
unit
data
evalu
spss
programm
use
chi
squar
student
test
questionnair
complet
one
one
interview
method
result
total
total
male
femal
age
hospit
clean
staff
volunt
enter
studi
evalu
accord
educ
statu
graduat
primari
school
work
hospit
three
year
mean
knowledg
level
maximum
knowledg
level
associ
gender
educ
statu
durat
work
clean
staff
p
mean
knowledg
level
staff
work
clinic
found
higher
staff
work
administr
section
p
receiv
formal
educ
prevent
ni
start
work
mean
knowledg
level
differ
other
p
knew
true
order
x
clean
patient
room
thought
could
prevent
ni
hand
wash
clean
process
state
obey
handwash
rule
state
use
glove
state
dri
hand
paper
towel
conclus
measur
level
knowledg
hospit
clean
staff
may
benefici
determin
exist
problem
period
wellestablish
educ
programm
start
improv
current
situat
object
methicillinresist
staphylococcu
aureu
mrsa
caus
increas
healthcar
problem
worldwid
rapid
sensit
screen
method
direct
detect
mrsa
essenti
limit
spread
hospit
purpos
studi
evalu
new
molecular
dipstick
assay
genoquick
mrsa
hain
lifesci
nehren
germani
direct
specif
detect
mrsa
clinic
specimen
method
analyt
specif
assay
evalu
use
subset
mrsa
isol
includ
sccmec
type
methicillinsuscept
aureu
mssa
coagulaseneg
staphylocococi
con
differ
cultur
collect
lower
detect
limit
assay
determin
serial
dilut
mrsa
strain
repres
sccmec
type
iv
test
evalu
direct
detect
mrsa
clinic
swab
specimen
mrsa
carriag
analys
standard
cultur
method
chromagar
mrsa
becton
dickinson
heidelberg
germani
columbia
blood
agar
trypticas
soy
broth
two
pcr
assay
genoquick
mrsa
genotyp
mrsa
direct
hain
lifesci
pcr
assay
perform
directli
swab
overnight
incub
trypticas
soy
broth
mrsa
isol
confirm
use
meca
gene
aureu
specif
pcr
suscept
test
perform
autom
system
vitek
germani
result
lower
detect
limit
cfu
determin
serial
dilut
mrsa
strain
analyt
specif
mrsa
strain
repres
sccmec
type
v
test
posit
assay
mssa
con
test
neg
respect
patient
specimen
test
clinic
evalu
identifi
mrsaposit
cultur
pcr
assay
one
specimen
posit
pcr
among
cultureneg
specimen
neg
pcr
assay
genoquick
assay
show
diagnost
sensit
diagnost
specif
posit
predict
valu
neg
predict
valu
timetoresult
direct
detect
mrsa
clinial
specimen
reduc
molecular
genoquick
mrsa
dipstick
assay
amplif
min
detect
conclus
genoquick
mrsa
dip
stick
assay
prove
rapid
sensit
specif
assay
direct
detect
mrsa
clinic
swab
specimen
throat
swab
necessari
reliabl
detect
carrier
staphylococcu
aureu
background
anterior
nare
consid
primari
colonis
site
staphylococcu
aureu
aureu
approxim
healthi
peopl
carri
bacteria
anterior
nare
howev
recent
studi
indic
throat
may
addit
import
site
colonis
nilsson
p
j
clin
microbiol
screen
programm
aureu
includ
methicillinresist
aureu
mrsa
requir
swab
nose
swab
throat
consid
standard
object
determin
frequenc
posit
aureu
cultur
posit
sampl
throat
neg
nare
method
specimen
obtain
steril
polyest
fibertip
swab
moisten
steril
salin
anterior
nare
rotat
anterior
nostril
posterior
wall
pharynx
soft
palat
swab
transport
laboratori
transport
tube
transystem
copan
brescia
itali
put
select
enrich
broth
chapman
broth
contain
brain
heart
infus
broth
nacl
biomed
madrid
spain
result
total
individu
screen
aureu
complet
data
unavail
individu
exclud
overal
aureu
isol
individu
site
screen
result
overal
nare
throat
individu
posit
po
po
po
neg
neg
po
neg
neg
conclus
limit
aureu
screen
nare
fail
identifi
carrier
addit
cost
avoid
pool
specimen
maintain
higher
sensit
therefor
optim
screen
aureu
includ
swab
nare
throat
may
even
import
screen
focus
mrsa
carriag
object
mrsa
rate
hospit
northeast
scotland
significantli
declin
due
seri
infect
control
intervent
eccmid
icc
oral
present
includ
termin
disinfect
environ
isol
room
cohort
area
applic
sodium
hypochlorit
place
deterg
eccmid
abstract
evalu
effect
replac
sodium
hypochlorit
standard
deterg
method
januari
may
monthli
percentag
nondupl
aureu
clinic
case
caus
mrsa
collat
februari
hypochlorit
clean
solut
replac
standard
deterg
infect
control
measur
remain
unchang
dynam
regress
analysi
linear
transfer
function
interrupt
timeseri
analys
use
estim
effect
intervent
result
previous
mrsa
rate
wee
success
reduc
due
environment
screen
p
use
hypochlorit
environment
disinfect
p
use
alcohol
base
hand
disinfect
p
patient
admiss
screen
p
stop
hypochlorit
disinfect
associ
sudden
increas
clinic
case
mrsa
month
period
p
level
approach
seen
prior
start
infect
control
programm
see
figur
conclus
stop
hypochlorit
environment
disinfect
strongli
associ
increas
clinic
mrsa
case
work
add
significantli
meagr
publish
evid
environment
contamin
import
spread
mrsa
object
determin
antibioticresist
enterococci
portugues
piggeri
sampl
analys
antibiot
resist
gene
among
strain
european
growth
promot
ban
method
sampl
wast
treatment
dri
faec
pig
farm
south
portug
studi
sampl
plate
onto
select
slanetzbartley
agar
without
antibiot
bacteri
identif
perform
standard
biochem
profil
amplif
speci
specif
gene
antibiot
suscept
antibiot
determin
disk
diffus
method
clsi
detect
gene
code
resist
vana
b
erma
b
c
tetm
l
k
aac
ieaph
ia
aph
ib
ic
id
aph
iiia
vat
e
search
pcr
result
identifi
enterococci
e
faecali
e
faecium
e
gallinarum
e
casseliflavu
enterococcu
spp
isol
show
decreas
suscept
tetracyclin
minocyclin
erythromycin
quinupristindalfopristin
respect
lesser
extent
highlevel
resist
hlr
streptomycin
nitrofurantoin
ciprofloxacin
hlr
gentamicin
chloramphenicol
ampicillin
suscept
glycopeptid
nonsuscept
isol
tetracyclin
aminoglycosid
macrolid
contain
tetm
tetl
tetmtetl
tet
aac
ieaph
ia
aac
ieaph
iaaph
iiia
ermb
link
e
gallinarum
e
casseliflavu
expect
conclus
although
growth
promot
progress
remov
eu
cours
last
year
antibiot
multiresist
enterococci
isol
portugues
piggeri
whether
persist
antibiot
resist
strain
due
select
antibiot
agent
deserv
studi
experi
result
surveil
programm
resist
feed
food
anim
norway
normvet
h
tharaldsen
sund
oslo
object
monitor
programm
antimicrobi
resist
veterinari
food
product
sector
normvet
establish
goal
programm
monitor
antimicrobi
resist
situat
feed
food
anim
time
relat
human
situat
resist
situat
countri
data
normvet
could
form
basi
risk
assess
tool
target
intervent
evalu
effect
intervent
studi
perform
summaris
experi
result
obtain
first
six
year
programm
method
zoonot
agent
salmonella
feed
anim
food
campylobact
jejuni
broiler
broiler
meat
monitor
annual
e
coli
enterococcu
spp
indic
bacteria
sampl
variou
anim
speci
meat
product
biannual
specif
clinic
isol
routin
diagnost
includ
biannual
isol
mainli
test
use
microdilut
techniqu
vetmictm
minimum
inhibitori
concentr
record
analys
whonet
categoris
isol
resist
suscept
epidemiolog
cutoff
valu
appli
occurr
resist
monitor
speci
product
intern
perspect
low
result
first
six
year
programm
show
situat
stabl
conclus
evalu
first
six
year
programm
recogn
rel
low
number
isol
speci
sourc
includ
complic
conclus
possibl
draw
data
especi
evalu
trend
time
even
though
run
cost
programm
limit
minimum
still
use
purpos
monitor
antimicrobi
resist
within
countri
norway
resist
problem
anim
food
sector
still
low
level
also
consist
valuabl
sourc
research
antimicrobi
resist
mechan
develop
howev
use
sourc
perform
risk
assess
limit
still
lack
even
specif
data
instanc
data
usag
anim
farm
level
comparison
antibiot
suscept
staphylococcu
aureu
intermediu
isol
dog
owner
dog
object
antibiot
resist
veterinari
isol
report
higher
human
isol
due
frequent
empir
use
concern
transfer
resist
staphylococc
speci
intermediu
common
colonis
speci
dog
aureu
includ
mrsa
may
also
present
case
report
suggest
crossinfect
companion
anim
man
increas
concern
mrsa
commun
led
recommend
surveil
antibiot
resist
isol
companion
anim
studi
compar
antibiot
resist
isol
aureu
intermediu
dog
owner
method
crosssect
studi
owner
dog
perform
use
conveni
sampl
pair
recruit
six
veterinari
practic
nasal
swab
collect
owner
resist
surveil
dog
held
transport
medium
cultur
within
h
collect
subject
complet
questionnair
provid
demograph
inform
owner
dog
state
dog
receiv
antibiot
within
last
month
swab
inocul
onto
blood
agar
mannitol
salt
agar
place
salt
meat
broth
enrich
aureu
intermediu
identifi
mean
coagulas
vp
polymyxin
suscept
trehalos
ferment
sever
coloni
isol
test
suscept
methicillin
antibiot
suscept
determin
disc
diffus
interpret
use
clsi
guidelin
result
aureu
owner
dog
colonis
owner
dog
concurr
colonis
dog
human
colonis
mrsa
resist
oxacillin
clindamycin
gentamicin
tetracyclin
fusid
acid
significantli
higher
dog
isol
intermediu
dog
owner
carri
intermediu
four
colonis
owner
colonis
dog
methicillin
resist
detect
resist
chloramphenicol
clindamycin
tetracyclin
cotrimoxazol
higher
dog
isol
resist
fluoroquinolon
gentamicin
display
dog
isol
conclus
methicillin
resist
found
aureu
resist
antibiot
higher
intermediu
dog
isol
resist
human
speci
veterinari
use
antibiot
may
increas
resist
risk
transmiss
resist
strain
object
antimicrobi
suscept
humanus
antibiot
investig
among
commens
bacteria
e
coli
ec
enterococcu
spp
ent
healthi
food
anim
slaughter
across
eu
method
colon
caecal
content
randomli
collect
abattoir
per
countri
n
per
host
herdflock
sampl
ec
ent
isol
use
standard
method
antibiot
suscept
test
done
agar
dilut
clsi
ec
ent
antibiot
central
laboratori
resist
clsi
assess
per
drugorganismcountri
result
total
ec
recov
cattl
n
pig
n
chicken
n
mean
resist
ec
ampicillin
cefepim
cefotaxim
ciprofloxacin
chloramphenicol
colistin
gentamicin
g
tetracyclin
trimethoprimsulfamethoxazol
respect
ec
itali
spain
consist
show
highest
resist
denmark
show
lowest
total
ent
isol
recov
compris
e
faecium
e
faecali
speci
includ
e
duran
e
hira
e
casseliflavu
ent
one
bovin
isol
suscept
linezolid
e
faecium
resist
g
vancomycin
v
resist
amount
wherea
resist
quinupristindalfopristin
qd
combin
vari
cattl
pig
chicken
though
low
preval
e
faecali
limit
conclus
particularli
chicken
n
g
v
resist
low
cattl
pig
resist
qd
high
respect
ent
speci
resist
among
host
g
v
low
resist
absent
except
chicken
qd
resist
among
highest
livestock
host
poultri
strike
differ
among
countri
absent
ent
conclus
paneu
survey
uniform
methodolog
show
antimicrobi
resist
among
enter
commens
bacteria
slaughter
variabl
ec
preval
antimicrobi
resist
vari
older
antimicrobi
countri
resist
newer
medic
import
antimicrobi
absent
low
respect
ent
antimicrobi
resist
rate
vari
quinupristindalfopristin
resist
absent
low
antimicrobi
includ
linezolid
vancomycin
demographi
antibacteri
suscept
communityacquir
respiratori
tract
infect
pathogen
year
vs
year
protekt
surveil
programm
dj
farrel
c
couturi
felmingham
london
uk
pari
fr
object
pattern
antibacteri
resist
among
communityacquir
respiratori
tract
infect
carti
pathogen
vari
among
countri
protekt
global
surveil
studi
monitor
antibacteri
resist
among
carti
pathogen
report
result
sixth
year
protekt
studi
chang
compar
method
clinic
isol
streptococcu
pneumonia
spn
haemophilu
influenza
hi
respiratori
sampl
submit
centr
countri
mic
suscept
determin
accord
clsi
guidelin
genotyp
perform
defin
macrolid
resist
mechan
frequenc
compar
common
site
use
c
fisher
exact
test
appropri
result
total
spn
hi
collect
spnhi
distribut
site
sputum
bal
blood
nasopharynx
ear
sinu
distribut
specimen
age
group
spn
penicillin
erythromycin
resist
pr
er
preval
respect
erm
b
mef
erm
b
mef
ribosom
mutat
spn
pr
er
far
east
south
africa
franc
hungari
poland
us
australia
signific
increas
pr
seen
poland
china
fall
pr
seen
itali
spain
japan
erythromycin
resist
stabl
countri
except
germani
venezuela
decreas
spn
multipl
drug
resist
antibiot
class
increas
poland
decreas
russia
preval
isol
resist
least
antibiot
class
increas
china
betalactamas
bl
product
hi
overal
hi
bl
neg
ampicillin
resist
blnar
bl
product
frequenc
stabl
countri
except
south
africa
increas
telithromycin
show
sustain
activ
spn
suscept
mgl
hi
suscept
mgl
conclus
resist
sever
firstlin
antibacteri
continu
problem
worldwid
last
year
protekt
indic
chang
pattern
resist
sever
countri
telithromycin
exhibit
signific
vitro
activ
princip
carti
pathogen
includ
strain
resist
agent
communityacquir
respiratori
tract
infect
europ
caus
pneumonia
h
influenza
moraxella
catarrhali
report
year
monitor
sentri
program
r
jone
stilwel
fritsch
h
sader
north
liberti
us
object
determin
antimicrobi
suscept
pattern
pneumonia
spn
h
influenza
hi
catarrhali
mcat
test
refer
clsi
method
use
sampl
collect
european
eur
nation
trend
occurr
well
defin
resist
r
mechan
assess
method
collect
communityacquir
respiratori
tract
infect
carti
pathogen
spn
hi
mcat
year
annual
forward
central
refer
laboratori
test
process
confirm
organ
ident
antimicrobi
test
clsi
method
result
interpret
qualiti
control
rigidli
appli
assur
accuraci
analysi
trend
use
mean
rate
nation
initi
last
year
sampl
oral
present
mobil
resist
element
gramneg
plasmid
clinicallysignific
gramneg
bacteria
bacteria
carri
extrachromosom
selfrepl
genet
element
call
plasmid
natur
plasmid
system
guarante
autonom
replic
also
mechan
control
copynumb
ensur
stabl
inherit
cell
divis
plasmid
evolv
integr
part
bacteri
genom
provid
addit
function
host
best
exampl
function
associ
plasmid
given
antimicrobi
resist
resist
gene
locat
plasmid
offer
immedi
advantag
host
antimicrobi
pressur
easili
exchang
among
bacteria
differ
speci
genera
natur
process
conjug
rapidli
spread
bacteria
divers
origin
sourc
plasmid
play
major
role
diffus
antimicrobi
resist
gramneg
bacteria
promot
spread
resist
gene
code
blactamas
ctxm
shv
tem
dha
cmi
veb
aminoglycosid
modifi
enzym
protein
mediat
quinolon
resist
plasmidmedi
antimicrobi
resist
aris
complex
multifactori
process
support
panopli
mobil
genet
element
contain
transfer
resist
determin
bacteri
plasmid
sequenc
comparison
provid
histor
event
genet
determin
assembl
transposit
homolog
recombin
illegitim
recombin
event
plasmid
also
play
import
role
bacteri
pathogenesi
carrier
virul
genet
trait
sever
resist
plasmid
describ
enterobacteriacea
carri
virul
factor
bacteriocin
siderophor
cytotoxin
adhes
factor
virul
plasmid
describ
carri
resist
gene
plasmid
consequ
fashion
field
scientif
research
among
import
issu
clinic
microbiolog
increas
preval
bacteri
pathogen
express
resist
multipl
antimicrobi
agent
special
concern
observ
high
frequenc
multiresist
suggest
mechan
bacteri
speci
concentr
effici
exchang
varieti
resist
determin
later
gene
transfer
propos
fundament
process
underli
bacteri
divers
mainli
mediat
plasmid
phage
integron
capabl
concentr
resist
gene
uncap
selftransposit
mobil
resist
gene
mediat
insert
sequenc
transposon
along
discoveri
novel
resist
gene
number
differ
transpos
element
isol
characteris
nucleotid
sequenc
level
explod
differ
iss
identifi
date
bacteri
insert
sequenc
small
dna
segment
kb
simpl
genet
organis
element
exhibit
short
termin
invertedrepeat
sequenc
ir
encod
transposas
enzym
requir
transposit
mobil
element
play
import
role
assembl
set
accessori
function
bacteria
gene
form
part
degrad
catabol
pathway
dissemin
resist
gene
insert
within
code
sequenc
may
inactiv
gene
insert
upstream
gene
may
modifi
express
iss
may
also
help
integr
plasmid
chromosom
bacteria
iss
capabl
mobilis
nearbi
dna
mechan
similar
oneendedtransposit
other
may
form
composit
transposon
capabl
carri
sequenc
locat
two
iss
true
transposon
larg
group
type
ii
transposon
famili
complic
structur
includ
multipl
antibiot
resist
gene
carri
integron
associ
integron
transfer
element
may
promot
rapid
dissemin
among
clinic
strain
creat
opportun
inclus
addit
resist
determin
recent
novel
genet
structur
repeat
element
describ
capabl
mobilis
resist
gene
transpositionrecombin
process
still
need
fulli
understood
studi
novel
resist
mechan
underli
genet
background
reveal
novel
mobil
dna
element
respons
mobilis
element
interest
clinic
microbiolog
sinc
associ
emerg
novel
antibiot
resist
gene
fundament
research
sinc
novel
genet
mechan
gene
mobilis
dissemin
identifi
synthet
antibacteri
drug
antifol
sulfonamid
quinolon
wide
use
human
veterinari
practic
last
year
clinic
efficaci
drug
undermin
integr
spread
resist
born
transmiss
plasmid
genet
island
pattishal
et
al
divid
plasmidborn
trimethoprim
resist
gene
two
distinct
structur
class
later
refer
dfra
dfrb
number
identifi
gene
type
grown
present
match
context
sequenc
dfr
gene
signatur
two
gene
captur
mechan
uptak
gene
cassett
integron
sitespecif
recombin
oneend
transposit
mediat
element
refer
common
region
iscr
data
assembl
show
trimethoprim
resist
gramneg
bacteria
spread
nearli
full
coverag
via
either
recombin
path
nineteen
type
dfr
gene
three
famili
examplifi
gene
type
born
integronbas
cassett
seven
dfr
gene
type
grape
et
al
unpublish
insert
via
second
recombin
path
famili
insert
element
use
oneend
transposit
mechan
produc
singlestrand
dna
roll
circl
replic
integron
cassett
use
recombin
site
fact
recogn
cognat
tyrosin
recombinas
form
harpin
suggest
might
enhanc
excis
integr
cassett
situat
within
replic
rang
element
two
gene
captur
system
inde
engag
function
crosstalk
could
explain
frequent
colocalis
spread
resist
synthet
drug
differ
instanc
sulfonamid
resist
gramneg
bacteria
ubiquit
much
less
divers
three
gene
type
metagenom
pool
recombin
spread
sul
gene
cryptic
may
divers
howev
one
gene
strongli
link
integron
common
region
type
sulfonamid
introduc
prior
modern
antibacteri
drug
suggest
key
select
factor
make
dual
recombin
platform
integron
element
fix
bacteri
popul
quinolon
resist
get
contribut
transmiss
qnr
allel
three
famili
report
connect
region
robicscek
et
al
eccmid
icc
oral
present
bacteria
noteworthi
remark
genet
plastic
respond
adapt
environment
chang
often
involv
exchang
dna
molecul
cell
bacteri
cell
insert
sequenc
common
region
iscr
first
discov
report
earli
dna
sequenc
bp
found
two
complex
class
integron
sequenc
initi
describ
common
region
cr
distinguish
conserv
sequenc
class
integron
iscr
also
interest
intim
associ
differ
resist
gene
carri
integron
iscr
element
found
mani
gramneg
bacteria
associ
array
differ
antibiot
resist
function
includ
qnr
esbl
ampc
blactamas
metalloblactamas
aminoglycosid
chloramphenicol
resist
dhfr
sul
gene
bacteria
contain
sever
copi
element
probabl
occur
via
replic
follow
homolog
recombin
locat
either
chromosom
orand
plasmid
least
known
type
iscr
element
align
share
key
amino
acid
motif
motif
shown
involv
dna
recognit
mobil
iscr
element
unusu
like
mobilis
larg
section
adjac
dna
via
roll
circl
replic
normal
termin
replic
occur
defin
site
misread
site
lead
replic
larg
section
dna
lefthand
end
element
includ
antibiot
resist
gene
mani
element
found
next
class
integron
believ
express
activ
possibl
driven
hybrid
promot
iscr
element
shown
express
commonli
found
enterobacteriacea
gramneg
nonfermentor
occasion
gramposit
bacteria
found
clinic
isol
everi
contin
impact
spread
antibiot
resist
gene
begin
understood
diagnosi
treatment
septic
shock
symposium
arrang
intern
sepsi
forum
innat
immun
respons
p
aeruginosa
human
monocyt
mediat
mainli
mannos
receptor
p
xaplanteri
v
le
cabec
g
dimitracopoulo
f
paliogianni
patra
gr
toulous
fr
p
aeruginosa
human
pathogen
caus
life
threaten
infect
immunocompromis
host
previous
shown
extracellular
slime
glycoliprotein
glp
produc
mucoid
non
mucoid
strain
potent
activ
nfkb
transcript
activ
tnfa
induct
fresh
human
monocyt
object
examin
innat
immun
receptor
involv
signal
proinflammatori
cytokin
product
induc
p
aeruginosa
method
stimul
h
fresh
human
monocyt
either
p
aeruginosa
slime
glp
mgml
viabl
bacteria
moi
presenc
absenc
specif
block
antibodi
mannos
receptor
mgml
proinflammatori
cytokin
product
tnfa
measur
cultur
supernat
elisa
phagocytosi
inhibit
addit
cytochalasin
mgml
min
stimul
receptor
mediat
activ
nfkb
examin
cotransfect
experi
use
human
embryon
kidney
hek
cell
plasmid
encod
mannos
receptor
complex
along
nfkb
report
drive
express
luciferas
gene
nfkb
activ
detect
measur
luciferas
activ
result
block
phagocytosi
mannos
receptor
function
result
inhibit
proinflammatori
cytokin
product
block
result
inhibit
wherea
block
less
promin
effect
challeng
cell
express
mannos
receptor
slime
glp
viabl
bacteria
result
nfkb
activ
fold
fold
correspondingli
co
express
cell
increas
nfkb
activ
fold
way
stimul
wherea
coexpess
result
detect
increas
fold
conclus
result
suggest
mannos
receptor
act
phagocytosi
receptor
p
aeruginosa
also
signal
receptor
cooper
maximum
nfkb
activ
proinflammatoti
cytokin
product
find
provid
new
insight
futur
develop
new
immunotherapi
challeng
pharmacokinet
pharmacodynam
pkpd
critic
ill
patient
antimicrobi
treatment
infect
critic
ill
patient
remain
signific
challeng
persist
high
mortal
morbid
earli
appropri
antibacteri
therapi
remain
import
intervent
patient
optimis
antibacteri
therapi
clinician
possess
knowledg
pharmacokinet
pharmacodynam
properti
commonli
use
antimicrobi
also
paramet
may
affect
pathophysiolog
chang
occur
sepsi
septic
shock
pathophysiolog
chang
contrast
sepsi
nonantibiot
treatment
increas
renal
preload
may
result
higher
antibacteri
clearanc
altern
sepsi
induc
multipl
organ
dysfunct
includ
renal
andor
hepat
dysfunct
caus
decreas
antibacteri
clearanc
aminoglycosid
blactam
carbapenem
distribut
plasma
interstiti
space
therefor
concentr
could
dramat
affect
sepsi
drug
higher
vd
sepsi
lead
reduc
cmax
patient
serum
creatinin
within
normal
rang
higher
normal
drug
clearanc
therebi
produc
low
serum
concentr
drug
need
minimum
serum
concentr
maintain
eg
blactam
high
drug
clearanc
lead
underdosag
renal
excret
drug
blactam
patient
administ
frequent
suggest
nonsepsi
patient
administr
continu
infus
consid
relat
aminoglycosid
mean
larg
dose
requir
administ
high
clcr
antibacteri
may
also
need
dose
even
frequent
everi
hour
regard
renal
clearanc
fluoroquinolon
presenc
high
clcr
assum
fluoroquinolon
clearanc
also
high
true
antibacteri
would
also
need
higher
daili
dose
propos
standard
literatur
conclus
treatment
infect
critic
ill
patient
remain
signific
challeng
given
persist
high
mortal
rate
data
suggest
effect
antibacteri
therapi
remain
import
intervent
avail
clinician
treat
sepsi
clinician
must
awar
impact
variou
pathophysiolog
subsequ
pharmacokinet
chang
occur
sepsi
bacteri
popul
kinet
hand
two
consecut
surgic
hand
disinfect
procedur
g
kampf
c
ostermey
kohlmann
hamburg
greifswald
de
europ
efficaci
surgic
hand
antisept
investig
singl
applic
clinic
practic
howev
consecut
applic
common
effect
bacteri
densiti
hand
larg
unknown
therefor
studi
effect
differ
consecut
applic
resid
bacteri
flora
hand
propanolbas
hand
rub
sterillium
base
mecetronium
etilsulf
refer
alcohol
en
npropanol
test
two
consecut
applic
h
four
variat
test
first
applic
sterillium
alway
min
second
applic
min
refer
alcohol
appli
min
applic
efficaci
three
product
variat
compar
refer
treatment
en
experi
perform
latinsquar
design
volunt
preand
postvalu
immedi
hr
applic
obtain
accord
en
first
refer
disinfect
min
reduc
bacteri
densiti
log
step
immedi
efficaci
log
step
h
sterillium
appli
min
yield
similar
reduct
sampl
time
immedi
second
min
refer
disinfect
bacteri
densiti
reduc
log
step
applic
sterillium
yield
larger
reduct
min
applic
time
min
applic
time
log
step
min
applic
time
differ
four
treatment
howev
signific
p
h
surgic
glove
bacteri
densiti
decreas
log
step
refer
disinfect
min
applic
sterillium
yield
largest
reduct
follow
min
treatment
min
treatment
signific
differ
four
treatment
p
friedman
test
none
short
treatment
sterillium
significantli
less
effect
min
refer
treatment
p
wilcoxonwilcox
test
overal
simpl
min
applic
wellformul
propanolbas
hand
rub
surgic
hand
disinfect
keep
bacteri
densiti
low
possibl
even
two
consecut
surgic
procedur
h
conclus
hpv
effect
standard
termin
clean
erad
nosocomi
pathogen
recontamin
immedi
mrsa
gnr
return
toward
preclean
level
mrsa
postclean
level
gnr
within
week
room
occupi
patient
colonis
mrsa
gnr
find
import
implic
optim
deploy
hpv
decontamin
hospit
trend
toward
greater
penand
eryr
note
countri
respect
fqr
overal
indic
levofloxacin
mic
mgl
belgium
itali
clonal
spain
uk
israel
ireland
mcat
uniform
blproduct
rate
rang
across
eur
macrolid
mgl
tetracyclin
mgl
fq
mgl
enzym
stabl
blactam
remain
potent
bl
rate
hi
rang
germani
franc
israel
blnar
hi
strain
tabl
found
nation
rang
overal
averag
acr
rare
note
nation
highest
spain
rate
document
ac
azithromycin
cro
fq
rf
chloramphenicol
oral
cephem
tetracyclin
averag
last
year
particip
pnsp
pennon
spn
ensp
erynon
spn
blp
blactamas
product
blnar
blactamaseneg
ampr
sentri
program
consist
monitor
eur
carti
pathogen
observ
rel
stabl
r
pattern
among
hi
mcat
variabl
rate
among
nation
spn
rrate
pen
macrolid
lesser
extent
fq
continu
evolv
vari
veloc
among
countri
sampl
result
corrobor
data
report
earr
object
determin
rate
characterist
risk
factor
intestin
carriag
nalidix
acid
na
resist
e
coli
e
coli
nar
healthi
children
never
receiv
quinolon
antibiot
treatment
method
two
consecut
survey
month
apart
carri
determin
preval
e
coli
nar
cohort
healthi
children
age
year
day
care
center
dcc
arab
villag
northern
israel
parent
interview
demograph
socioeconom
characterist
medic
histori
children
famili
stool
sampl
obtain
cohort
children
subsampl
sibl
mother
inocul
onto
macconkey
agar
plate
contain
na
na
minim
inhibitori
concentr
mic
determin
broth
microdilut
techniqu
e
coli
nar
strain
examin
ciprofloxacin
resist
select
strain
evalu
efflux
pump
activ
point
mutat
gyra
parc
gene
uniand
multivari
analys
use
identifi
risk
factor
e
coli
nar
carriag
result
found
children
carri
e
coli
nar
first
survey
second
among
children
examin
survey
n
harbour
e
coli
nar
first
survey
becam
neg
second
children
found
neg
first
survey
carri
e
coli
nar
second
e
coli
nar
isol
screen
among
children
e
coli
nar
strain
also
resist
ciprofloxacin
first
second
survey
respect
persist
resist
na
associ
increas
mic
number
mutat
gyra
parc
gene
presenc
efflux
pump
acquisit
resist
na
significantli
higher
two
dcc
locat
one
villag
carriag
e
coli
nar
associ
child
age
gender
use
antibiot
carriag
e
coli
nar
among
mother
sibl
conclus
lack
evid
intrafamiliar
spread
e
coli
nar
signific
acquisit
e
coli
nar
specif
dcc
suggest
mean
transmiss
food
waterborn
rout
may
explain
high
carriag
rate
e
coli
nar
persist
carriag
e
coli
nar
concern
view
associ
increas
phenotyp
genet
marker
resist
quinolon
rare
cultur
enterococci
mgl
rang
mgl
corynebacterium
spp
suscept
linezolid
mgl
enterococci
listeria
less
mgl
evalu
r
trend
speci
fail
identifi
mic
creep
seven
year
monitor
data
shown
tabl
linezolid
potenc
uncommonli
isol
gramposit
organ
ii
given
contin
pvlposit
camrsa
spread
countri
countri
instanc
europ
pvlposit
camrsa
recent
detect
slovenia
romania
croatia
iii
new
pvlposit
camrsa
clone
emerg
differ
genet
background
clone
describ
background
newli
describ
clone
clone
found
europ
clone
type
v
sccmec
report
simultan
europ
australia
iv
pvlposit
camrsa
initi
suscept
antistaphylococc
antibiot
acquir
new
antibiot
resist
determin
gentamicin
ofloxacin
instanc
v
preval
pvlposit
camrsa
vari
consider
one
contin
anoth
high
instanc
usa
greec
algeria
low
european
countri
vi
pvlposit
camrsa
gradual
caus
increas
number
hospitalacquir
infect
countri
preval
high
conclus
counter
emerg
global
threat
public
health
systemat
surveil
hospit
commun
isol
requir
togeth
measur
design
limit
spread
nordic
countri
netherland
nosocomi
mrsa
success
contain
year
keep
preval
mrsa
countri
accomplish
enforc
prevent
contact
isol
hospitalis
patient
suspect
confirm
mrsa
posit
facilit
fact
countri
predomin
risk
factor
patient
mrsa
acquisit
hospitalis
abroad
make
atrisk
patient
rel
easi
identifi
addit
secondari
case
seldom
aros
hospit
discharg
recent
chang
epidemiolog
transmiss
mrsa
increasingli
occur
outsid
hospit
chang
situat
increas
number
mrsa
report
mention
countri
sinc
number
new
case
mrsa
denmark
increas
major
mrsa
identifi
primari
healthcar
commun
onset
approxim
case
patient
connect
healthcar
institut
least
one
year
prior
diagnosi
case
therefor
consid
commun
acquir
camrsa
camrsa
infect
especi
report
children
younger
adult
skin
soft
tissu
infect
domin
repres
approxim
case
approxim
camrsa
case
report
person
anoth
ethnic
danish
could
indic
continu
influx
mrsa
high
preval
area
denmark
strain
belong
complex
frequent
caus
camrsa
denmark
howev
increas
diversif
recent
observ
includ
almost
strain
known
associ
camrsa
time
period
number
mrsa
diagnos
hospit
also
increas
happen
despit
continu
use
contact
isol
mrsa
posit
patient
hospitalis
mrsa
carrier
identifi
admiss
due
lack
risk
factor
probabl
one
import
factor
respons
increas
number
nosocomi
mrsa
denmark
increas
preval
mrsa
outsid
hospit
includ
otherwis
healthi
person
thu
great
concern
give
rise
camrsa
infect
also
inevit
increas
risk
nosocomi
mrsa
infect
outbreak
order
keep
denmark
low
preval
countri
believ
mrsa
contain
erad
hospitalis
patient
also
diagnos
commun
lead
new
nation
guidelin
prevent
erad
mrsa
includ
make
carriag
infect
mrsa
mandatori
report
first
question
ask
consid
screen
programm
identif
camrsa
carriag
import
epidemiolog
data
underestim
data
preval
inform
empir
therapi
requir
help
design
intervent
strategi
preval
establish
popul
gener
specif
subgroup
children
militari
personnel
indigen
disadvantag
popul
target
commun
intervent
measur
similar
search
destroy
techniqu
use
hospit
would
requir
largescal
screen
narrow
approach
concentr
highrisk
group
enabl
programm
educ
hygien
reduc
transmiss
would
allow
target
screen
programm
second
pragmat
area
screen
admiss
hospitalis
area
world
blur
boundari
camrsa
hamrsa
organ
report
caus
hospit
acquir
bacteraemia
surgic
prosthet
joint
infect
colonis
neonat
adult
patient
hospit
target
screen
highrisk
patient
patient
entri
highrisk
unit
strategi
prevent
camrsa
becom
endem
hospit
screen
control
recogn
outbreak
entail
identif
reservoir
enabl
appropri
isol
cohort
decolonis
measur
valu
screen
healthcar
worker
carriag
camrsa
yet
establish
screen
next
question
site
give
best
yield
laboratori
method
use
ideal
test
would
high
neg
posit
predict
valu
rapid
inexpens
applic
routin
laboratori
high
put
capabl
current
use
test
tradit
microbiolog
cultur
identif
method
use
select
media
includ
variou
type
chromagar
molecular
techniqu
use
real
time
pcr
requir
broth
amplif
increas
sensit
method
also
increas
time
identif
mani
differ
camrsa
clone
world
western
australia
alon
differ
multi
locu
sequenc
mlst
sccmec
camrsa
clone
molecular
test
must
therefor
abil
identifi
clone
divers
region
world
last
question
screen
answer
much
depend
purpos
screen
rang
largescal
period
popul
screen
epidemiolog
purpos
continu
hospit
unit
highrisk
patient
screen
establish
guidelin
recommend
screen
camrsa
mani
question
yet
answer
particularli
whether
control
transmiss
commun
possibl
look
evid
avail
move
step
closer
control
signific
commun
pathogen
rate
infect
caus
camrsa
continu
increas
caus
skin
soft
tissu
infect
seen
emerg
depart
recent
report
strategi
control
camrsa
patient
famili
includ
use
infect
control
techniqu
household
well
decolonis
mupirocin
chlorhexidin
antibiot
case
given
camrsa
implic
healthcareassoci
infect
effort
reduc
spread
organ
within
healthcar
environ
also
import
includ
appropri
handhygien
isol
environment
decontamin
incis
debrid
remain
critic
manag
camrsa
infect
use
antibiot
indic
mani
camrsa
infect
therapeut
option
includ
older
agent
clindamycin
trimethoprimsulfamethoxazol
tetracyclin
rifampin
newer
agent
linezolid
addit
new
agent
develop
pneumococc
pneumonia
pathogen
global
signific
repres
lead
caus
infectionrel
mortal
age
recent
develop
field
pneumococc
pathogenesi
reflect
signific
develop
genom
proteom
breadth
microbi
genet
divers
increasingli
recogn
understand
import
tradit
virul
factor
polysaccharid
capsul
pneumolysin
gener
hydrogen
peroxid
evolv
import
role
factor
pneumococc
pili
emerg
genet
screen
identifi
increas
role
previous
poorli
characteris
protein
involv
metabol
transport
key
molecul
import
physic
state
bacteria
differ
tissu
compart
also
becom
evid
improv
rang
model
variou
aspect
infect
rang
colonis
subclin
infect
fulmin
pneumonia
invas
diseas
allow
assess
microbi
host
factor
central
diseas
pathogenesi
rang
receptor
involv
innat
respons
pneumococci
respiratori
tract
start
appreci
includ
tolllik
receptor
receptor
primarili
involv
phagocytosi
bacteria
interact
solubl
factor
resid
phagocyt
lung
clarifi
complex
cytokin
network
involv
innat
host
respons
elucid
import
role
tlymphocyt
natur
killer
cell
dendrit
cell
respons
pneumococci
identifi
furthermor
understand
regul
inflammatori
respons
signific
role
apoptosi
regul
inflammatori
respons
lead
import
insight
cell
surviv
outcom
infect
close
link
observ
enabl
scientif
interpret
mani
central
clinic
featur
pneumococc
pneumonia
may
encourag
novel
approach
therapi
improv
diseas
respons
streptococcu
pneumonia
pneumococcu
continu
lead
caus
morbid
mortal
worldwid
particularli
among
young
children
elderli
immunocompromis
age
infect
preced
colonis
nasopharynx
ecolog
nich
pneumococci
individu
colonis
asymptomat
evolv
diseas
carrier
state
frequent
young
children
may
reach
popul
attend
daycar
centr
inde
latter
group
found
major
reservoir
pneumococci
play
key
role
amplif
transmiss
bacteria
individu
interest
sever
drugresist
clone
intern
dissemin
found
frequent
carri
popul
recent
year
debat
rel
contribut
serotyp
genet
background
invas
diseas
potenti
pneumococc
strain
present
studi
address
question
studi
conduct
portug
result
detail
comparison
two
larg
collect
pneumococc
isol
group
invas
diseas
isol
group
colonis
isol
collect
time
period
characteris
detail
antibiogram
serotyp
pfge
macrorestrict
profil
multilocu
sequenc
type
invas
diseas
potenti
serotyp
clone
discuss
pneumococci
caus
spectrum
diseas
human
reason
mild
diseas
like
sinus
conjunct
potenti
lifethreaten
diseas
like
mening
bacteraemia
current
conjug
vaccin
ideal
aim
protect
pneumococc
diseas
success
prevent
invas
pneumococc
diseas
understand
invas
diseas
epidemiolog
preced
vaccin
implement
vaccin
introduct
crucial
design
develop
futur
vaccin
sever
recent
studi
shown
pneumococc
serotyp
differ
invas
diseas
potenti
particular
relev
select
serotyp
includ
futur
conjug
vaccin
also
essenti
understand
serotypespecif
chang
occur
subsequ
conjug
vaccin
implement
usa
model
might
occur
postvaccin
implement
countri
recent
histori
pneumococc
diseas
prevent
domin
develop
conjug
pneumococc
vaccin
administr
infant
implement
start
usa
vaccin
current
formul
afford
protect
invas
pneumococc
diseas
ipd
due
common
serotyp
caus
ipd
among
children
less
year
age
prior
vaccin
introduct
usa
formul
optim
mani
develop
countri
serotyp
import
global
second
gener
vaccin
therefor
includ
least
serotyp
import
prevent
pneumococc
diseas
extend
beyond
ipd
pneumonia
mening
otiti
media
prevent
antibioticresist
infect
even
prevent
mortal
young
infant
present
specif
challeng
vaccin
shown
prevent
caus
xray
confirm
pneumonia
impli
level
protect
pneumococc
pneumonia
due
vaccin
serotyp
excess
reduct
pneumonia
translat
reduct
allcaus
mortal
due
vaccin
rural
africa
major
prevent
burden
diseas
africa
may
among
hiv
infect
children
vaccin
also
shown
reduc
pneumonia
burden
innov
aspect
vaccin
fact
may
reduc
pneumococc
super
infect
follow
viral
respiratori
infect
influenza
conjug
vaccin
children
may
thu
use
adjunct
pandem
influenza
plan
prepared
interrupt
carriag
vaccin
serotyp
shown
reduc
ipd
adult
usa
due
herd
immun
popul
benefit
influenza
pandem
may
extend
beyond
protect
immunis
children
herd
immun
also
recent
shown
protect
young
unimmunis
infant
ipd
conjug
vaccin
littl
impact
caus
otiti
media
randomis
trial
postmarket
studi
usa
suggest
healthcar
utilis
otiti
episod
reduc
significantli
post
vaccin
introduct
suggest
major
role
herd
immun
allow
physician
feel
comfort
wait
see
attitud
otiti
prospect
signific
complic
due
pneumococcu
like
rare
conjug
pneumococc
polysaccharid
haemophilu
influenza
protein
allow
develop
efficaci
vaccin
otiti
media
dramat
reduct
antibiot
resist
among
vaccin
serotyp
caus
ipd
usa
children
adult
resist
driven
continu
high
level
antibiot
use
select
resist
nonvaccin
serotyp
particular
multiresist
global
clone
serotyp
domin
usa
vaccin
formul
includ
serotyp
develop
implement
immunis
programm
includ
conjug
pneumococc
vaccin
infant
european
countri
afford
opportun
monitor
impact
health
outcom
children
adult
infect
endocard
time
chang
treatment
option
infect
endocard
new
drug
bad
bug
usa
infect
due
hospit
communityacquir
methicillin
resist
staphylococcu
aureu
mrsa
increas
rapidli
frequenc
sever
result
new
treatment
option
badli
need
present
first
address
role
tradit
therapi
focus
gradual
develop
increas
resist
vancomycin
among
mrsa
next
focu
altern
oral
therapi
clindamycin
cotrimoxazol
minocyclin
role
treatment
communityacquir
mrsa
organ
displac
tradit
mrsa
mani
venu
efficaci
newli
approv
antibiot
linezolid
daptomycin
tigecyclin
address
present
result
larg
phase
clinic
trial
complic
skin
skin
structur
infect
hospitalacquir
pneumonia
bacteraemia
discuss
focu
efficaci
agent
mrsa
subgroup
final
efficaci
antibiot
develop
present
focus
mrsa
subgroup
phase
studi
antibiot
includ
dalbavancin
telavancin
oritavancin
iclaprim
ceftobiprol
ceftarolin
epidemiolog
staphylococc
infect
chang
new
therapeut
agent
becom
avail
clinician
therapeut
util
depend
understand
uniqu
characterist
efficaci
new
agent
clinic
trial
order
clearli
understand
role
new
therapeut
paradigm
antimicrobi
resist
seriou
problem
increas
strain
bacteria
becom
resist
mani
avail
antibiot
tetracyclin
alreadi
introduc
year
ago
undergon
consider
resist
develop
nosocomi
communityacquir
pathogen
june
minocyclin
deriv
new
glycylcyclin
antimicrobi
tygecyclin
approv
fda
treatment
complic
intraabdomin
complic
skin
skinstructur
infect
tigecyclin
bacteriostat
agent
bind
ribosom
unit
block
entri
aminoacyl
trna
molecul
prevent
protein
synthesi
broad
antibacteri
spectrum
activ
gramposit
gramneg
pathogen
includ
multidrugresist
organ
anaerob
modif
basic
tetracyclin
molecul
overcom
two
resist
mechan
seen
tetracyclin
efflux
ribosom
protect
tigecyclin
exhibit
linear
pharmacokinet
long
halflif
hour
highli
protein
bound
larg
volum
distribut
lkg
tigecyclin
extens
metabolis
primari
rout
elimin
biliari
excret
excret
unchang
urin
recommend
dose
regimen
initi
dose
mg
follow
mg
everi
hour
time
mic
aucmic
ratio
import
pharmacodynam
paramet
two
doubleblind
studi
safeti
efficaci
tigecyclin
versu
aztreonam
plu
vancomycin
compar
hospitalis
adult
complic
skin
skinstructur
infect
patient
randomis
result
pool
analysi
determin
tigecyclin
monotherapi
effect
statist
noninferior
aztreonam
plu
vancomycin
two
doubleblind
studi
includ
patient
analys
safeti
efficaci
tigecyclin
versu
imipenemcilastatin
adult
complic
intraabdomin
infect
result
pool
analysi
determin
tigecyclin
efficaci
statist
noninferior
imipenem
nausea
vomit
common
advers
effect
observ
clinic
trial
usual
occur
within
first
two
day
therapi
common
women
men
may
also
age
relat
tigecyclin
import
addit
antimicrobi
armentarium
broad
spectrum
activ
abil
evad
numer
mechan
resist
make
promis
solut
treatment
multidrug
resist
organ
help
select
patient
icu
increas
resist
gramneg
bacteria
particularli
amongst
pseudomona
aeruginosa
acinetobact
baumannii
rais
major
therapeut
problem
lack
new
effect
agent
near
futur
reviv
interest
reus
molecul
abandon
toxic
colistin
colistimeth
sodium
polymyxin
antibiot
avail
parenter
formul
use
intraven
aerosolis
intrathecalintraventricular
administr
bactericid
activ
colistin
due
deterg
effect
cell
membran
therefor
depend
upon
bacteri
metabol
activ
drug
develop
littl
pharmacokinet
pharmacodynam
inform
avail
optim
daili
dose
sever
ill
patient
still
unknown
colistin
use
intraven
inhal
use
last
decad
mainli
cystic
fibrosi
patient
recent
colistin
use
non
cystic
fibrosi
patient
salvag
therapi
treatment
infect
gramneg
bacteria
resist
antibiot
clinic
report
efficaci
intraven
colistin
patient
randomis
studi
colistin
frequent
associ
antimicrobi
agent
lack
control
group
good
outcom
occur
infect
poorest
result
observ
pneumonia
vitro
studi
shown
synergist
effect
colistin
rifampin
clinic
studi
design
confirm
synergi
nephrotox
neurotox
common
toxic
colistin
howev
recent
studi
demonstr
reduc
toxic
compar
previou
studi
even
higher
dosag
use
low
renal
toxic
rate
observ
critic
ill
patient
patient
treat
prolong
cours
colistin
also
recent
clinic
report
use
colistin
continu
intraven
infus
minimis
potenti
toxic
reduct
toxic
without
impair
efficaci
concentrationdepend
kill
invitro
timekil
studi
confirm
studi
neurotox
also
frequent
report
case
renal
dysfunct
develop
resist
colistin
major
problem
especi
baumannii
highlight
urgent
need
preserv
molecul
best
appropri
dose
regimen
optim
synergist
combin
antibiot
fosfomycin
phosphon
broad
spectrum
antibiot
discov
spain
licens
mani
countri
sinc
use
sporad
clinic
set
fact
mention
specif
current
edit
prestigi
textbook
intern
medicin
infecti
diseas
emerg
infect
caus
bacteria
resist
almost
antimicrobi
agent
may
renew
interest
address
contribut
limit
futur
clinic
indic
drug
fosfomycin
exhibit
rapid
bactericid
activ
larg
number
aerob
gram
posit
gram
neg
bacteri
speci
inhibit
initi
step
cell
wall
syntesi
import
multiresist
pathogen
penicillinresist
pneumococci
methicillinresist
staphylococci
vancomycinresist
enterococci
esblproduc
enterobacteriacea
usual
suscept
drug
date
crossresist
antibiot
report
favour
pharmacokinet
properti
includ
low
molecular
weight
neglig
protein
bind
larg
volum
distribut
human
tissu
good
penetr
inflam
csf
disodium
salt
fosfomycin
administ
intraven
high
dose
due
low
toxic
achiev
plasmat
peak
level
sever
time
mic
suscept
microorgan
breakpoint
gml
oral
salt
fosfomycin
tromethamin
enhanc
bioavail
also
avail
sinc
major
drawback
fosfomycin
frequent
develop
resist
therapi
phenomenon
demonstr
vitro
vivo
studi
preclud
parenter
use
singl
agent
clinic
practic
counterbal
fosfomycin
act
synergist
antibiot
especi
inhibit
later
point
cellwal
synthesi
synerg
shown
repeatedli
differ
strain
staphylcoccu
aureu
cn
streptococcu
pneumonia
pseudomona
aeruginosa
moreov
experiment
anim
model
mrsa
endocard
cefalosporinresist
pneumococc
mening
fosfomycin
blactam
vancomycin
combin
prove
superior
monotherapi
prevent
emerg
drugresist
popul
well
howev
report
clinic
experi
combin
scarc
therefor
evidencebas
recommend
support
use
hand
variou
clinic
trial
indic
fosfomycin
trometamol
sole
antibiot
effect
safe
treatment
uncompl
uti
provid
high
long
last
urinari
fosfomycin
level
help
prevent
emerg
resist
strain
increas
preval
ctxm
type
esblproduc
e
coli
commun
oral
administr
singl
dose
gr
fosfomycin
trometamol
may
consid
nowaday
first
line
therapi
uncompl
uti
young
women
howev
possibl
emerg
fosfomycinresist
mutant
among
esblproduc
enterobacteriacea
taken
account
conclus
year
discoveri
oral
form
fosfomycin
tromethamin
attain
solid
posit
antimicrobi
guidelin
combin
iv
fosfomycin
antibiot
may
consid
select
case
whether
combin
yield
improv
outcom
specif
infect
due
multirresist
pathogen
remain
determin
logist
reason
financi
limit
make
difficult
realis
appropri
prospect
studi
answer
issu
near
futur
chloramphenicol
still
use
extens
nonindustrialis
countri
treatment
sever
infect
like
pneumonia
typhoid
fever
cheap
effect
chloramphenicol
prove
effect
altern
treatment
pneumococc
meningococc
diseas
also
patient
mening
caus
haemophilu
influenza
chloramphenicol
loss
favour
began
shown
two
distinct
toxic
effect
hematopoiesi
frequent
observ
dosedepend
anaemia
revers
cessat
therapi
irrevers
idiosyncrat
aplast
anaemia
incid
approxim
case
per
cours
therapi
high
case
fatal
rate
correl
durat
treatment
use
chloramphenicol
becom
restrict
lifethreaten
infect
accept
altern
treatment
like
brain
abscess
analogu
chloramphenicol
develop
lack
aromat
group
thought
caus
irrevers
marrow
aplasia
although
clinic
efficaci
compound
evalu
effect
vitro
bacteria
even
resist
chloramphenicol
data
provid
support
hypothesi
molecul
need
nitro
group
order
caus
blood
dyscrasia
insuffici
florfenicol
follow
chloramphenicol
veterinari
medicin
potenti
florfenicol
caus
blood
dyscrasia
aplast
anaemia
human
discuss
relat
chemic
relat
chemic
chloramphenicol
thiamphenicol
human
epidemiolog
data
could
use
demonstr
safeti
florfenicol
florfenicol
never
use
human
medicin
nevertheless
yet
way
monitor
potenti
irrevers
bone
marrow
toxic
unlik
compound
becom
avail
treatment
chloramphenicolresist
infect
gener
meningococc
diseas
particular
futur
chloramphenicol
entir
certain
one
hand
wellstudi
longstand
treatment
fight
number
differ
infect
also
inexpens
consequ
widespread
use
would
howev
good
thing
could
find
new
drug
group
drug
produc
similar
result
fight
infect
mani
seriou
side
effect
would
take
long
time
drug
could
ever
replac
chloramphenicol
broad
use
low
cost
tropic
medicin
basic
scienc
field
work
evalu
malaria
statu
immun
respons
plasmodium
falciparum
object
studi
highli
polymorph
kda
merozoit
surfac
antigen
immunogen
malaria
antigen
consid
promis
vaccin
candid
end
region
gene
highli
conserv
wherea
larg
central
region
variabl
mani
studi
suggest
protect
role
specif
igg
antibodi
variabl
region
studi
design
analys
reactiv
human
sera
peopl
live
malariaendem
area
gambia
villag
keneba
differ
domain
associ
haemoglobin
parasitaemia
two
indic
clinic
malaria
acquir
immun
analys
elucid
pattern
protect
immun
current
studi
design
carri
liverpool
school
tropic
medicin
human
sera
randomli
select
mcgregor
keneba
sera
collect
differ
domain
synthes
use
gst
gene
fusion
system
crude
schizont
extract
prepar
vitro
cultur
plasmodium
falciparum
total
igg
igg
subclass
respons
measur
elisa
checkerboard
studi
perform
antigen
standardis
concentr
antigen
antibodi
result
sera
predominantli
recogn
immunodomin
region
molecul
increas
age
neg
correl
parasitaemia
posit
igg
antibodi
respons
haemoglobin
level
indic
total
igg
respons
domain
crude
schizont
extract
coincident
decreas
parasitaemia
densiti
frequenc
respons
main
igg
parasitaemia
final
time
point
increas
amongst
individu
parasitaemia
higher
level
haemoglobin
higher
age
exposur
parasit
long
period
time
conclus
main
antibodi
mainli
domain
associ
increas
haemoglobin
level
decreas
parasitaemia
suggest
domain
prefer
domain
crude
schizont
extract
present
clearer
pictur
immun
malaria
result
could
evid
protect
role
antibodi
malaria
diseas
therefor
domain
consid
reliabl
vaccin
candid
antigen
object
countri
hyperendem
dengu
viru
infect
serosurveil
indic
almost
nativ
adult
infect
mostli
asymptomat
longheld
mechan
explain
clinic
sever
involv
sequenti
infect
differ
serotyp
even
though
peer
flavivirus
known
resid
persist
within
host
contribut
host
ill
dengu
viru
shown
behav
similar
fashion
dengu
haematotrop
viru
sought
find
evid
persist
bone
marrow
previouslyinfect
person
method
studi
patient
clinic
suspect
known
haematolog
malign
indic
diagnost
bone
marrow
initi
followup
studi
fraction
cellular
marrow
employ
rna
extract
revers
transcriptionpolymeras
chain
reaction
rtpcr
denguespecif
primer
serolog
assess
haemagglutun
inhibit
test
hi
dengu
chikungunya
virus
enzymelink
immunosorb
assay
elisa
dengu
perform
studi
bone
marrow
studi
case
day
later
minimis
chanc
includ
patient
recent
dengu
infect
serolog
interpret
made
accord
standard
criteria
demograph
data
patient
analys
especi
histori
recent
febril
ill
could
due
dengu
infect
background
intermitt
prevent
antimalari
treatment
infant
ipti
consid
promis
malaria
control
strategi
among
factor
influenc
extent
protect
provid
ipti
malaria
endem
season
drug
resist
pattern
ipti
applic
schedul
studi
model
effect
malaria
incid
ipti
scarc
aim
studi
describ
far
protect
efficaci
ipti
depend
incid
rate
clinic
malaria
method
onethousand
seventi
infant
enrol
regist
control
trial
efficaci
sulfadoxinepyrimethamin
base
ipti
ashanti
region
ghana
ecolog
analysi
malaria
incid
rate
first
year
follow
ipti
stratifi
villag
resid
month
birth
particip
spatiotempor
variat
malaria
incid
protect
efficaci
ipti
analys
find
rate
malaria
attack
first
year
followup
highli
depend
month
birth
villag
resid
children
protect
efficaci
first
ipti
administr
correl
malaria
incid
children
live
particular
villag
born
particular
month
p
p
respect
correspond
trend
seen
second
third
drug
administr
interpret
correl
ipti
efficaci
malaria
incid
may
implic
ipti
implement
strategi
discuss
role
mathemat
model
pandem
plan
respons
recent
research
examin
whether
antivir
prophylaxi
social
distanc
measur
could
use
contain
nascent
pandem
point
origin
review
contain
potenti
feasibl
requir
rapid
detect
initi
transmiss
case
cluster
rapid
organis
respons
new
case
may
demand
criteria
much
se
asia
contain
fail
slow
spread
becom
polici
prioriti
context
discuss
potenti
impact
restrict
intern
travel
conclud
discuss
pandem
mitig
strategi
make
best
use
limit
vaccin
antivir
suppli
infect
among
frequent
complic
occur
cancer
patient
undergo
antineoplast
chemoor
immunotherapi
invas
fungal
infect
today
repres
main
caus
fatal
outcom
earli
diagnosi
probabl
proven
invas
aspergillosi
therefor
one
import
object
support
care
patient
profound
prolong
neutropenia
advent
effect
welltoler
antifung
activ
aspergillosi
incid
mould
infect
zygomycosi
rise
use
highli
aggress
chemotherapi
induc
sever
mucos
damag
mani
cancer
patient
apart
neutropaen
enterocol
broad
spectrum
infect
associ
impair
mucos
barrier
may
clinic
import
eg
streptococc
bacteraemia
septic
enterococc
infect
candidaemia
wide
spread
use
multilumen
central
venou
cathet
caus
consider
number
bloodstream
infect
caus
coagulaseneg
staphylococci
aureu
gramneg
bacilli
candida
spp
primari
remov
foreign
materi
may
import
success
manag
catheterrel
infect
allogen
hematopoiet
stem
cell
transplant
reducedintens
condit
becom
common
also
treatment
aggress
haematolog
malign
elderli
patient
well
patient
sever
comorbid
formerli
taken
consider
myeloabl
transplant
procedur
despit
mark
reduct
complic
relat
pancytopenia
combin
acut
graftversushost
reaction
rate
sever
lifethreaten
fungal
infect
cytomegaloviru
diseas
turn
compar
convent
allogen
transplant
importantli
half
infecti
complic
emerg
day
post
transplant
ie
patient
alreadi
manag
outpati
basi
tuberculosi
fast
forward
new
approach
broad
introduct
monoclon
antibodi
nucleosid
analog
treatment
patient
bor
tcell
lymphoma
lead
longterm
deplet
b
cell
eventu
associ
decreas
level
serum
immunoglobulin
tcell
defici
last
mani
year
particularli
patient
treat
compound
relaps
refractori
malign
high
number
infect
caus
pathogen
virus
cmv
invas
fungi
pneumocysti
jiroveci
observ
target
prophylaxi
warrant
select
patient
group
wherea
high
alert
earli
preemptiv
antimicrobi
intervent
mandatori
major
patient
last
decad
restrict
fragment
length
polymorph
rflp
type
gain
recognit
gold
standard
molecular
epidemiolog
tuberculosi
applic
rflp
type
provid
new
insight
eg
natur
histori
tuberculosi
infect
inter
nation
transmiss
multidrug
resist
tuberculosi
europ
present
howev
method
technic
demand
labour
intens
requir
week
cultur
obtain
suffici
dna
complex
rflp
pattern
difficult
interpret
exchang
new
gener
genotyp
mycobacterium
tuberculosisbas
detect
variabl
number
tandem
repeat
vntr
mycobacteri
interspers
repetit
unit
miru
increasingli
use
solv
problem
vntr
type
base
pcr
amplif
multipl
genom
loci
determin
number
tandem
repeat
site
type
much
easier
perform
type
applic
crude
lowconcentr
dna
extract
current
studi
even
orient
appli
vntr
type
directli
clinic
materi
moreov
result
express
numer
code
therefor
easi
compar
exchang
recent
intern
collabor
resolut
stabil
technic
applic
miruvntr
loci
compar
studi
compris
initi
explor
loci
appli
usa
exploit
loci
disclos
intern
context
far
type
result
tuberculosi
isol
reveal
optim
loci
use
select
loci
recommend
new
intern
gold
standard
type
tuberculosi
complex
isol
recent
studi
point
vntr
type
basi
loci
use
studi
phylogeni
complex
experienc
standardis
rflp
type
expect
recent
decemb
j
clin
microbiol
intern
consensu
vntr
type
facilit
comparison
molecular
epidemiolog
data
variou
geograph
region
spread
multidrug
resist
europ
establish
intern
vntr
databas
metaanalysi
worldwid
type
result
order
studi
popul
structur
spread
tuberculosi
mani
institut
world
larg
databas
rflp
pattern
tuberculosi
isol
extend
time
period
epidemiolog
tuberculosi
transmiss
manifest
diseas
separ
time
multipl
year
switch
vntr
type
done
without
overlap
applic
two
type
method
eccmid
meet
first
retyp
result
netherland
consider
underli
choic
isol
retyp
discuss
larg
proport
new
case
tuberculosi
tb
world
aris
reservoir
peopl
latent
infect
mycobacterium
tuberculosi
mtb
tb
endem
area
world
averag
time
diagnosi
case
tb
onset
activ
diseas
month
month
case
tb
like
infect
averag
close
contact
one
newli
infect
contact
develop
tb
sometim
life
time
infect
person
diagnosi
cycl
repeat
thu
tb
control
programm
focus
treatment
activ
case
tb
never
come
control
fundament
question
tb
control
therefor
predict
among
latent
infect
peopl
progress
activ
diseas
person
given
prevent
treatment
answer
question
mechan
mtb
persist
reactiv
need
better
understood
varieti
model
bacteri
persist
propos
recent
genet
studi
provid
evid
put
role
gene
persist
base
demonstr
mtb
strain
disrupt
gene
attenu
anim
model
tb
howev
sever
recent
gene
disrupt
studi
shown
mtb
mutant
also
becom
hypervirul
anim
model
suggest
mtb
gene
may
actual
help
temper
virul
potenti
mtb
organ
establish
stabl
nich
host
without
harm
host
provid
evid
cluster
gene
operon
call
mtb
involv
lipid
transport
metabol
help
remodel
bacteri
cell
envelop
operon
appear
respond
signal
induc
host
granuloma
cell
turnov
host
proinflammatori
cell
compris
granuloma
appear
respond
chang
bacteri
cell
envelop
lipid
turnov
mtb
mutant
disrupt
operon
becom
hypervirul
mous
model
tb
unabl
induc
wellorganis
granuloma
mous
lung
mous
die
uncontrol
bacteri
prolifer
mutant
accumul
free
mycol
acid
surfac
hand
mtb
strain
disrupt
neg
regul
operon
constitut
express
gene
vivo
mutant
also
hypervirul
opposit
reasonit
caus
rapidli
progress
hyperproinflammatori
respons
thu
operon
appear
serv
homeostat
regul
proinflammatori
respons
host
help
establish
balanc
relationship
favour
host
mtb
understand
exploit
relationship
may
lead
new
way
predict
subset
latent
infect
peopl
progress
activ
diseas
may
also
lead
develop
therapeut
vaccin
prevent
latent
infect
peopl
ever
develop
tb
strain
sequenc
upand
downstream
cpsa
approxim
kb
dna
kb
upstream
cpsa
start
kb
downstream
compris
upstream
dexb
downstream
alia
gene
gene
found
cpsa
start
alia
stop
compris
gene
ident
pneumococc
capsul
gene
wzg
capsular
polysaccharid
express
regul
wzh
wze
phosphotyrosin
phosphatas
wzd
wze
phosphoryl
wze
autophosphoryl
proteintyrosin
kinas
wcha
undecaprenyl
phosphat
glucosephosphotransferas
wzi
oligosaccharid
repeat
unit
polymeras
wzx
flippas
sever
gene
put
glycosyl
glycerol
acetyl
transferas
activ
put
udpgalactopyranos
mutas
four
gene
upstream
cpsa
start
dexb
start
compris
dexb
alialik
gene
unidentifi
gene
object
staphylococcu
aureu
respiratori
pathogen
cystic
fibrosi
cf
pathogen
relat
combin
virul
antibioticresist
gene
littl
known
agrgroup
cfisol
studi
investig
antibioticresist
distribut
virul
determin
aureu
strain
singl
serial
isolatessam
strain
remov
subdivid
agrclass
isol
period
month
sputum
cf
patient
receiv
variou
cours
antibiotictherapi
follow
perform
agrtyp
scairflp
method
investig
virul
gene
multiplexpcr
antibioticresist
disk
diffus
method
accord
clsi
guidelin
result
mrsa
isol
case
staphylococci
show
follow
resist
profil
eri
gm
da
cip
lvx
rd
te
c
among
strain
agrii
preval
agriiiiiv
isol
approxim
case
within
agrgroup
distribut
virul
determin
reveal
common
conservedcor
background
sararnaiiispaicaahlahlg
wherea
accessorygen
alway
repres
differ
combin
copossess
significantli
capsul
preval
agri
preval
agriiiii
agri
associ
presenc
mani
virulencegen
cytotoxin
proteas
sealukesplb
one
agri
isol
luksfpvl
found
agrii
also
possess
adhesin
sdre
agriii
associ
adhesin
enterotoxin
fnbaseacna
exfoliatina
never
detect
agriv
possess
cytotoxin
luke
adhesin
cna
exfoliatina
eta
proteas
gene
splb
alway
found
associ
cytotoxin
luke
agriiiiii
mostli
sdre
adhesin
associ
frequent
inversecorrel
found
cna
lukesplb
agrgroup
close
correl
observ
cna
agriiiiv
conclus
data
demonstr
first
time
increas
mrsa
centr
furthermor
cfpersist
infect
associ
distinct
agrspecif
group
diffus
antibioticresist
strain
rather
aureu
isol
complex
distribut
combin
virul
determin
contribut
aureu
pathogen
cf
patient
object
prolifer
differenti
neural
progenitor
cell
dentat
gyru
increas
infect
anim
model
pneumococc
mening
method
evalu
neurogenesi
patient
acut
infect
central
nervou
system
brain
section
patient
die
bacteri
mening
patient
die
nonneurolog
diseas
investig
immunohistochemistri
result
dentat
gyru
hippocamp
format
densiti
prolifer
cell
nuclear
antigen
pcna
express
cell
higher
patient
bacteri
mening
compar
control
group
p
furthermor
number
cell
express
immatur
neuron
marker
protein
increas
brain
section
person
die
bacteri
mening
compar
control
case
p
subventricular
zone
differ
cell
express
observ
group
p
immatur
neuron
express
morpholog
featur
apoptot
cell
death
evid
dna
fragment
increas
prolifer
neural
progenitor
suggest
endogen
mechan
may
limit
consequ
neuron
destruct
mening
stimul
neurogenesi
might
help
improv
therapi
acut
inflammatori
diseas
brain
method
n
train
find
hidden
underwat
platform
within
less
trial
day
swim
track
latenc
escap
water
record
video
camera
thereaft
mice
receiv
cpgdna
mgd
volum
steril
salin
day
right
ventricl
stereotact
implant
cathet
connect
subcutan
osmot
pump
water
maze
test
peform
weekli
result
initi
treatment
latenc
reach
hidden
platform
water
maze
sigificantli
longer
mice
receiv
cpgdna
control
anim
p
day
initi
treatment
histolog
show
profound
inflamm
invas
activ
tand
bcell
axon
damag
furthermor
ependym
damag
loss
seen
cpgtreat
anim
addit
experi
mice
show
major
inflamm
cpgtreatment
day
background
earli
detect
microorgan
blood
essenti
earli
diagnosi
treatment
bloodstream
infect
calorimetr
detect
microbi
growth
may
sensit
rapid
blood
cultur
system
compar
microbi
detect
spike
blood
specimen
use
commerci
system
co
detect
colour
chang
isotherm
microcalorimet
method
escherichia
coli
atcc
staphylococcu
aureu
atcc
ad
differ
concentr
anticoagul
blood
obtain
healthi
volunt
aliquot
ml
spike
blood
ad
aerob
blood
cultur
bottl
contain
ml
growth
medium
incub
blood
cultur
instrument
bactalert
durham
nc
usa
incub
ml
bottl
content
inocul
glass
ampoul
contain
ml
steril
trypticas
soy
broth
calorimetri
tam
iii
thermometr
ab
sweden
blood
cultur
calorimetri
ampoul
simultan
load
correspond
instrument
incub
hour
time
posit
defin
interv
incub
start
posit
signal
bactalert
heat
flow
rate
increas
mw
baselin
calorimet
detect
limit
mw
result
time
posit
consider
shorter
use
calorimetri
tabl
blood
without
ad
pathogen
produc
heat
signal
baselin
spike
specimen
heat
signal
rose
mw
pathogen
multipli
incub
period
object
work
carri
determin
increas
rate
mrsa
detect
use
enrich
step
compar
direct
cultur
chromogen
agar
mrsa
screen
swab
neonat
nicu
compar
swab
first
cultur
directli
onto
chromogen
mrsa
id
agar
incub
brain
heart
infus
broth
hour
broth
subsequ
subcultuerd
onto
mrsa
id
agar
plate
incub
hour
aerob
check
presenc
green
coloni
indic
mrsa
hour
green
coloni
confirmatori
test
mrsa
limit
detect
determin
direct
enrich
cultur
mrsa
id
agar
use
doubl
dilut
initi
mcfarland
suspens
plate
incub
hour
aerob
coloni
count
perform
total
swab
test
use
direct
enrich
cultur
method
direct
cultur
isol
mrsa
detect
hour
incub
hour
incub
total
follow
enrich
isol
detect
hour
incub
one
follow
hour
incub
total
enrich
yield
increas
number
isol
mrsa
detect
compar
direct
cultur
limit
detect
direct
cultur
cfuml
dilut
cfuml
dilut
follow
enrich
result
show
limit
detect
higher
follow
enrich
indic
increas
sensit
compar
direct
cultur
comparison
patient
sampl
correl
show
increas
rate
detect
mrsa
follow
enrich
conclus
enrich
proven
dramat
increas
sensit
rate
detect
mrsa
compar
direct
cultur
alon
order
ensur
maximum
sensit
detect
mrsa
enrich
employ
method
choic
routin
laboratori
limit
addit
help
inflammatori
marker
crp
pct
bacteraemia
predict
compar
model
clinic
assess
routin
laboratori
inform
requir
septic
evalu
suggest
need
justif
use
measur
costconstrain
set
object
increas
crossbord
transfer
patient
healthcar
worker
hcw
within
eu
caus
enorm
problem
regard
control
spread
multiresist
pathogen
especi
within
dutchgerman
border
region
great
differ
preval
methicillinresist
staphylococcu
aureu
mrsa
netherland
addit
within
last
two
year
increas
number
communityacquir
ca
mrsa
could
also
note
netherland
repres
addit
danger
object
studi
elucid
molecular
crossbord
epidemiolog
mrsa
within
euregio
method
first
mrsa
isol
patient
hcw
obtain
within
euregio
mrsanet
type
epidemiolog
backbon
project
type
network
provid
common
languag
base
aureu
protein
spa
gene
sequenc
result
sinc
begin
project
juli
isol
inand
outpati
nurs
home
inhabit
type
three
spa
type
detect
within
euregio
spa
type
determin
german
part
euregio
howev
major
spa
type
german
side
concord
nation
epidemiolog
trend
spa
common
spa
type
spa
type
often
associ
camrsa
central
europ
detect
side
german
dutch
side
border
underlin
emerg
problem
camrsa
focus
hospitalis
patient
mrsa
blood
cultur
detect
german
side
mainli
spa
type
conclus
summari
use
spa
type
elucid
differ
region
epidemiolog
mrsa
howev
crossbord
spread
mrsa
also
detect
therefor
new
coordin
region
crossbord
strategi
develop
mrsanet
fight
mrsa
object
success
pandem
hospitalacquir
mrsa
clone
may
due
high
adhes
properti
adhes
mediat
variou
differ
cell
wall
protein
call
adhesin
tightli
regul
accessori
gene
regul
agr
one
act
regul
agr
dysfunct
associ
overexpress
certain
adhesin
seem
respons
success
clone
canada
way
compar
adhes
properti
adhesin
gene
content
function
agr
mrsa
lyon
clone
isol
mssa
isol
method
studi
aureu
isol
respons
bloodstream
infect
intens
care
unit
nineteen
isol
suscept
methicillin
mrsa
isol
characterist
mrsa
lyon
clone
sequenc
type
agr
allel
type
posit
sea
gene
bind
behaviour
onto
airway
epitheli
cell
haec
determin
quantifi
number
adher
bacteria
per
cell
cell
per
strain
use
adhesin
gene
profil
bbp
eno
ebp
fib
clfa
clfb
fnba
fnbb
determin
multiplex
pcr
isol
dysfunct
agr
detect
absenc
deltahaemolysin
product
result
number
aureu
isol
per
cell
homogen
mssa
isol
mrsa
isol
adhes
mrsa
isol
significantli
higher
mssa
isol
respect
p
figur
mrsa
isol
posit
eno
fib
clfa
clfb
fnba
fnbb
mssa
isol
posit
eno
clfa
clfb
fnbb
inconstantli
posit
other
absenc
deltahaemolysin
product
tend
frequent
among
mrsa
isol
versu
isol
differ
signific
p
correl
adhes
properti
absenc
deltahaemolysin
product
observ
mrsa
mssa
isol
demonstr
adhes
properti
onto
haec
mrsa
lyon
clone
isol
higher
mssa
isol
heterogen
despit
similar
genet
background
adhesin
gene
profil
could
result
overexpress
adhesin
independ
agr
dysfunct
object
although
mani
distinct
genet
lineag
communityassoci
mrsa
camrsa
report
worldwid
one
clone
prove
highli
success
usa
iva
socal
clone
associ
commun
outbreak
nosocomi
transmiss
identifi
primari
caus
skin
soft
tissu
infect
ssti
present
emerg
depart
across
usa
follow
enhanc
surveil
camrsa
light
observ
map
epidemiolog
clone
england
wale
method
year
period
mrsa
refer
nation
staphylococcu
refer
unit
england
wale
characteris
microbiolog
isol
identifi
camrsa
subject
detail
characteris
includ
mlst
spa
type
toxin
gene
profil
pfge
antibiot
suscept
test
epidemiolog
demograph
clinic
data
also
collat
result
ca
camrsa
identifi
belong
clonal
lineag
third
common
camrsa
occur
nation
isol
pvlposit
spa
belong
agr
group
nine
differ
subtyp
distinguish
pfge
almost
half
belong
singl
pulsotyp
resist
blactam
resist
erythromycin
ciprofloxacin
gentamicin
tetracyclin
fusid
acid
variabl
suscept
clindamycin
trimethoprim
vancomycin
linezolid
mupirocin
major
patient
communitybas
includ
male
femal
age
rang
median
present
skin
infect
eg
boil
abscess
insect
bite
soft
tissu
infect
one
patient
die
case
sporad
communitybas
cluster
identifi
involv
msm
household
contact
individu
attend
gp
surgeri
eight
patient
gave
histori
foreign
travel
eg
usa
remaind
acquir
domest
lineag
camrsa
occur
england
wale
sinc
least
whilst
number
remain
small
occurr
communitybas
cluster
death
one
patient
give
caus
concern
emerg
resist
multipl
class
antimicrobi
alli
evid
clonal
expans
highlight
need
continu
surveil
underpin
effect
therapeut
infect
control
strategi
secondari
efficaci
endpoint
three
treatment
arm
similar
term
clinic
mycolog
respons
signific
differ
incid
emerg
fungal
infect
studi
incid
relaps
posttreat
clinic
signific
differ
three
treatment
arm
term
advers
event
includ
special
interest
hepat
renal
function
advers
event
incid
death
treatment
similar
across
treatment
group
conclus
equal
effect
noninferior
ca
primari
efficaci
endpoint
treatment
success
defin
investig
signific
differ
mica
treatment
arm
ca
secondari
endpoint
three
treatment
regimen
similar
safeti
profil
object
compar
efficaci
safeti
micafungin
mica
ambisom
lamb
paediatr
subpopul
larg
randomis
phase
iii
trial
patient
invas
candidiasi
candidaemia
method
doubleblind
multicentr
studi
nonneutropaen
neutropaen
paediatr
patient
age
year
clinic
microbiolog
evid
invas
candidiasi
candidaemia
randomis
receiv
intraven
mica
mgkgday
lamb
mgkgday
minimum
day
randomis
patient
includ
full
analysi
set
fa
efficaci
analys
also
perform
per
protocol
set
pp
includ
patient
confirm
invas
candidiasi
candidaemia
invas
infect
caus
noncandida
fungal
pathogen
investig
assess
overal
treatment
success
end
therapi
eot
avail
receiv
least
five
dose
studi
drug
receiv
prohibit
antifung
medic
safeti
set
includ
fa
patient
overal
treatment
success
base
clinic
mycolog
respons
end
therapi
assess
investig
posttreat
followup
period
week
result
total
patient
mica
lamb
patient
includ
fa
patient
includ
pp
age
group
includ
prematur
birth
well
repres
candidaemia
primari
infect
major
patient
treatment
group
key
efficaci
result
shown
tabl
incid
treatmentrel
advers
event
ae
lower
mica
lamb
versu
respect
incid
seriou
ae
versu
respect
addit
fewer
patient
receiv
mica
lamb
discontinu
therapi
ae
versu
respect
one
ciproresist
isol
mic
isol
ciprotr
subject
levo
subject
clinic
success
failur
cipro
subject
clinic
success
failur
outcom
unknown
urin
pathogen
erad
unknown
levo
subject
compar
erad
persist
unknown
ciprotr
subject
repeat
blood
cultur
obtain
levo
cipro
subject
blood
pathogen
erad
subject
one
ciprotr
subject
blood
pathogen
presum
persist
base
clinic
failur
outcom
ciproresit
e
coli
unknown
conclus
overal
popul
cuti
ap
cuti
ap
cohort
dose
levo
noninferior
dose
cipro
levo
cipro
erad
blood
pathogen
subject
blood
cultur
approxim
twothird
patient
usa
remaind
recruit
canada
australia
south
africa
russia
variou
countri
across
europ
asia
south
america
patient
infect
due
mrsa
tend
younger
year
age
greater
proport
black
race
compar
patient
infect
due
mrsa
nonmrsa
tabl
mrsa
commonli
associ
major
abscess
wherea
nonmrsa
commonli
associ
deepextens
cellul
regardless
mrsa
statu
csssi
occur
frequent
lower
extrem
conclus
togeth
atla
repres
largest
prospect
doubleblind
studi
ever
conduct
patient
csssi
mrsa
cohort
also
largest
ever
enrol
registr
programm
mrsa
infect
appear
common
patient
younger
black
racial
origin
major
abscess
compar
patient
infect
due
mrsa
object
use
aminoglycosid
decreas
due
doubt
regard
lack
efficaci
advers
effect
yet
preval
microbi
resist
aminoglycosid
remain
low
studi
sought
compar
efficaci
advers
effect
aminoglycosid
singl
antibiot
antibiot
treatment
patient
infect
search
randomis
trial
compar
efficaci
aminoglycosid
antibiot
treatment
nonaminoglycosid
antibiot
patient
infect
cochran
librari
medlin
embas
lilac
databas
ongo
trial
confer
proceed
two
review
assess
trial
elig
qualiti
extract
data
pool
rel
risk
rr
confid
interv
ci
calcul
dichotom
data
conclud
three
major
clone
readili
demarc
baumannii
member
molecular
diagnost
could
develop
identifi
rapidli
analysi
recombinationmut
rate
show
nucleotid
chang
recombin
frequent
mutat
show
recombin
unlik
disrupt
clonal
frame
clone
therefor
expect
stabl
long
period
time
object
molecular
epidemiolog
studi
clinic
relev
microorgan
frequent
focu
comparison
assign
type
differ
type
method
therefor
critic
need
understand
correspond
type
produc
differ
method
may
use
comparison
genet
background
particular
set
isol
studi
also
produc
broader
view
result
differ
type
method
relat
achiev
goal
framework
measur
quantit
comparison
type
method
result
develop
et
al
illustr
common
framework
relat
multipl
type
method
applic
macrolideresist
streptococcu
pyogen
j
clin
microbiol
implement
freeaccess
webbas
interfac
user
analys
data
anonym
retriev
result
method
facilit
use
framework
develop
webbas
interfac
implement
provid
research
userfriendli
interfac
compar
type
method
result
websit
also
provid
set
bionumer
tm
script
allow
user
implement
propos
analysi
bionumer
databas
offlin
webbas
interfac
bionumer
script
allow
calcul
sever
measur
simpson
index
divers
confid
interv
access
divers
type
result
differ
method
adjust
rand
wallac
coeffici
bidirect
unidirect
respect
comparison
result
two
type
method
result
base
measur
user
quantit
evalu
discriminatori
power
type
methodolog
use
concord
webbas
interfac
bionumer
script
provid
user
abil
quantit
assess
correspond
type
method
result
use
evalu
predict
power
type
methodolog
compar
anoth
guid
user
choic
gold
standard
clone
definit
furthermor
new
microbi
type
method
propos
methodolog
allow
comparison
term
type
assign
establish
methodolog
despit
sever
case
control
studi
enhanc
surveil
human
case
anim
environment
isol
still
much
unknown
epidemiolog
campylobact
infect
describ
multiag
project
evalu
util
sequenc
type
human
infect
isol
inform
surveil
distinguish
environment
sourc
human
infect
multilocu
sequenc
type
mlst
develop
c
jejuni
c
coli
appli
human
case
isol
four
local
author
north
west
england
two
larg
rural
two
larg
urban
continu
period
isol
drink
water
suppli
recreat
surfac
water
also
sequenc
type
describ
analysi
three
year
studi
data
step
taken
adapt
methodolog
use
routin
surveil
set
studi
demonstr
sever
interest
correl
specif
sequenc
type
number
explanatori
variabl
diseas
eg
month
infect
local
resid
travel
abroad
studi
provid
increas
evid
hostassoci
specif
mlst
type
campylobact
find
relat
three
year
dataset
addit
mani
new
type
describ
surfac
water
project
evid
distinct
waterborn
popul
far
describ
human
infect
recent
year
use
cell
cultur
molecular
biolog
deepli
chang
knowledg
rickettsia
matter
fact
pathogen
rickettsi
speci
identifi
new
rickettsi
diseas
found
main
condit
place
none
identifi
typic
rickettsi
diseas
includ
fever
rash
found
japan
china
place
typic
rickettsios
could
caus
differ
organ
case
new
rickettsia
misdiagnos
previous
identifi
bacterium
r
massilia
r
conorii
case
atyp
clinic
find
found
rash
fever
caus
rickettsi
organ
r
slovaca
r
helvetica
find
challeng
old
dogma
postul
one
tick
born
rickettsiosi
preval
one
geograph
area
mani
year
exampl
r
rickettsii
agent
rocki
mountain
spot
fever
consid
spot
fever
group
rickettsia
usa
ticktransmit
rickettsiosi
america
r
feli
fleatransmit
spot
fever
r
parkeri
ticktransmit
spot
fever
shown
sinc
infect
human
be
usa
urugay
moreov
r
africa
found
patient
west
indi
mani
rickettsia
identifi
tick
current
found
patient
rickettsia
consid
potenti
pathogen
new
find
stimul
investig
identifi
new
rickettsi
diseas
patient
atyp
rash
fever
arthropod
bite
target
skin
biopsi
prefer
sampl
purpos
molecular
test
use
purpos
propos
pharmacokineticpharmacodynam
paramet
drive
dose
regimen
less
vulner
resist
pharmacokineticpharmacodynam
paramet
drive
dose
regimen
less
vulner
resist
pro
recent
year
rule
select
antimicrobi
agent
undergo
critic
revis
term
optimum
dose
control
infecti
diseas
goal
potenti
treatment
efficaci
reduc
risk
select
multidrug
resist
pathogen
import
criterion
ration
choic
antimicrobi
agent
defin
pharmacodynam
pd
characterist
thu
antimicrobi
activ
summaris
minimum
inhibitori
concentr
mic
minimum
bactericid
concentr
mbc
second
criterion
select
antibiot
due
pharmacokinet
pk
characterist
sinc
demonstr
antibiot
concentr
infect
site
influenc
intens
durat
effect
togeth
pd
paramet
provid
gener
interrelationship
contribut
defin
potenti
clinic
efficaci
drug
pharmacodynam
upgrad
last
year
vitro
anim
model
help
identifi
fairli
precis
correl
therapeut
efficaci
antibiot
moreov
principl
link
concentr
antibiot
human
effect
outlin
order
determin
optim
dose
interv
antimicrobi
drug
concentrationdepend
activ
ie
newer
quinolon
aminoglycosid
administ
singl
daili
dose
maximis
peak
serum
concentrationm
ratio
aucmic
ratio
also
import
paramet
pkpd
correl
exist
data
fluoroquinolon
suggest
ratio
correl
high
bacteri
erad
optim
clinic
outcom
infect
due
gramneg
pathogen
ratio
associ
high
probabl
erad
pneumonia
strain
group
antibiot
new
concept
call
mutant
prevent
concentr
mpc
mutant
select
window
msw
may
help
restrict
enrich
mutant
subpopul
consequ
least
partial
control
spread
resist
betalactam
timedepend
efficaci
usual
great
post
antibiot
effect
pae
paramet
seem
better
correl
pd
pk
time
durat
concentr
higher
mic
mic
antibiot
need
given
short
dose
interv
even
continu
infus
maintain
plasma
level
exceed
mic
suffici
long
period
summari
theoret
optimis
dosag
regimen
antibiot
dose
administr
rout
interv
dose
clinic
practic
correl
pk
pd
pertain
antibiot
class
base
experiment
anim
studi
pkpd
paramet
may
contribut
contain
resist
drug
class
especi
import
one
use
seriou
infect
intens
care
patient
bartoloni
florenc
antibiot
commonli
purchas
class
drug
lowresourc
countri
infecti
diseas
extrem
frequent
bacteri
infect
major
caus
death
especi
childhood
phenomenon
microbi
drug
resist
repres
global
public
health
problem
particularli
seriou
countri
resist
rate
even
higher
industrialis
countri
therapeut
option
often
unavail
expens
surveil
antibiot
suscept
key
element
provid
updat
inform
magnitud
trend
resist
plan
monitor
intervent
strategi
aim
preserv
therapeut
efficaci
antibiot
lowresourc
countri
effect
surveil
programm
difficult
implement
number
reason
includ
scarc
financi
resourc
lack
laboratori
facil
laboratori
exist
lack
qualiti
control
reliabl
reagent
adequ
supervis
set
develop
reliabl
lowcost
altern
method
could
facilit
implement
largescal
surveil
increas
agreement
import
extend
surveil
antibiot
resist
commens
microbiota
human
anim
bacteri
popul
although
specif
target
continu
expos
select
pressur
gener
antimicrobi
chemotherapi
may
becom
potenti
reservoir
resist
strain
caus
infect
resist
determin
transfer
pathogen
bacteria
therefor
surveil
antibioticresist
bacteria
carri
healthi
individu
consid
indic
spread
antibiot
resist
could
also
use
predict
emerg
resist
pathogen
bacteria
perspect
resist
pattern
member
commens
microbiota
faecal
escherichia
coli
evalu
variou
epidemiolog
set
purpos
differ
microbiolog
approach
implement
evalu
use
tool
conduct
larg
scale
resist
surveil
studi
monitor
resist
control
programm
costeffect
manner
emerg
extendedspectrum
blactamas
esbl
enterobacteriacea
mark
import
turn
point
routin
laboratori
diagnost
soon
discoveri
phenotyp
method
develop
detect
confirm
confirm
depend
larg
abil
clavulan
inhibit
main
culprit
enzym
time
tem
shv
variant
later
techniqu
prove
reliabl
ctxm
type
enzym
mani
suscept
test
method
recommend
use
esbl
screen
confirm
test
routin
basi
includ
clsi
bsac
casfm
srga
howev
number
issu
emerg
routin
use
year
problem
defin
adequ
number
substrat
ensur
suffici
sensit
screen
ideal
one
includ
minimum
name
cefpodoxim
ceftazidim
ceftriaxon
cefotaxim
aztreonam
concentr
often
differ
use
suscept
breakpoint
lack
reliabl
phenotyp
method
detect
esbl
speci
induc
ampc
blactamas
speci
shown
import
reservoir
esbl
resist
extendedspectrum
cephalosporin
sole
attribut
stabl
derepress
ampc
failur
current
method
provid
advic
interpret
posit
screen
test
neg
confirm
test
especi
isol
suscept
extendedspectrum
cephalosporin
use
methodrecommend
breakpoint
strain
shown
harbour
oxa
enzym
inhibitorresist
tem
enzym
particularli
plasmidborn
ampc
enzym
signific
frequenc
thu
current
phenotyp
genotyp
test
practic
effect
appli
routin
laboratori
suffici
sensit
detect
emerg
rang
transmiss
enzym
howev
reli
great
extent
select
chang
appropri
suscept
breakpoint
rang
recent
studi
suggest
failur
treatment
extendedspectrum
cephalosporin
like
strain
enterobacteriacea
mic
elev
wildtyp
applic
pharmacokineticpharmacodynam
pkpd
principl
wide
recommend
dose
schedul
cephalosporin
suggest
suscept
breakpoint
recommend
mani
method
high
lower
valu
fortun
coincid
wildtyp
cutoff
valu
henc
lower
suscept
breakpoint
extendedspectrum
cephalosporin
defin
pkpd
indic
presenc
esbl
plasmidborn
ampc
enzym
suffici
high
likelihood
allow
laboratori
report
resist
agent
provid
advic
appropri
infect
control
procedur
object
sinc
antibiot
resist
often
associ
biolog
fit
cost
bacteria
assum
reduct
antibiot
use
follow
reduct
resist
rate
last
year
trimethoprim
tri
resist
escherichia
coli
increas
sweden
kronoberg
counti
tri
resist
increas
antibiot
usag
far
prospect
intervent
commun
carri
investig
whether
substanti
decreas
use
singl
antibiot
result
correspond
decreas
antibiot
resist
method
materi
physician
n
counti
kronoberg
approx
popul
sweden
convinc
person
visit
mail
ceas
use
tri
cotrimoxazol
two
year
start
octob
monthli
sale
data
oral
antibiot
retriev
nation
corpor
swedish
pharmaci
made
known
physician
e
coli
isol
urinari
tract
specimen
dept
clin
microb
includ
analysi
suscept
test
methodolog
stabl
sinc
baselin
consist
quantit
data
order
studi
divers
among
isol
e
coli
period
preced
isol
end
intervent
phenotyp
use
pheneplatetm
system
result
immedi
sustain
decreas
total
use
tri
achiev
tri
use
case
replac
mecillinam
mec
nitrofurantoin
nit
ciprofloxacin
total
decreas
antibiot
use
uti
treatment
resist
tri
decreas
respect
resist
nit
mec
increas
despit
substanti
increas
use
drug
respect
resist
fluoroquinolon
fq
increas
phenotyp
divers
index
period
prior
intervent
first
month
last
month
intervent
conclus
substanti
sustain
decreas
use
tri
popul
result
drastic
chang
resist
rate
whether
increas
fqresist
relat
increas
use
remain
evalu
divers
index
base
e
coli
phenotyp
stabl
indic
intervent
favour
certain
clone
expand
commun
object
increas
use
antibiot
spread
resist
pneumococc
clone
begin
alarm
medic
profess
medic
author
sweden
coordin
effort
prevent
spread
preserv
effect
antimicrobi
agent
therefor
initi
method
strama
swedish
strateg
programm
ration
use
antimicrobi
agent
surveil
resist
initi
strama
network
includ
broad
represent
medic
disciplin
profession
organis
relev
author
programm
includ
surveil
antibiot
use
resist
implement
ration
use
antibiot
develop
new
knowledg
main
goal
preserv
effect
antimicrobi
agent
result
yearli
valid
data
antibiot
use
resist
made
publicli
avail
websit
multidisciplinari
stramagroup
form
counti
dissemin
knowledg
implement
ration
antibiot
use
studi
perform
indic
antibiot
use
outpati
care
hospit
care
nurs
home
antibiot
use
outpati
decreas
dddtid
prescript
per
inhabit
year
reduct
promin
children
year
old
macrolid
period
number
hospit
admiss
acut
mastoid
rhinosinus
quinsi
stabl
declin
although
epidem
spread
southern
sweden
penicillinresist
pneumonia
curb
nation
frequenc
increas
hospit
outbreak
mrsa
could
termin
use
aggress
infectioncontrol
measur
resist
remain
low
bacteri
speci
period
conclus
multidisciplinari
coordin
programm
contribut
reduct
antibiot
use
without
measur
neg
consequ
despit
antibiot
resist
sever
bacteri
speci
slowli
increas
call
continu
sustain
effort
preserv
effect
avail
antibiot
effort
includ
intervent
improv
antibiot
use
improv
complianc
basic
hygien
precaut
protocol
design
present
demograph
data
well
amount
indic
antimicrobi
agent
bacteria
treatment
record
relat
diagnos
prophylact
use
commun
acquir
cai
hospit
acquir
infect
hai
predefin
diagnosi
group
use
previous
present
strama
protocol
webbas
report
system
use
result
hospit
particip
studi
patient
treat
antimicrobi
agent
includ
admit
patient
treat
antimicrobi
treatment
record
given
children
year
women
indic
treatment
cai
hai
prophylaxi
adult
cultur
taken
parenter
treatment
oral
treatment
commonli
use
antimicrobi
adult
ddd
treatment
prophylaxi
penicillin
betalactamas
inhibitor
cephalosporin
fluoroquinolon
total
amount
antimicrobi
use
adult
admit
patient
two
diagnosi
group
predomin
pneumonia
therapi
skin
soft
tissu
infect
analysi
antibiot
usag
differ
countri
show
countri
mainli
penicillin
betalactamas
inhibitor
cephalosporin
predomin
drug
seven
countri
show
vari
use
drug
pattern
treatment
prophylact
usag
similar
countri
heavi
use
one
atcclass
length
periop
prophylaxi
domin
day
surgic
special
gener
surgeri
orthopaed
surgeri
urolog
ent
onedos
periop
prophylaxi
rang
oneday
prophylaxi
orthopaed
surgeri
studi
describ
wide
differ
three
fold
consumpt
european
hospit
periop
prophylaxi
long
surgic
special
limit
variat
use
differ
antibiot
group
hospit
risk
factor
emerg
antibiot
resist
webbas
pp
provid
tool
qualiti
assess
antibiot
prescrib
european
hospit
method
face
face
structur
interview
conduct
countri
austria
netherland
sweden
uk
belgium
itali
malta
israel
czech
republ
lithuania
croatia
studi
popul
includ
respond
previou
survey
agre
interview
aim
recruit
least
respond
countri
includ
group
user
selfmed
nonus
scale
group
base
theoret
concept
confirm
factor
analysi
four
scale
attitud
toward
appropri
selfmed
antibiot
bronchiti
belief
antibiot
minor
ailment
attitud
toward
situat
use
antibiot
knowledg
antibiot
virus
bacteria
knowledg
antibiot
resist
measur
openend
question
analysi
deal
possibl
confound
effect
use
selfmed
educ
perform
stratifi
analys
ie
studi
differ
countri
separ
user
nonus
selfmed
respond
high
low
educ
differ
countri
consid
relev
regress
coeffici
signific
stratumspecif
analys
object
antimicrobi
resist
ciprofloxacin
valuabl
secondlin
antibiot
increas
limit
increas
appropri
use
ciprofloxacin
encourag
object
studi
reduc
number
inappropri
prescript
improv
qualiti
ciprofloxacin
prescript
way
educ
intervent
method
five
unit
bed
depart
intern
medicin
gastroenterolog
surgeri
urolog
pulmonari
diseas
select
high
rate
ciprofloxacin
prescript
particip
prospect
intervent
studi
studi
compris
three
period
three
month
observ
period
phase
intervent
period
phase
follow
month
done
month
start
intervent
two
observ
period
ciprofloxacin
prescript
regist
qualiti
ciprofloxacin
prescript
evalu
standardis
manner
two
expert
infecti
diseas
independ
intervent
period
physician
prescrib
ciprofloxacin
interview
medic
microbiologist
educ
present
given
physician
particip
unit
result
phase
prescript
per
admiss
ciprofloxacin
written
declin
prescript
per
admiss
phase
reduct
greatest
reduct
observ
unit
depart
surgeri
urolog
respect
mainli
due
reduct
errat
prophylact
use
unjustifi
prescript
use
antibiot
indic
decreas
inappropri
prescript
wrong
choic
antibiot
durat
prescript
declin
mainli
due
decreas
ciprofloxacin
cours
long
durat
appropri
prescript
increas
nine
month
intervent
prescript
per
admiss
ciprofloxacin
prescrib
total
reduct
intervent
direct
consult
medic
microbiologist
educ
present
led
signific
reduct
use
ciprofloxacin
improv
qualiti
ciprofloxacin
prescript
nine
month
intervent
use
ciprofloxacin
declin
even
indic
sustain
effect
intervent
measur
trend
toward
greater
rise
creatinin
group
versu
group
final
creatinin
increas
vs
baselin
p
revers
stop
studi
drug
treatment
mortal
week
differ
two
group
conclus
amphotericin
b
flucytosin
rapidli
fungicid
treatment
hivassoci
cryptococc
mening
compar
standard
dose
amphotericin
b
increas
dose
amphotericin
b
result
clinic
signific
increas
nephrotox
case
diagnos
cultur
confirm
restrict
fragment
length
polymorph
c
gattii
hiv
neg
case
diagnos
serolog
histopatholog
exposur
intern
endem
area
includ
case
report
provinci
author
interview
determin
clinic
present
epidemiolog
characterist
frequenc
calcul
base
denomin
avail
use
spss
novemb
case
locallyacquir
case
c
gattii
infect
occur
bc
annual
provinci
averag
casesmillion
popul
mean
age
year
year
male
case
asymptomat
dermatolog
find
common
symptom
includ
cough
short
breath
fever
night
sweat
chest
xray
reveal
nodul
case
infiltr
case
case
oral
steroid
year
prior
diagnosi
current
smoker
hiv
posit
organ
transplant
recipi
chronic
lung
diseas
histori
cancer
case
cultureconfirm
c
gattii
isol
genotyp
vgiia
case
die
due
c
gattii
infect
case
treat
fluconazol
amphotericin
b
sever
month
case
expos
vancouv
island
rang
fungu
spread
year
recent
case
expos
bc
mainland
clinician
awar
c
gattii
acquir
canada
epidemiolog
clinic
characterist
diseas
differ
c
neoforman
object
incid
invas
zygomycosi
iz
appear
increas
especi
patient
treat
haematolog
malign
present
biolog
marker
exsist
facilit
earli
diagnosi
one
reli
convent
diagnost
method
cultur
lack
sensit
investig
presenc
zygomyceteantigen
zag
zygomycet
dna
bronchoalveolar
lavag
fluid
balf
patient
document
iz
risk
diseas
method
balf
neutropaen
patient
underw
bronchoscopi
suspicion
invas
fungal
infect
ifi
investig
presenc
watersolubl
somat
zag
immunoblot
commerci
avail
monoclon
antibodi
antirhizomucor
dakocytom
denmark
five
patient
proven
iz
remain
patient
without
document
iz
proven
probabl
invas
aspergillosi
ia
balf
nonhaematolog
patient
use
control
balf
sampl
also
investig
presenc
zygomycet
dna
pcr
use
primer
result
balf
patient
proven
iz
posit
zag
remain
neutropaen
patient
zag
detect
balf
four
probabl
proven
ia
number
zag
posit
balf
neutropaen
patient
suspect
ifi
higher
control
group
versu
p
zygomycet
dna
detect
balf
sampl
posit
zag
balf
sampl
neg
zag
also
neg
zygomycet
dna
pcr
conclus
zag
zygomycet
dna
present
balf
patient
iz
might
use
tool
earli
diagnosi
presenc
marker
balf
sampl
highrisk
patient
without
clinic
manifest
diseas
might
indic
presenc
colonis
subclin
infect
result
strain
test
abl
form
biofilm
media
test
howev
differ
detect
differ
media
isol
abl
form
biofilm
faster
middlebrook
surfac
cover
day
strain
tap
water
surfac
cover
day
strain
day
none
strain
cover
surfac
use
glucos
differ
found
speci
biofilm
develop
conclus
nprgm
test
abl
develop
biofilm
test
media
biofilm
develop
depend
type
cultur
media
faster
rich
media
use
differ
detect
biofilm
develop
among
differ
speci
acknowledg
tj
kinnari
fund
grant
academi
finland
n
zamora
fund
grant
conchita
de
madrid
spain
vitro
sessil
bacteria
gapb
express
high
medium
low
fe
content
irrespect
glucos
content
simultan
increas
express
gapb
pia
product
could
visualis
clsm
sessil
bacteria
media
vivo
express
gapa
high
remain
constant
period
two
week
express
gapb
decreas
initi
phase
implant
reach
express
level
gapa
two
week
implant
persist
express
gapa
sessil
bacteria
could
indic
role
biofilm
format
especi
earli
stage
express
level
gapb
could
indic
role
later
phase
biofilm
format
result
gene
express
clsm
indic
link
gapb
pia
product
influenc
fe
glucos
exampl
ssp
surfaceassoci
lipas
aa
autolysin
adhesin
sdri
collagen
bind
protein
ureas
activ
purportedli
uropathogen
saprophyticu
attribut
abil
cope
high
rang
variat
saltand
ureaconcentr
human
urin
aim
studi
elucid
virul
factor
uropathogen
method
bacteri
growth
examin
differ
condit
use
modifi
model
artifici
urin
previous
describ
bacteri
aggreg
observ
bright
light
electron
micrograph
biofilm
format
test
use
nativ
polystyren
crystallin
precoat
microtit
plate
result
saprophyticu
strain
ccm
contrast
wildtyp
strain
generationtim
increas
saprophyticu
wildtyp
strain
bacteri
aggreg
appear
near
larg
crystal
structur
contrast
ureas
neg
deriv
strain
wild
type
strain
ccm
nativ
polystyren
crystallin
precoat
microtit
plate
biofilm
format
observ
strain
contrast
strain
ccm
biofilm
format
saprophyticu
seem
independ
agr
ssp
sdri
sinc
differ
knockout
mutant
wild
type
strain
observ
conclus
bacteri
aggreg
could
due
increas
adhes
lipas
activ
may
modul
hydrophob
ca
bind
higher
local
ca
concentr
well
strengthen
bacteri
aggreg
may
lead
increas
crystal
format
bacteria
may
adher
crystal
addit
later
mechan
due
biofilm
format
crystallis
process
bacteria
embed
crystal
structur
may
new
model
infecti
stone
genesi
studi
strongli
suggest
saprophyticu
wildtyp
strain
ccm
lack
import
virul
factor
contrast
wildtyp
strain
biofilm
format
may
play
import
role
saprophyticu
urinari
tract
infect
object
influenc
biofilm
format
catheterrel
candidiasi
establish
shown
develop
biofilm
colonis
yeast
confer
resist
antifung
purpos
work
demonstr
product
candida
albican
yeast
grow
biofilm
molecul
abl
reduc
biofilm
growth
method
vitro
model
c
albican
biofilm
associ
silicon
cathet
use
supernat
medium
recov
c
albican
atcc
biofilm
age
hour
ad
cours
new
biofilm
format
made
c
albican
strain
atcc
influenc
subsequ
evalu
xtt
method
ultrafiltr
purif
assay
characteris
modul
fungal
molecul
respons
biofilm
supernat
activ
present
studi
result
addit
supernat
adher
c
albican
cell
induc
signific
p
inhibit
biofilm
growth
activ
observ
supernat
ad
preform
biofilm
ultrafiltr
purif
assay
demonstr
molecul
small
da
hydrophil
conclus
preliminari
result
suggest
new
molecul
natur
produc
within
yeast
commun
could
good
candid
prevent
biofilm
associ
indwel
medic
devic
first
articl
describ
earli
secret
antigen
cultur
filtrat
tuberculosi
publish
three
key
properti
antigen
highli
immunogen
found
bcg
mani
environment
mycobacteria
key
virul
factor
immunogen
specif
led
seri
studi
assess
potenti
major
compon
new
diagnost
test
test
evolv
two
major
formsa
whole
blood
assay
market
name
quantiferon
elispot
assay
market
name
tspot
new
antigen
assess
improv
test
perform
notabl
studi
inhous
version
assay
recent
commerci
kit
shown
encourag
result
tb
case
diagnosi
diseas
close
contact
diagnosi
tuberculosi
infect
clear
test
confound
prior
bcg
vaccin
probabl
subject
boost
inject
tuberculin
quantit
readout
may
also
provid
import
inform
respect
infecti
load
howev
find
caus
concern
dispar
test
perform
temper
nontb
endem
tropic
tbendem
set
evid
rel
poor
sensit
presenc
certain
tuberculosi
strain
eg
africanum
certain
subgroup
eg
pulmonari
tb
certain
tb
contact
rapid
unexplain
test
revers
therefor
becom
clear
cell
assay
may
nich
diagnosi
certain
tb
case
certain
individu
suspect
tuberculosi
infect
nich
yet
fulli
defin
longitudin
studi
especi
follow
tb
case
contact
develop
diseas
indic
also
studi
undertaken
tb
endem
area
final
test
role
tb
control
global
would
need
much
cheaper
easi
use
advanc
respect
two
issu
alreadi
taken
place
last
ten
year
unpreced
progress
made
treatment
hiv
infect
applic
combin
antiretrovir
therapi
cart
three
class
drug
contribut
success
nucleosid
nrti
nonnucleosid
nnrti
revers
transcriptas
inhibitor
proteas
inhibitor
pi
advent
fusion
inhibitor
enfuvirtid
field
open
new
class
drug
last
year
whole
bundl
drug
new
target
studi
human
among
develop
compound
antagonist
integras
inhibitor
class
earlier
phase
clinic
develop
includ
attach
inhibitor
matur
inhibitor
expect
integras
inhibitor
introduc
clinic
practic
drug
class
first
studi
heavili
treatment
experienc
patient
fail
nrti
nnrti
pi
therapi
preliminari
analys
integras
inhibitor
combin
optimis
background
treatment
obt
shown
clinic
superior
obt
alon
patient
treat
reach
complet
viral
suppress
hivrna
cml
week
preliminari
data
also
suggest
high
virolog
potenc
drug
treatment
patient
appli
bid
well
toler
pretreat
treatment
patient
two
antagonist
current
studi
clinic
trial
maraviroc
vicriviroc
vicriviroc
togeth
obt
shown
superior
obt
alon
treatment
experienc
patient
fail
phase
ii
studi
treatment
patient
presum
due
matter
dose
studi
defin
optim
dose
togeth
ritonavir
boost
underway
maraviroc
result
studi
treatment
experienc
patient
exhibit
dual
tropic
viru
avail
popul
maraviroc
show
addit
virolog
efficaci
placebo
lead
greater
increas
cell
conclus
new
drug
new
class
improv
treatment
option
patient
multiresist
hiv
consider
sinc
drug
seem
well
toler
also
potenti
use
treatment
patient
futur
antiretrovir
therapi
highli
effect
control
hiv
replic
induc
immun
reconstitut
prevent
aidsrel
morbid
mortal
current
antiretrovir
regimen
howev
achiev
viru
erad
virolog
rebound
virtual
alway
occur
therapi
discontinu
longterm
highli
activ
antiretrovir
therapi
haart
life
save
pose
sever
challeng
potenti
advers
event
categoris
problem
relat
adher
pharmacokinet
toxic
drug
resist
variou
intervent
explor
improv
maintain
good
adher
among
treat
individu
rang
treatment
simplif
strategi
address
mental
health
problem
major
challeng
relat
need
integr
biomed
social
behaviour
intervent
inadequ
adher
howev
account
subset
subtherapeut
drug
level
clinic
practic
signific
degre
interindividu
variabl
absorpt
metabol
cellular
transport
antiretrovir
drug
potenti
impact
efficaci
toxic
therapi
import
determin
includ
gender
age
ethnic
origin
genet
polymorph
although
evid
influenc
pharmacogenom
grow
remain
limit
data
guid
clinic
practic
proton
pump
inhibitor
exampl
commonli
prescrib
medic
affect
antiretrovir
drug
level
reduc
absorpt
certain
proteas
inhibitor
pi
increas
exposur
other
herbal
medicin
st
john
wort
wide
use
hiv
patient
also
potenti
interact
antiretrovir
drug
thu
patient
educ
good
commun
across
care
provid
paramount
prevent
unfavour
drugdrug
interact
risk
toxic
associ
longterm
antiretrovir
therapi
difficult
predict
reliabl
age
popul
hivinfect
person
major
exampl
haartrel
toxic
includ
mitochondri
damag
lipoatrophi
associ
use
nucleo
ide
revers
transcriptas
inhibitor
nrti
fat
accumul
dyslipidaemia
insulin
resist
associ
proteas
inhibitor
pi
risk
cardiovascular
diseas
particular
concern
due
combin
effect
cardiovascular
system
hiv
infect
haart
lifestyl
relat
risk
factor
smoke
common
among
hivinfect
person
addit
renal
hepat
bone
toxic
repres
emerg
side
effect
longterm
treatment
patient
start
therapi
recommend
firstlin
regimen
achiev
high
degre
virolog
immunolog
success
howev
drug
resist
continu
emerg
result
problem
adher
toler
furthermor
remain
larg
number
hivinfect
person
accumul
drug
resist
mono
dual
therapi
prehaart
era
suboptim
use
therapi
earli
haart
era
addit
substanti
proport
newli
infect
person
acquir
drugresist
viru
new
drug
drug
class
requir
optimis
treatment
among
drugexperienc
person
reduc
risk
side
effect
sever
new
compound
recent
enter
clinic
use
show
improv
toler
profil
activ
drug
resist
viru
improv
method
detect
interpret
drug
resist
also
develop
adequ
guid
treatment
spite
concern
howev
benefit
haart
far
outweigh
risk
advers
event
result
strongli
suggest
keratinocyt
abl
produc
cytokin
respons
l
major
stimul
aspergillu
fumigatu
termotoler
saprophyt
associ
wide
spectrum
diseas
human
includ
saprophyt
colonis
preexist
caviti
allerg
asthma
allerg
bronchopulmonari
aspergillosi
occur
complic
bronchial
asthma
cystic
fibrosi
invas
aspergillosi
immunocompromis
patient
immunocompet
nonatop
subject
rel
resist
fumigatu
diseas
diseas
occur
set
host
damag
inher
resist
diseas
caus
fumigatu
suggest
occurr
regulatori
mechan
provid
host
adequ
defenc
without
necessarili
elimin
fungu
caus
unaccept
level
host
damag
respiratori
toler
mediat
plasmacytoid
dendrit
cell
produc
induc
develop
regulatori
cell
express
regul
inflamm
allergi
indoleamin
ido
depend
pathway
thu
idodepend
pathway
uniqu
e
central
role
process
particip
effector
induct
phase
immun
toler
fungu
vaccinia
viru
vacv
vaccin
use
erad
smallpox
like
poxvirus
vacv
larg
dna
viru
replic
cytoplasm
produc
multipl
infecti
form
viru
encod
mani
virul
factor
nonessenti
viru
replic
cell
cultur
mani
virul
factor
encod
termin
region
viru
genom
call
immunomodul
interfer
host
respons
infect
immunomodul
present
within
infect
cell
inhibit
signal
pathway
induc
ligand
engag
cytokin
interferon
toll
like
receptor
molecul
inhibit
pathway
lead
induct
apoptosi
talk
describ
protein
vacv
inhibit
apoptosi
intracellular
signal
pathway
lead
induct
interferon
proinflammatori
cytokin
studi
illustr
studi
structur
function
molecul
increas
understand
viru
pathogenesi
cell
biolog
current
trend
parasitolog
european
consensu
malaria
chemoprophylaxi
everi
year
sever
thousand
malaria
case
mortal
around
report
europ
visit
friend
rel
vfr
particular
risk
complex
situat
malaria
transmiss
variou
endem
area
requir
differenti
recommend
malaria
prophylaxi
malaria
prophylaxi
compris
multipl
compon
malaria
risk
reduc
compliant
exposur
prevent
chemoprophylact
drug
travel
high
risk
area
avail
key
point
malaria
prevent
manag
includ
awar
endem
region
return
avoid
mosquito
bite
complianc
chemoprophylaxi
seek
immedi
diagnosi
therapi
case
fever
import
exposur
prophylaxi
emphas
recommend
use
mosquito
repel
dusk
especi
outdoor
activ
perform
lightcolour
loosefit
insecticidetr
cloth
long
trouser
long
sleev
suggest
sleep
insecticid
treat
bed
net
aircondit
room
pretreat
insecticid
knockdown
spray
recommend
chemoprophylaxi
recommend
high
risk
area
set
either
mefloquin
lariam
atovaquoneproguanil
malaron
doxycyclin
monohydr
use
german
speak
countri
emerg
treatment
recommend
trip
region
low
intermedi
malaria
risk
strategi
recommend
infect
risk
lower
risk
sever
drug
side
effect
good
inform
consult
doctor
person
respons
travel
essenti
correct
handl
emergencyselftreat
drug
use
includ
artemetherlumefantrin
riamet
atovaquoneproguanil
malaron
mefloquin
lariam
guidelin
applic
emergencyselftreat
discuss
thoroughli
travel
make
sure
case
fever
correct
action
taken
case
fever
sudden
onset
rapidli
progress
axillari
temperatur
oral
tympan
rectal
doctor
seen
malaria
blood
test
perform
work
thermomet
essenti
tropic
doctor
seen
within
travel
endem
region
least
day
fever
lower
malaria
emerg
medic
taken
adequ
amount
fluid
everi
case
also
intak
malaria
drug
doctor
must
consult
earliest
possibl
time
term
echinococcosi
describ
two
diseas
markedli
differ
present
behaviour
manag
alveolar
echinococcosi
ae
caus
metacestod
echinococcu
multiloculari
cystic
echinococcosi
ce
e
granulosu
larval
growth
two
bug
differ
separ
malign
ae
benign
ce
thu
current
trend
discuss
separ
ae
recent
european
initi
echinorisk
discov
continu
increas
spread
parasit
final
host
fox
parallel
human
case
observ
region
outsid
known
endem
area
baltic
state
hungari
slowakia
risk
factor
human
farm
longstand
close
contact
dog
initi
asymptomat
liver
diseas
still
rare
central
europ
diagnosi
often
made
late
stage
diseas
anatom
classif
system
use
pnm
adapt
tnm
system
tumour
allow
comparison
disord
time
first
diagnosi
differ
clinic
set
new
foci
discov
chinatibet
preval
rate
affect
popul
imag
techniqu
ultrasound
ct
mri
petct
contribut
much
better
descript
lesion
howev
expertis
radiologist
often
avail
due
low
incid
ae
serolog
help
may
mislead
due
nonstandardis
test
surgeri
anymor
treatment
choic
instead
mani
centr
appli
short
term
cycl
benzimidazol
act
parasitocid
acceler
degener
cyst
other
favour
watch
wait
concept
care
observ
natur
degener
cyst
filari
worm
infect
human
caus
morbid
even
death
develop
countri
tropic
current
antifilari
drug
therapi
target
first
stage
larva
requir
mani
year
annualbiannu
treatment
anoth
problem
control
filari
infect
lack
altern
drug
use
current
mass
drug
administr
programm
resist
develop
wolbachia
endosymbiot
bacteria
found
human
filari
worm
excel
target
discoveri
new
antifilari
drug
requir
worm
embryogenesi
develop
adult
surviv
lymphat
filariasi
onchocerciasi
administr
week
doxyclin
dose
mgday
result
high
macrofilaricid
effect
respect
target
wolbachia
antirickettsi
drug
lead
recommend
doxycyclin
use
individu
basi
may
recommend
area
resist
current
drug
may
develop
evid
elimin
endobacteria
reduc
advers
reaction
current
drug
therapi
even
reduc
earli
stage
lymphat
patholog
also
accru
research
underway
discov
new
drug
prefer
alreadi
approv
use
human
antiwolbachi
activ
work
shorter
time
wide
applic
vancomycin
mic
mgl
respect
studi
abil
adher
fibrinogen
fg
fibronectin
fn
vitro
ii
persist
bloodstream
intraven
inocul
iii
colonis
aortic
veget
rat
iv
multipli
situ
thereaft
v
compet
valv
colonis
inocul
mix
cultur
method
gisa
select
vancomycin
exposur
glycopeptidesuscept
methicillinresist
aureu
agr
type
ii
laboratori
phenotyp
express
resist
vancomycin
stabil
phenotyp
analys
popul
analysi
adher
test
immobilis
fg
fn
rat
catheterinduc
aortic
veget
inocul
cfu
test
strain
rat
kill
h
veget
spleen
cultur
lower
inoculum
infect
veget
record
blood
cultur
drawn
within
first
min
infect
also
compar
coinocul
rifampinresist
variant
parent
discrimin
organ
cultur
result
gisa
mutant
grew
plate
contain
mgl
vancomycin
resist
phenotyp
remain
stabl
passag
drugfre
medium
gisa
parent
strain
adher
similarli
fg
fn
vitro
rat
gisa
clear
faster
blood
p
requir
bacteria
parent
versu
cfu
infect
anim
gisa
also
lower
bacteri
densiti
veget
spleen
coinocul
gisa
produc
similar
veget
densiti
earli
inject
howev
veget
count
parent
increas
h
count
gisa
remain
stabl
conclus
gisa
show
attenu
pathogen
fit
intraveget
growth
rat
experiment
endocard
thu
gisa
phenotyp
global
detriment
infect
might
explain
cluster
immunocompromis
patient
whether
prolong
exposur
glycopeptid
might
restor
pathogen
fit
defect
remain
determin
adult
cystic
fibrosi
cf
patient
chronic
infect
p
aeruginosa
lung
two
major
featur
p
aeruginosa
abil
form
biofilm
becom
mucoid
recent
report
timedepend
reduct
abil
form
biofilm
nonmucoid
p
aeruginosa
isol
cf
patient
obtain
period
year
order
investig
whether
declin
abil
pfgeident
isol
form
biofilm
vitro
correl
pathogen
vivo
nonmucoid
clone
earli
clone
late
clone
embed
algin
instal
lung
five
group
balbc
mice
mice
sacrif
day
infect
experi
evalu
macroscop
lung
patholog
histopatholog
quantit
bacteriolog
cfulung
pulmonari
cytokin
product
surviv
significantli
higher
mice
infect
late
clone
compar
mice
infect
earli
clone
p
macroscop
patholog
dissemin
mice
infect
earli
clone
compar
mice
infect
late
clone
p
inflamm
involv
polymorphonuclear
neutrophil
pmn
present
often
mice
infect
earli
clone
compar
mice
infect
late
clone
p
addit
higher
degre
inflamm
well
mice
athelectasi
observ
infect
earli
clone
p
cfu
higher
mice
infect
earli
clone
compar
mice
infect
later
clone
p
result
anim
treat
probiot
display
reduc
incid
sever
durat
diarrhoea
anim
also
gain
weight
greater
rate
control
anim
mean
faecal
number
salmonella
significantli
reduc
probiotictr
anim
day
post
infect
probiot
mixtur
use
lead
amelior
clinic
sign
salmonella
typhimuriuminfect
pig
earli
cours
infect
significantli
reduc
pathogen
shed
longer
timefram
exact
mechan
remain
fulli
elucid
demonstr
valid
use
commens
lactic
acid
bacteria
strain
prevent
gastrointestin
infect
vitro
vivo
procedur
use
isol
select
bacteria
also
valid
probiot
examin
studi
obviou
interest
involv
pig
product
industri
similar
pig
human
gastrointestin
tract
suggest
probiot
offer
potenti
case
human
salmonellosi
given
methodolog
use
also
like
applic
human
diseas
control
object
plasmidmedi
quinolon
resist
qnr
gene
identifi
enterobacteria
sever
countri
resist
frequent
associ
strain
produc
extendedspectrum
blactamas
esbl
salmonella
resist
quinolon
antimicrobi
becom
increasingli
common
isol
human
england
wale
studi
initi
investig
occurr
gene
isol
human
food
assess
import
public
health
method
panel
isol
enterica
resist
nalidix
acid
concomit
decreas
suscept
ciprofloxacin
mic
mgl
case
human
infect
food
england
wale
screen
presenc
qnra
qnrb
qnr
pcr
isol
qnr
plasmid
test
pcr
gene
esbl
gene
commonli
occur
replicon
strain
posit
qnr
gene
characteris
pfge
result
isol
neg
qnra
qnrb
isol
belong
four
serovar
stanley
typhimurium
virginia
virchow
posit
qnr
isol
stanley
typhimurium
patient
infect
abroad
isol
virginia
patient
travel
abroad
two
isol
virchow
one
import
frozen
chicken
one
patient
associ
seri
infect
qnr
plasmid
transfer
either
conjug
transform
molecular
mass
rang
kb
virginia
kb
stanley
four
six
plasmid
code
addit
resist
two
case
resist
addit
antimicrobi
qnr
plasmid
virchow
isol
similar
size
confer
similar
resist
phenotyp
first
qnr
plasmid
identifi
shigella
flexneri
japan
result
indic
plasmid
quinolon
resist
often
link
resist
appear
enterica
britain
particular
concern
treatment
infect
invas
serovar
virchow
object
rapid
characteris
drugresist
mycobacterium
tuberculosi
mtb
would
use
research
treatment
tuberculosi
tb
mani
import
genet
marker
mtb
identifi
notabl
drug
resist
also
genotyp
bacteri
lineag
adapt
potenti
singl
assay
allow
identif
marker
would
aid
control
effort
multiplex
pcr
unsuit
simultan
amplif
sever
genet
loci
one
reaction
multiplex
ligationdepend
probe
amplif
mlpa
one
primerpair
use
amplif
multipl
genet
target
explor
util
mlpa
screen
tool
rapidli
characteris
mtbstrain
method
mlpa
identifi
multipl
singl
nucleotid
polymorph
snp
amplif
sequencespecif
mlpaprob
rather
target
dna
sensit
ligationstep
ensur
specif
assay
design
mlpaprob
specif
rang
discriminatori
snp
mtb
addit
select
three
sequenc
conserv
region
use
intern
control
quantit
size
mlpaproduct
correspond
specif
snp
target
amplifi
mlpaproduct
identifi
agarosegel
fragment
analysi
use
capillari
electrophoresi
result
probe
initi
valid
dna
refer
strain
probe
combin
singl
mixtur
use
characteris
laboratori
strain
panel
clinic
isol
brazil
peru
netherland
determin
predict
valu
mtbspecif
mlpa
screen
dna
mtbstrain
unknown
genotyp
result
confirm
sequenc
high
correl
sequenc
result
result
obtain
via
mlpa
addit
posit
neg
predict
valu
high
mlpaproduct
clearli
visibl
agaros
gel
shown
mtbspecif
mlpa
possibl
identifi
drug
resist
associ
mutat
mtb
lineag
specif
snp
singl
assay
depend
applic
probe
ad
remov
probemix
make
flexibl
multipurpos
method
mlpa
product
easili
identifi
agarosegel
make
especi
suitabl
screen
tb
lessdevelop
world
base
result
feel
addit
use
mlpa
dna
extract
cultur
perform
mlpa
directli
dna
sputum
sampl
also
feasibl
object
speci
escherichia
coli
compris
four
differ
phylogenet
group
gener
major
infecti
well
colonis
strain
isol
patient
belong
phylogenet
group
yet
known
dispar
fluoroquinolonesuscept
resist
isol
assum
arisen
suscept
popul
small
proport
resist
isol
belong
group
major
belong
group
possibl
explan
dispar
distribut
among
phylogenet
group
work
analys
ciprofloxacinsuscept
resist
icu
isol
phylogenet
group
differ
virul
factor
vf
mutat
frequenc
method
hundr
fortysix
suscept
resist
isol
collect
patient
icu
strain
assign
phylogenet
group
mean
triplex
pcr
protocol
order
compar
isol
differ
group
suscept
similar
larg
number
possibl
suscept
resist
strain
chosen
randomli
group
occurr
differ
vf
determin
use
pcr
summaris
isol
vf
score
moreov
mutat
frequenc
determin
plate
mgl
rifampicin
contain
agar
result
assign
phylogenet
group
confirm
differ
suscept
resist
isol
distribut
among
phylogenet
group
suscept
isol
belong
group
contrast
resist
isol
major
isol
belong
group
vf
score
highest
strain
belong
group
without
signific
differ
suscept
resist
isol
howev
small
signific
differ
median
mutat
rate
isol
differ
group
increas
order
median
mutat
rate
isol
differ
significantli
p
remain
isol
convers
group
isol
conclus
slightli
significantli
reduc
mutat
rate
strain
deep
root
phylogenet
group
might
explan
rare
occurr
among
fluoroquinoloneresist
isol
object
resist
ceftazidim
caz
mostli
emerg
among
enzym
lineag
aim
studi
understand
evolut
caz
resist
among
caz
suscept
esbl
belong
cluster
stepwis
vitro
select
experi
method
gene
clone
plasmid
vector
kanr
use
ecori
psti
restrict
enzym
recombin
plasmid
transform
e
coli
strain
delampc
plasmid
free
hypermut
isogen
strain
mut
transform
correspond
esbl
submit
daili
serial
passag
increas
concentr
caz
fold
respect
mic
plasmid
contain
mutant
obtain
distinct
concentr
transform
cell
select
caz
correspond
mic
mic
caz
cefotaxim
ctx
cefuroxim
cxm
cefepim
fep
amoxicillinclavulan
amx
determin
carri
differ
evolv
nonevolv
recombin
plasmid
blactxm
gene
strain
contain
recombin
plasmid
display
reduc
suscept
caz
sequenc
result
high
frequenc
caz
mutant
detect
transform
test
signific
increment
caz
resist
interestingli
except
two
variant
cxm
concomit
loss
resist
antibiot
test
antagonist
pleiotropi
observ
mutant
contain
new
blactxm
variant
except
evolv
frequent
mutat
found
later
confer
higher
resist
caz
former
howev
chang
determin
lower
decreas
fep
cxm
addit
two
variant
recov
evolv
gene
found
mgl
caz
respect
doubl
mutant
yield
higher
resist
level
caz
ctx
lesser
extent
fep
variant
chang
one
three
polymorph
whose
mutant
obtain
reveal
highest
resist
level
caz
ctx
studi
conclus
work
demonstr
antagonist
relationship
suscept
caz
blactam
antibiot
test
could
secondari
mutat
site
affect
caz
could
involv
reequilibrium
ctxrcazr
coresist
object
fluoroquinolon
fq
r
group
streptococcu
ga
worldwid
predominantli
serotyp
ga
intrins
lowlevel
fqr
due
polymorph
fqbind
region
parc
confer
resist
older
fq
like
ciprofloxacin
cip
new
respiratori
fq
levofloxacin
lev
moxifloxacin
mox
retain
activ
firststep
parc
mutant
although
concern
widespread
use
might
select
secondstep
highlevel
fqr
mutant
lev
mox
introduc
clinic
use
respect
belgium
studi
preval
evolut
fqr
ga
recov
tonsillopharyng
invas
infect
belgium
method
total
isol
collect
provinc
isol
resist
cip
mic
mgml
corrobor
mic
fq
presenc
absenc
reserpin
clonal
studi
pulsedfield
gel
electrophoresi
pfge
emm
type
clonal
isol
cip
mic
mgml
sequenc
mutat
fq
bind
region
parc
gyra
gyrb
pare
result
fqr
ga
increas
predomin
emm
type
form
total
fqr
ga
three
year
isol
togeth
constitut
fqr
ga
isol
cip
mic
mgml
show
previous
identifi
mutat
parc
lead
amino
acid
substitut
chang
gyra
gyrb
pare
howev
throat
isol
recov
old
femal
exhibit
highlevel
resist
cip
mic
mgml
full
resist
lev
mic
mgml
decreas
suscept
mox
mic
mgml
isol
also
show
secondstep
mutat
fqbind
region
gyra
predict
substitut
reserpinesensit
efflux
observ
fqr
ga
conclus
report
dramat
increas
fqr
ga
belgium
probabl
relat
natur
fluctuat
lowlevel
fqr
clone
importantli
describ
first
time
emerg
highlevel
fq
resist
clinic
isol
although
respiratori
fq
usual
therapeut
option
ga
infect
dissemin
parcgyra
doublemut
strain
need
close
monitor
method
replac
phage
type
combin
smaimacrorestrict
analysi
routin
aureu
strain
type
studi
review
type
result
six
month
respect
typeabl
reproduc
discriminatori
power
concord
altern
type
method
method
total
aureu
isol
characteris
polymorph
xregion
protein
gene
sequenc
spa
type
assign
use
ridom
staphtyp
softwar
algorithm
burp
base
upon
repeat
pattern
use
cluster
result
spa
type
differ
group
verifi
result
subset
isol
subject
smaimacrorestrict
analysi
mlst
result
among
aureu
isol
differ
spatyp
defin
twenti
spatyp
frequent
found
compris
isol
includ
type
link
predomin
clonal
lineag
mrsa
central
europ
previous
defin
phage
type
smaimacrorestrict
analysi
among
clonal
lineag
distinct
differ
spatyp
variabl
seen
lineag
e
g
barnim
epidem
mrsa
encompass
varieti
close
relat
spatyp
other
e
g
subclon
rhinehess
epidem
mrsa
repres
singl
type
assess
wide
dissemin
lineag
exhibit
singl
spatyp
addit
marker
must
appli
one
hundr
spatyp
determin
isol
burp
prove
valuabl
tool
assign
particular
clonal
group
therebi
result
burp
group
overal
concord
smaimacrorestrict
analysi
mlst
conclus
spatyp
combin
burp
base
group
isol
prove
valuabl
tool
strain
type
regard
demand
nation
refer
centr
burp
algorithm
reveal
extrem
use
group
new
uncommon
spatyp
increas
amount
type
data
obtain
outbreak
situat
enabl
comparison
close
relat
spatyp
within
burp
group
thu
facilit
definit
criteria
strain
related
accord
alreadi
defin
smaimacrorestrict
analysi
import
prerequisit
definit
isol
ident
relat
differ
essenti
success
epidemiolog
outbreak
investig
although
bacteri
colonis
common
mostli
asymptomat
children
frequent
result
wide
spectrum
respiratori
tract
infect
rti
acut
otiti
media
aom
sinus
conjunct
pneumonia
lower
respiratori
infect
lri
children
major
bacteri
rti
caus
streptococcu
pneumonia
pnc
haemophilu
influenza
mostli
nontyp
nthi
aom
nthi
pnc
equal
common
pnc
slightli
aggress
nthi
ie
higher
temperatur
higher
polymorphonuclear
count
complic
frequent
nthi
still
caus
signific
diseas
role
nthi
recurr
nonrespons
aom
infant
older
children
recogn
suggest
differ
biolog
pathway
compar
pnc
acut
subacut
sinus
nthi
found
commonli
pnc
nthi
common
caus
agent
conjunct
signific
relat
copres
aom
system
symptom
sign
role
nthi
lri
gener
pneumonia
particular
yet
clear
cystic
fibrosi
howev
nthi
import
pathogen
although
h
influenza
type
b
diseas
practic
elimin
vaccin
popul
pictur
pneumonia
pneumococc
conjug
vaccin
era
much
complex
owe
limit
serotyp
coverag
replac
nonvaccin
serotyp
vaccin
addit
pneumococc
serotyp
activ
nthi
would
welcom
addit
vaccin
armamentarium
otiti
media
om
highli
preval
paediatr
diseas
associ
signific
morbid
socioeconom
cost
om
caus
synergist
interact
upper
respiratori
tract
virus
three
predomin
bacteri
speci
member
commens
flora
paediatr
nasopharynx
despit
similar
role
opportunist
pathogen
middl
ear
pathogen
mechan
utilis
bacteria
nontyp
haemophilu
influenza
streptococcu
pneumonia
moraxella
catarrhali
uniqu
thu
date
laboratori
investig
pathogenesi
prevent
diseas
caus
microb
individu
recent
becom
appreci
om
particularli
chronic
recurr
om
diseas
includ
biofilm
compon
definit
bacteria
resid
within
biofilm
commun
inher
resist
erad
due
significantli
enhanc
abil
resist
action
antibodi
well
antibiot
moreov
resid
within
biofilm
promot
bacteri
exchang
dna
confer
resist
antibiot
induc
markedli
reduc
bacteri
growth
rate
commonli
result
falseneg
bacteri
cultur
past
year
demonstr
three
predomin
bacteria
involv
om
form
biofilm
vitro
assay
system
anim
model
particip
biofilm
form
middl
ear
mucosa
specimen
recov
children
recurr
chronic
om
enhanc
understand
biofilm
compon
middl
ear
infect
greatli
influenc
current
approach
manag
om
design
novel
strategi
treat
better
prevent
om
particularli
intrigu
paediatr
middl
ear
mucosaderiv
biofilm
characteris
mix
bacteri
aetiolog
suggest
progress
made
singlemicrob
direct
strategi
treatment
andor
prevent
om
highli
encourag
also
like
inadequ
therefor
significantli
greater
understand
microbi
physiolog
relat
involv
biofilm
om
requir
identifi
point
diseas
cours
perhap
amen
treatment
strategi
also
biofilmrelev
antigen
target
would
help
ration
design
vaccin
candid
prevent
om
protein
pd
highli
conserv
surfac
expos
kda
lipoprotein
found
nthi
encapsul
hi
highli
immunogen
human
evid
suggest
pd
involv
pathogenesi
respiratori
tract
infect
implic
nthi
adhes
invas
host
cell
isogen
pddefici
nthimut
compar
wild
type
strain
approxim
lower
capac
caus
acut
otiti
media
om
rat
induc
significantli
less
impair
ciliari
function
human
nasopharyng
tissu
cultur
model
like
mechan
pathogen
pd
enzym
glycerophosphodiest
phosphodiesteras
glpq
releas
phosphorylcholin
chop
host
epitheli
cell
lipooligosaccharid
lo
nthi
loschop
interact
plateletactiv
factor
receptor
inhibit
ciliari
beat
frequenc
human
bronchial
epitheli
cell
activ
g
proteinrel
pathway
pd
also
capabl
induc
bactericid
antiprotein
antibodi
protect
nthi
diseas
pdimmunis
rat
clear
nthi
significantli
better
nonimmunis
anim
middl
ear
pulmonari
bacteri
challeng
addit
chinchilla
pdimmunis
passiv
given
antipd
sera
show
protect
nthidepend
om
pd
recent
introduc
antigen
activ
carrier
protein
experiment
pneumococc
conjug
vaccin
recent
phase
iii
clinic
trial
experiment
vaccin
signific
protect
achiev
om
caus
pneumococci
andor
nthi
current
licens
pneumococc
conjug
vaccin
pcv
integr
infant
immunis
programm
sever
industrialis
countri
new
pcv
candid
develop
wider
serotyp
coverag
new
pcv
formul
infant
adult
evalu
efficaci
larg
efficaci
trial
feasibl
accept
new
pcv
reli
immunogen
studi
guidelin
http
wwwwhointbiologicalspublicationstr
areasvaccinespneumoenindexhtml
primari
threshold
trial
proport
subject
antibodi
concentr
mgml
serotyp
measur
via
elisa
protect
function
mechan
antibodi
pneumococc
capsular
polysaccharid
resid
opsonophagocytosi
demonstr
opsonophagocyt
activ
opa
regard
import
secondari
threshold
thu
far
publish
pcv
efficaci
trial
connect
opa
data
good
correl
consid
data
becom
evid
measur
opa
ad
valu
evalu
vaccin
efficaci
base
immunogen
studi
gener
opa
titer
antibodi
concentr
correl
well
differ
serotyp
show
variou
opaeia
ratio
mean
certain
serotyp
like
antibodi
need
kill
bacteria
rest
importantli
elderli
hiv
posit
patient
seem
antibodi
low
function
activ
measur
opa
studi
elderli
hiv
patient
consid
import
variou
assay
determin
opa
develop
laboratori
alreadi
perform
extens
valid
step
multilaboratori
standardis
opa
assay
immin
measur
opa
classic
kill
assay
consum
serum
time
thu
measur
opa
larg
materi
alway
feasibl
howev
develop
multiplex
andor
high
throughput
assay
end
wider
use
technolog
futur
clinic
trial
would
concord
guidelin
evalu
meningococc
conjug
vaccin
serum
bactericid
activ
assay
case
studi
poet
bacteri
respiratori
tract
infect
lead
caus
morbid
mortal
young
children
effect
immunis
strategi
infect
contend
multipl
pathogen
host
diseas
syndrom
streptococcu
pneumonia
pneumococcu
encapsul
nonencapsul
form
haemophilu
influenza
hi
lead
pathogen
serotyp
pneumococci
exist
serogroup
appear
respons
invas
pneumococc
diseas
pneumococc
otiti
media
om
worldwid
rang
rel
rare
clinic
sever
mening
frequent
infect
bloodstream
lung
pneumonia
final
extrem
common
middl
ear
infect
among
young
children
middl
ear
infect
often
associ
diagnost
uncertainti
frequent
use
misus
antibiot
recurr
persist
diseas
recurr
infect
occur
mani
children
year
age
recurr
persist
diseas
lead
temporari
even
perman
hear
loss
surgeri
tube
placement
order
address
issu
prevent
acut
om
aom
strategi
includ
vaccin
broader
pneumococc
serotyp
coverag
well
protect
addit
otopathogen
present
describ
novel
vaccin
approach
polysaccharid
lead
streptococc
paediatr
serotyp
conjug
carrier
protein
protein
deriv
hi
resist
erythromycin
clindamycin
moxifloxacin
tetracyclin
found
respect
strain
fulli
suscept
metronidazol
vancomycin
resist
moxifloxacin
erythromycin
tightli
associ
mic
moxifloxacin
significantli
higher
patient
previous
treat
fluoroquinolon
preval
epidem
strain
found
ireland
n
netherland
n
belgium
n
strain
exhibit
phenotyp
genotyp
featur
clone
describ
north
america
posit
binari
toxin
gene
delet
tcdc
gene
resist
erythromycin
moxifloxacin
mean
incid
cdad
case
per
patientday
vari
wide
one
hospit
anoth
patient
infect
strain
like
sever
diseas
rr
ci
p
receiv
less
antimicrobi
month
preced
diarrhoea
rr
ci
p
specif
treat
metronidazol
vancomycin
rr
p
ongo
epidemiolog
surveil
cdad
case
period
characteris
strain
need
time
detect
cluster
case
monitor
emerg
specif
hypervirul
clone
incid
sever
nosocomi
c
difficil
diseas
seem
increas
addit
diseas
commun
onset
becom
common
previous
recogn
case
group
acinetobact
gramneg
mrsa
previous
low
risk
report
c
difficil
also
emerg
import
anim
pathogen
hors
calv
piglet
describ
chang
correl
chang
popul
c
difficil
present
human
new
type
increas
virul
spread
sinc
part
recent
increas
mortal
morbid
caus
c
difficil
infect
account
new
highli
virul
type
proport
binari
toxin
posit
type
also
rise
among
human
isol
binari
toxin
posit
strain
use
often
associ
anim
human
host
earli
type
comparison
show
mani
similar
human
anim
strain
howev
recent
studi
found
mark
overlap
isol
calv
human
includ
two
predomin
outbreak
type
c
difficil
also
found
retail
meat
sampl
suggest
food
could
involv
transmiss
c
difficil
anim
human
respons
new
develop
c
difficil
epidemiolog
new
diagnost
type
method
develop
aim
quick
sensit
detect
c
difficil
also
quick
recognit
strain
higher
virul
earli
diagnosi
cdad
prompt
isol
symptomat
patient
reduc
antimicrobi
treatment
essenti
first
step
infect
control
measur
includ
recommend
isol
infect
patient
singl
room
design
toilet
appli
proper
hand
hygien
soap
water
use
appropri
protect
cloth
glove
apron
gown
intensifi
environment
clean
chlorin
contain
disinfect
take
specif
precaut
use
devic
dispos
dedic
individu
patient
patient
isol
must
continu
least
diarrhoea
ceas
hospit
appropri
surveil
system
recogn
increas
incid
cdad
earli
stage
infect
control
measur
written
local
protocol
addit
measur
carri
soon
problem
cdad
aris
outbreak
occur
addit
recommend
includ
reinforc
gener
hand
wash
measur
intensifi
test
patient
diarrhoea
c
difficil
reinforc
environment
clean
inform
educ
healthcar
worker
clean
depart
visitor
cohort
infect
patient
eventu
closur
unit
follow
intens
environment
clean
restrict
antibiot
prescrib
also
highli
recommend
reduc
polypharmaci
durat
administr
second
third
gener
cephalosporin
clindamycin
recent
fluoroquinolon
identifi
potenti
risk
factor
although
hospit
report
success
enhanc
environment
clean
potenti
effect
agent
hydrogen
peroxid
vapour
evid
scarc
consid
evidencebas
approach
acinetobact
gramneg
mrsa
global
epidemiolog
acinetobact
member
genu
acinetobact
particularli
acinetobact
baumannii
recogn
signific
nosocomi
pathogen
particularli
subset
criticallyil
patient
requir
mechan
ventil
hospit
intens
care
unit
howev
acinetobact
infect
also
acquir
outsid
healthcar
set
wound
infect
caus
acinetobact
common
among
trauma
patient
conflict
zone
follow
natur
disast
also
report
communityacquir
infect
mainli
patient
type
comorbid
latter
report
origin
tropic
subtrop
area
may
becom
common
follow
ongo
chang
global
climat
strain
baumannii
harbour
inher
acquir
resist
mechan
vast
major
avail
antimicrobi
agent
includ
carbapenem
organ
also
remark
capac
persist
hospit
environ
caus
epidem
outbreak
infect
hospit
recent
increas
number
carbapenemresist
strain
particularli
eastern
europ
current
great
concern
recent
eufund
arpac
studi
reveal
particip
european
hospit
european
countri
encount
carbapenemresist
isol
acinetobact
rang
rare
sporad
resist
isol
endemicepidem
situat
certain
multiresist
epidem
clone
current
spread
worldwid
epidem
multiresist
baumannii
infect
occur
follow
repatri
casualti
recent
war
kuwait
iraq
afghanistan
european
american
hospit
gener
multipl
isol
singl
hospit
usual
belong
clone
hospit
yield
isol
belong
one
clone
three
european
clone
lineag
identifi
hospit
throughout
europ
numer
localis
clone
also
characteris
show
problem
baumannii
confin
sole
widespread
european
clone
ii
iii
reason
certain
baumannii
lineag
success
other
understood
present
overal
avail
epidemiolog
evid
suggest
baumannii
becom
one
signific
microbi
challeng
current
era
strain
hospit
alreadi
effect
untreat
scientif
effort
resourc
urgent
need
elucid
epidemiolog
infect
control
issu
relat
infect
acinetobact
baumannii
opportunist
pathogen
mostli
involv
nosocomi
infect
immunocompromis
patient
wherea
baumannii
quit
high
level
naturallyoccur
antibiot
resist
may
acquir
addit
resist
trait
sourc
multidrug
resist
resist
mechan
may
involv
antibiot
molecul
ie
aminoglycosid
blactam
fluoroquinolon
rate
spread
specif
mechan
resist
depend
countri
similar
trend
number
baumannii
infect
antibiot
resist
may
observ
worldwid
acquir
resist
gene
locat
chromosom
plasmid
insert
sequenc
transposon
integron
recent
describ
resist
island
one
worri
antibiot
resist
problem
baumannii
increas
trend
carbapenem
resist
sinc
carbapenem
often
use
antibiot
last
resort
carbapenem
resist
result
metalloblactamas
carbapenemhydrolyz
oxacillinas
often
combin
mechan
resist
method
two
flight
patient
cough
urinari
tract
cathet
disconnect
reservoir
releas
relev
amount
urin
passeng
seat
patient
urin
test
posit
lassa
viru
taken
account
risk
assess
contribut
decis
trace
back
copasseng
potenti
expos
passeng
risk
defin
sit
maximum
three
row
distanc
patient
addit
person
airlin
airport
expos
help
airlin
passeng
list
flight
avail
within
two
day
passeng
nine
countri
identifi
everi
countri
receiv
list
name
contact
telephon
number
passeng
risk
alloc
countri
well
questionnair
symptom
fill
trace
passeng
trace
back
concern
staff
done
airlin
belgian
public
health
author
case
magnitud
reproduct
number
compar
two
wave
best
estim
initi
reproduct
number
r
although
could
rang
depend
assumpt
regard
incub
lifespan
mosquito
best
fit
case
infect
individu
may
contamin
mosquito
mosquito
contamin
person
averag
use
data
first
season
alon
modelbas
extrapol
suggest
epidem
outbreak
possibl
long
one
third
popul
remain
suscept
conclus
despit
thousandfold
chang
incid
two
season
transmiss
characterist
chikungunya
similar
therefor
epidemiolog
evid
increas
virul
season
time
inform
system
make
easier
monitor
cours
emerg
diseas
method
time
effici
analysi
data
must
also
develop
result
studi
period
total
case
invas
hi
diseas
report
ak
n
among
invas
hi
case
serotyp
inform
avail
serotyp
serotyp
b
serotyp
f
among
hia
isol
occur
aborigin
peopl
median
age
year
rang
mo
year
male
two
hia
case
child
fatal
common
clinic
present
includ
mening
pneumonia
septic
arthriti
case
epiglotitti
overal
annual
hia
incid
case
per
popul
annual
incid
rate
aborigin
ak
n
per
person
respect
rate
aborigin
children
year
age
case
per
person
respect
pfge
analysi
reveal
genet
similar
hia
strain
ak
n
conclus
serotyp
common
hi
serotyp
seen
north
american
arctic
highest
rate
among
indigen
children
research
need
determin
sequela
risk
factor
outbreak
potenti
util
chemoprophylaxi
diseas
object
telavancin
novel
multival
lipoglycopeptid
antibiot
exert
rapid
bactericid
activ
broad
rang
gramposit
pathogen
telavancin
uniqu
multifunct
mechan
action
includ
inhibit
bacteri
cell
wall
synthesi
disrupt
bacteri
membran
function
previou
studi
methicillinresist
staphylococcu
aureu
mrsa
reveal
telavancin
increas
cell
membran
permeabl
caus
rapid
dissip
bacteri
membran
potenti
studi
aim
characteris
effect
telavancin
function
integr
mrsa
cell
membran
use
flow
cytometri
method
cell
membran
potenti
membran
permeabl
studi
telavancintr
aureu
atcc
mrsa
cell
fluoresc
dye
propidium
iodid
use
assess
membran
potenti
permeabl
respect
flow
cytometri
use
analys
uptak
dye
telavancintr
cell
result
telavancin
mic
mgml
caus
concentrationand
timedepend
dissip
membran
potenti
mrsa
cell
minut
exposur
telavancin
bacteri
popul
depolaris
mgml
approxim
human
plasma
trough
concentr
mgml
result
depolaris
membran
permeabl
also
concentrationand
timedepend
seen
cell
expos
telavancin
concentr
rang
mgml
mgml
yield
rapid
permeabilis
cell
popul
conclus
exposur
mrsa
cell
telavancin
initi
concentrationand
timedepend
membran
depolaris
increas
permeabl
demonstr
telavancin
interfer
bacteri
cell
membran
function
effect
observ
telavancin
concentr
achiev
clinic
mgkg
intraven
dose
highlight
therapeut
relev
telavancin
multifunct
mechan
action
object
telavancin
tlv
novel
rapidli
bactericid
lipoglycopeptid
activ
methicillinresist
staphylococcu
aureu
mrsa
tlv
possess
uniqu
multival
multifunct
mechan
contribut
enhanc
activ
includ
inhibit
cell
wall
peptidoglycan
pg
biosynthesi
disrupt
bacteri
membran
barrier
function
vitro
studi
suggest
tlv
exhibit
superior
antibacteri
potenc
rel
vancomycin
van
may
due
lipophil
decylaminoethyl
side
chain
target
tlv
bacteri
cell
membran
isol
erm
gene
suscept
oleandomycin
wherea
inhibit
zone
observ
isol
erm
c
gene
conclus
aureu
erm
c
gene
readili
suscept
develop
constitut
resist
clindamycin
erm
gene
regardless
methicillin
resist
suscept
induc
resist
oleandomycin
associ
presenc
induc
erm
erm
c
gene
respect
might
constitut
marker
gene
risk
analysi
clindamycin
use
therapi
infect
due
aureu
induc
resist
erythromycin
might
includ
natur
resist
gene
object
multipl
resist
escherichia
coli
distinct
class
antimicrobi
usual
attribut
simultan
increas
express
acrabtolc
efflux
system
loss
porin
f
gener
transcript
activ
mara
sox
rob
acrabtolc
also
upregul
sdia
e
coli
protein
regul
cell
divis
studi
multidrug
resist
mutant
select
vitro
diazepam
dz
lomefloxacin
lom
two
e
coli
suscept
clinic
isol
characteris
method
mutant
select
dz
lom
mic
toler
strain
cyclohexan
measur
liquid
medium
inner
outer
membran
protein
imp
omp
analys
electrophoresi
polyacrylamid
gel
penicillinbindingprotein
pbp
detect
bocillin
fl
imperi
protein
stain
activ
efflux
evidenc
mm
carbonyl
cyanid
mchlorophenylhydrazon
cccp
express
acra
acrb
mara
sox
rob
sdia
gene
studi
revers
transcript
total
rna
pcr
cdna
rtpcr
use
gapa
gene
intern
control
express
pcr
product
separ
polyacrylamid
gel
detect
use
silver
stain
strain
induc
noninduc
mm
salicyl
mm
paraquat
control
strain
result
nine
differ
clone
select
dz
lom
select
frequenc
around
nine
mutant
increas
resist
quinolon
chloramphenicol
blactam
fold
ceftazidim
cefpirom
aztreonam
mic
presenc
cccp
increas
suscept
mutant
antimicrobi
agent
omp
tolc
increas
mutant
coincid
increas
cyclohexan
toler
mutant
parent
strain
show
high
express
acra
acrb
gene
nevertheless
mutant
show
overexpress
sdia
sox
ompf
decreas
neither
parent
strain
mutant
show
mara
rob
overexpress
increas
express
detect
mutant
select
mic
dz
lom
dz
nonantimicrobi
drug
lom
select
multipl
antibiot
resist
mutant
overexpress
transcript
regul
sox
sdia
result
tolc
increas
express
mutant
ii
ompf
decreas
gener
sox
overexpress
increas
tolc
express
contribut
increment
ceftazidim
aztreonam
cefpirom
mic
mutant
object
studi
role
qnrlike
pentapeptid
protein
sever
gramposit
speci
resist
quinolon
vitro
method
enterococcu
faecali
homologu
qnra
protein
sequenc
use
search
pentapeptid
protein
differ
level
aminoacid
ident
ncbi
databas
pcrbase
strategi
use
clone
express
gene
code
qnrlike
pentapeptid
protein
e
faecali
atcc
e
faecali
e
faecium
listeria
monocytogen
clinic
isol
clostridium
perfringen
clinic
isol
bacillu
cereu
atcc
ppcrscript
vector
stratagen
escherichia
coli
accord
clsi
guidelin
mic
nalidix
acid
ofloxacin
norfloxacin
ciprofloxacin
levofloxacin
moxifloxacin
determin
clinic
strain
refer
strain
escherichia
coli
harbour
recombin
plasmid
contain
gene
code
pentapeptid
protein
result
aminoacid
ident
qnrlike
pentapeptid
protein
gramposit
strain
compar
plasmidmedi
quinolon
resist
protein
rang
compar
homologu
qnra
e
faecali
aminoacid
ident
rang
clone
obtain
e
coli
express
pentapentid
protein
gram
posit
strain
confer
reduc
suscept
quinolon
recombin
plasmid
express
pentapentid
protein
e
coli
increas
mic
fold
nalidix
acid
fold
ofloxacin
fold
norfloxacin
fold
ciprofloxacin
fold
levofloxacin
fold
moxifloxacin
pentapeptid
protein
analys
confer
reduc
suscept
phenotyp
e
coli
data
could
provid
evid
possibl
role
pentapeptid
protein
differ
gramposit
speci
natur
resist
quinolon
gram
posit
speci
could
constitut
reservoir
qnrlike
quinolon
resist
protein
object
silverman
model
mode
action
daptomycin
dap
base
leakag
potassium
ion
k
membran
deenergis
subsequ
cell
death
without
lysi
howev
unknown
whether
loss
k
suffici
caus
cell
death
studi
determin
kinet
cell
death
lysi
aureu
treat
dap
establish
relationship
two
method
timekil
experi
perform
variou
concentr
dap
determin
kinet
cell
death
sampl
taken
prepar
scan
transmiss
electron
microscopi
em
cultur
sampl
taken
interv
extracellular
intracellular
amount
atp
determin
extracellular
intracellular
level
bgalactosidas
bgal
aureu
strain
express
bgal
cytoplasm
also
measur
timekil
experi
show
dap
rapidli
bactericid
mgl
dap
mgl
show
bacteriostat
effect
first
min
becom
slowli
bactericid
evid
dosedepend
leakag
atp
bgal
cell
treat
dap
leakag
occur
differ
rate
min
treatment
dap
mgl
total
atp
releas
neglig
amount
bgal
percentag
bgal
releas
increas
steadili
period
hour
reach
h
h
min
treatment
dap
mgl
total
atp
releas
amount
continu
increas
steadili
leakag
bgal
less
appar
h
cell
releas
less
em
imag
show
cellular
disrupt
first
hour
dap
treatment
damag
becom
appar
widespread
follow
hour
imag
clearli
show
rate
extent
cellular
lysi
dosedepend
conclus
find
support
silverman
model
mode
action
dap
hypothesi
caus
rapid
cell
death
without
whole
cell
lysi
howev
shown
cell
lysi
occur
time
em
imag
leakag
larg
amount
bgal
find
uphold
silverman
model
suggest
simpl
conclud
cell
death
due
loss
k
membran
deenergis
rapid
loss
atp
would
equal
like
caus
cell
death
object
studi
effect
efflux
pump
inhibitor
cccp
pabn
carbapenem
p
aeruginosa
pa
investig
correl
resist
phenotyp
express
level
efflux
pump
pa
discuss
mechan
differ
phenotyp
resist
pa
contrast
isol
neg
replicon
result
clearli
indic
gene
encod
identifi
concomitantli
given
isol
alway
locat
plasmid
belong
group
may
vari
size
digest
pattern
addit
plasmid
carri
gene
lack
also
type
opposit
plasmid
distinct
replicon
type
suggest
independ
acquisit
qnra
gene
differ
plasmid
restrict
pattern
analysi
plasmid
dna
perform
use
psti
endonucleas
reveal
plasmid
exhibit
differ
restrict
profil
also
share
common
band
like
correspond
common
plasmid
backbon
hybridis
perform
probe
show
ident
signal
reveal
band
carri
replic
control
region
plasmid
ident
size
expect
plasmid
lineag
conclus
shown
plasmid
may
main
vehicl
gene
determin
may
ad
understand
pattern
help
identifi
potenti
target
public
health
intervent
object
controversi
still
surround
indic
intrapartum
antibiot
prophylaxi
iap
group
b
streptococci
gb
women
labour
argument
two
recogn
care
pathway
antenat
screen
risk
factor
assess
use
data
obtain
larg
test
accuraci
studi
rapid
detect
intrapartum
gb
colonis
aim
determin
preval
vagin
rectal
gb
labour
women
compar
standard
cultur
enrich
cultur
techniqu
proport
women
present
differ
risk
factor
cultur
posit
risk
factor
correl
frequenc
iap
administr
babi
colonis
rate
regard
matern
colonis
site
whether
iap
given
method
vagin
rectal
swab
collect
women
labour
direct
cultur
streptococc
select
agar
cna
enrich
cultur
lim
broth
ear
swab
neonat
collect
within
hour
birth
enrich
cultur
data
risk
factor
antibiot
therapi
collect
prospect
enrich
cultur
gave
overal
vagin
andor
rectal
colonis
rate
compar
standard
cultur
women
studi
least
one
risk
factor
commonli
prolong
ruptur
membran
women
risk
factor
receiv
iap
tabl
gb
carrier
receiv
iap
whilst
women
receiv
iap
gbsneg
tabl
babi
colonis
rate
posit
vagin
cultur
identifi
posit
babi
posit
rectal
cultur
rectal
vagin
posit
cultur
combin
object
staphylococcu
aureu
remain
preval
bacterium
caus
acut
osteomyel
children
involv
methicillinresist
aureu
mrsa
caus
acut
childhood
osteomyel
investig
method
includ
studi
children
treat
acut
osteomyel
due
aureu
western
greec
januari
august
bone
scan
mri
xray
perform
order
ascertain
diagnosi
assess
sever
diseas
aureu
isol
blood
andor
bone
tissu
surgic
drainag
necessari
staphylococc
cassett
chromosom
sccmec
type
pantonvalentin
leukocidin
pvl
gene
lukspv
lukfpv
detect
pcr
mrsa
clone
defin
pfge
smai
dna
digest
sign
symptom
laboratori
find
prospect
regist
statist
evalu
mannwhitneyu
test
patient
cessat
activ
diseas
result
nineteen
patient
male
femal
median
age
year
rang
year
diagnos
acut
staphylococc
osteomyel
three
children
suspect
site
bacteri
entranc
injuri
burn
insect
bite
aureu
isol
blood
nine
patient
tissu
nine
patient
clinic
specimen
one
patient
five
children
communityacquir
mrsa
camrsa
carri
sccmec
type
iv
pvl
identifi
among
mssa
isol
remain
patient
two
pvlposit
maxim
esr
crp
valu
well
time
necessari
normalis
esr
crp
differ
statist
significantli
patient
pvl
posit
stain
mrsa
mssa
compar
pvlneg
mssa
p
surgic
drainag
often
necessari
among
patient
pvlposit
stain
conclus
pvlposit
camrsa
recov
patient
superfici
also
invas
musculoskelet
infect
product
pvl
seem
main
factor
contribut
cours
acut
osteomyel
describ
first
report
famili
transmiss
cmrsa
pvl
patient
pt
osteomyel
case
report
octob
alcohol
man
medic
histori
admit
depart
infecti
diseas
acromioclavicular
osteoarthr
marri
two
children
yearold
traumat
disloc
right
acromioclavicular
joint
oper
one
year
later
tendon
refect
use
homogen
graft
two
week
surgeri
purul
discharg
postop
wound
note
mrsa
cultur
swab
strain
resist
oxacillin
kanamycin
tobramycin
suscept
ofloxacin
trimethoprimsulfamethoxazol
pristinamycin
clindamycin
vancomycin
intermedi
fusid
acid
given
oral
pristinamycin
g
tid
week
one
week
end
treatment
octob
admit
right
acromioclavicular
osteoarthr
requir
surgic
debrid
intraven
vancomycin
treatment
cmrsa
strain
grew
intraop
sampl
famili
carriag
screen
includ
pt
show
pt
children
colonis
mrsa
strain
accord
antibiot
suscept
profil
pvl
tsst
detect
still
process
member
pt
famili
healthcar
associ
risk
factor
cmrsa
vancomycin
switch
oral
trimethoprimsulfamethoxazol
rifampicin
combin
month
discuss
new
type
mrsa
produc
describ
franc
switzerland
best
knowledg
famili
transmiss
cmrsa
pvl
strain
never
report
present
case
report
cross
contamin
pt
famili
highli
suspect
conclus
present
case
show
cmrsa
pvl
tsst
might
associ
famili
transmiss
preval
pathogen
enterocolitica
swiss
pig
high
use
pcr
howev
isol
rate
clearli
lower
german
pig
swiss
pig
infect
bioserotyp
common
type
found
among
human
enterolitica
gastroenter
german
switzerland
type
isol
german
slaughter
pig
pig
also
shown
reservoir
bioserotyp
switzerland
genet
divers
ailposit
enterocolitica
pig
tonsil
collect
one
swiss
slaughterhous
limit
van
significantli
associ
cdad
incid
conclus
hospitalwid
use
antibiot
known
risk
factor
cdad
patient
level
fluoroquinolon
associ
institut
level
higher
incid
type
cdad
possibl
investig
wardlevel
might
correl
better
wear
apron
give
special
instruct
visitor
case
diarrhoea
appear
protect
object
acanthamoeba
report
repres
environment
host
sever
human
pathogen
vibrio
cholera
requir
cell
caus
cholera
accordingli
need
environment
host
enhanc
growth
studi
shown
extracellular
v
cholera
grown
surviv
acanthamoeba
castellanii
aim
studi
examin
abil
castellanii
protect
v
cholera
enhanc
growth
abl
infect
human
method
v
cholera
produc
green
fluoresc
protein
cocultiv
castellanii
antibiot
assay
use
examin
abil
amoeba
protect
intracellular
bacteria
differenti
extracellular
intracellular
bacteria
castellanii
cultiv
v
cholera
one
week
gentamicin
kill
wash
extracellular
v
cholera
number
intracellular
bacteria
found
cellsml
amoeba
harbour
v
cholera
recultiv
growth
microorgan
examin
viabl
count
week
result
gentamicin
kill
extracellular
bacteria
ciprofloxacin
kill
thu
amoeba
protect
intracellular
v
cholera
gentamicin
antibiot
assay
differenti
extracellular
bacteria
kill
gentamicin
intracellular
bacteria
kill
ciprofloxacin
could
diffus
amoeba
cell
recultiv
castellanii
harbour
intracellular
v
cholera
result
enhanc
growth
v
cholera
cfuml
bacteria
surviv
two
week
thu
amoeba
act
biolog
incub
intracellular
growth
bacteria
occur
increas
number
million
fold
maintain
overal
viabil
exist
v
cholera
extracellularli
well
intracellularli
cultur
medium
confirm
facult
intracellular
behaviour
enhanc
growth
surviv
utilis
antibiot
assay
differenti
extracellular
intracellular
bacteria
freeliv
amoeba
possibl
biolog
factor
protect
enhanc
growth
v
cholera
exceed
infect
dose
support
idea
amoeba
second
host
bacterium
natur
besid
man
common
oral
condit
gingiv
chronic
periodont
found
worldwid
among
wide
preval
microbi
diseas
mankind
primari
trigger
condit
complex
microbiota
found
dental
plaqu
complex
microbi
biofilm
despit
year
histori
demonstr
influenc
oral
statu
gener
health
recent
decad
seen
acceler
effort
prevent
manag
condit
groundbreak
advanc
one
outcom
advanc
realis
periodont
diseas
associ
system
condit
coronari
heart
diseas
stroke
higher
risk
preterm
low
birth
weight
babi
pose
threat
chronic
diseas
diabet
respiratori
diseas
osteoporosi
present
highlight
recent
research
associ
periodont
diseas
system
diseas
relationship
oral
infect
system
diseas
repres
paradigm
shift
current
research
portion
lectur
devot
examin
role
chronic
infect
associ
cardiovascular
diseas
cvd
infect
includ
helicobact
pylori
chlamydophila
pneumonia
cytomegaloviru
cmv
recent
periodontopath
bacteria
includ
porphyromona
gingivali
although
number
potenti
mechan
postul
mechan
infect
associ
cvd
still
unclear
variou
hypothes
concern
relationship
includ
common
suscept
inflamm
via
increas
circul
cytokin
inflammatori
mediat
direct
infect
blood
vessel
final
possibl
crossreact
molecular
mimicri
bacteri
self
antigen
evid
mechan
present
clinic
implic
medic
dental
practition
discuss
introductori
lectur
set
stage
subsequ
speaker
highlight
medicodent
interfac
requir
shift
health
practic
futur
medicin
dentistri
healthcar
profess
devot
patient
care
interact
two
disciplin
remain
limit
rare
dental
profession
integr
member
medic
team
hospitalhealthcar
set
referr
two
profess
occur
improv
commun
profession
requir
optimis
treatment
option
increasingli
requir
capitalis
recent
advanc
health
scienc
manag
chronic
diseas
reduc
morbid
improv
longev
result
uniqu
popul
special
oral
care
need
includ
cancer
head
neck
immunocompromis
hivaid
geriatr
resid
longterm
care
facil
patient
lifelong
condit
organ
transplant
prescript
medic
like
bloodpressur
control
anticoagul
therapi
session
highlight
uniqu
oral
care
need
chang
patient
popul
oral
health
improv
dentist
physician
work
togeth
role
prescript
medic
treat
medic
condit
advers
reaction
oral
caviti
form
separ
anoth
area
discuss
mani
medic
instanc
xerostom
patient
xerostomia
increas
risk
tooth
decay
periodont
diseas
need
increas
collabor
dentist
physician
prevent
reduc
complic
maintain
better
oral
medic
health
form
core
theme
session
longer
ignor
oral
health
medic
health
profession
must
unit
optim
manag
patient
health
primari
step
improv
oral
health
routin
control
dental
plaqu
natur
biofilm
oral
hygien
formul
signific
effect
dental
biofilm
augment
ineffect
practic
routin
prophylaxi
chlorhexidin
triclosan
formul
oral
hygien
formul
extens
histori
clinic
proven
efficaci
safeti
overview
clinic
effect
oral
hygien
formul
role
therapeut
strategi
commenc
present
triclosan
serv
casestudi
talk
bring
togeth
recent
advanc
assess
oral
biofilm
analys
clinic
strain
includ
suscept
demonstr
microbiolog
safeti
efficaci
oral
hygien
formul
past
three
decad
wit
gener
reduct
effect
triclosan
target
bacteria
includ
periodont
bacteria
whilst
triclosan
note
activ
enter
bacteria
pseudomonad
laboratori
studi
demonstr
chronic
subleth
exposur
escherichia
coli
select
mutant
clone
significantli
reduc
suscept
mutant
either
mutat
enzym
fabi
associ
fattyacid
biosynthesi
overexpress
multidrug
efflux
pump
initi
concern
mutat
fabi
might
capabl
horizont
transfer
environment
bacteria
noscomi
pathogen
parallel
process
might
occur
directli
gramposit
pathogen
subsid
similarli
concern
possibl
select
resist
toward
thirdparti
agent
antibiot
might
share
fabi
gene
target
proven
unfound
select
effluxon
mutant
whilst
demonstr
laboratori
support
analys
isol
hospit
domest
environ
agent
triclosan
wide
deploy
evid
suggest
effluxon
mutant
unabl
compet
natur
microbi
commun
whilst
insuffici
evid
suggest
uncontrol
use
triclosan
domest
product
total
free
risk
deploy
oral
hygien
especi
use
might
limit
number
refractori
infect
possibl
complic
contribut
ultim
reduct
antibiot
use
encourag
collect
evid
longterm
applic
triclosan
formul
oral
caviti
skin
select
triclosanresist
bacteri
popul
increas
elderli
popul
retain
natur
teeth
later
life
periodont
diseas
pose
increas
problem
dentit
potenti
gener
health
mainten
effect
level
oral
hygien
cornerston
attempt
prevent
control
periodont
diseas
yet
widespread
preval
diseas
indic
inabl
peopl
achiev
level
plaqu
control
commensur
periodont
health
inclus
antibacteri
agent
chlorhexidin
triclosancopolym
oral
care
product
provid
consum
mean
improv
oral
health
randomis
control
clinic
trial
demonstr
dentifric
contain
triclosancopolym
significantli
improv
gingiv
health
prevent
onset
periodont
furthermor
reduc
progress
diseas
benefit
initi
attribut
antibacteri
action
triclosan
evid
suggest
also
antiinflammatori
agent
deliveri
benefit
consider
implic
mainten
oral
gener
health
cost
dental
care
emerg
multidrug
resist
mdr
pathogen
pseudomona
aeruginosa
acinetobact
baumannii
enterobacteriacea
produc
extendedspectrum
betalactamas
esbl
alarm
increas
mdr
patient
treat
nosocomi
infect
caus
increas
cost
morbid
mortal
tradit
narrowspectrum
drug
use
first
potent
drug
reserv
subsequ
use
unfortun
tradit
approach
increas
chanc
treatment
failur
emerg
multidrugresist
strain
fact
inappropri
choic
antibiot
import
independ
risk
factor
death
esbl
produc
resist
penicillin
cephalosporin
often
crossresist
aminoglycosid
fluoroquinolon
well
carbapenem
shown
provid
superior
outcom
compar
agent
infect
caus
esbl
produc
consequ
firstlin
use
carbapenem
optim
seriou
infect
esbl
pathogen
suspect
major
nonfer
gramneg
pathogen
concern
p
aeruginosa
p
aeruginosa
common
caus
nosocomi
infect
lead
caus
ventilatorassoci
pneumonia
initi
therapi
includ
antipseudomon
blactam
piperacillintazobactam
antipseudomon
carbapenem
antipseudomon
cephalosporin
plu
aminoglycosid
fluoroquinolon
baumannii
gener
suscept
carbapenem
aminoglycosid
sulbactam
colistin
tigecyclin
carbapenem
one
class
remain
excel
choic
nonferment
doripenem
new
broadspectrum
carbapenem
activ
superior
carbapenem
p
aeruginosa
similar
carbapenem
baumannii
antibiot
resist
increas
empir
therapi
sever
infect
base
local
pathogen
etiolog
resist
pattern
new
approach
start
highdos
broadspectrum
antibiot
tailor
individu
therapi
base
microbiolog
result
carbapenem
like
remain
import
option
seriou
gramneg
infect
forese
futur
sinc
number
new
intraven
agent
activ
gramneg
organ
extrem
limit
develop
new
carbapenem
may
help
reduc
mortal
morbid
cost
seriou
nosocomi
infect
wide
market
carbapenem
long
compris
imipenem
launch
meropenem
famili
grow
ertapenem
doripenem
anticip
develop
use
also
grow
driven
spread
extendedspectrum
blactamas
esbl
carbapenem
much
common
broader
activ
better
stabil
esbl
ampc
enzym
blactam
labil
metalloand
kpc
blactamas
oxa
carbapenemas
acinetobact
clone
three
carbapenem
group
nevertheless
defin
group
agent
lack
activ
versu
nonferment
repres
ertapenem
perhap
futur
also
oral
analogu
ertapenem
util
lie
treatment
communityacquir
infect
esbl
produc
like
proven
conveni
oncedaili
dose
vulner
carbapenem
combin
esbl
ampc
plu
imperm
group
compris
imipenem
meropenem
doripenem
plu
analogu
avail
east
asia
activ
versu
nonferment
appropri
nosocomi
set
pathogen
like
doripenem
meropenem
similar
doripenem
circa
twofold
activ
versu
speci
imipenem
slightli
less
activ
gramneg
bacteria
except
acinetobact
sole
carbapenem
activ
versu
enterococcu
faecali
doripenem
meropenem
need
two
mutat
loss
oprd
upregul
efflux
resist
pseudomona
aeruginosa
imipenem
resist
aris
loss
oprd
alon
select
therapi
nevertheless
imipenem
uniqu
evad
pseudomon
efflux
meropenem
doripenem
rel
stabl
renal
dehydropeptidas
imipenem
need
protect
cilastatin
doripenem
meropenem
chemic
stabl
allow
prolong
infus
wherea
imipenem
doripenem
meropenem
littl
seizur
potenti
meropenem
licens
mening
cn
sideeffect
limit
imipenem
dosag
group
compris
analogu
activ
versu
mrsa
repres
development
agent
minimum
inhibitori
concentr
mrsa
wide
distribut
antimrsa
cephalosporin
wider
spectrum
typic
carbapenem
carbapenem
usag
expand
critic
understand
differ
appropri
analogu
select
increas
antibiot
resist
lack
new
drug
class
develop
drive
need
optimis
use
current
avail
drug
goal
antimicrobi
chemotherapi
optimis
combin
pharmacokinet
pk
pharmacodynam
pd
profil
drug
greatest
percentag
patient
achiev
pd
target
associ
favour
outcom
minimis
develop
resist
organ
integr
popul
pk
pd
target
microbiolog
surveil
data
mont
carlo
simul
gener
empir
dose
strategi
maximis
likelihood
antibiot
regimen
achiev
desir
pd
end
point
exposur
target
blactam
exposur
target
percentag
time
free
drug
level
minimum
inhibitori
concentr
mic
carbapenem
mic
requir
lower
blactam
extend
infus
period
achiev
necessari
mic
lower
dose
achiev
efficaci
higher
dose
lower
cost
potenti
toxic
exampl
recent
public
show
infus
meropenem
rate
target
attain
pseudomona
aeruginosa
isol
hospit
hungari
wherea
infus
g
meropenem
would
rate
target
attain
retrospect
studi
compar
h
piperacillintazobactam
infus
g
infus
g
patient
infect
p
aeruginosa
infus
reduc
mortal
p
median
length
stay
day
patient
apach
ii
score
p
doripenem
stabl
upon
reconstitut
carbapenem
potenti
make
conveni
easier
use
extend
infus
furthermor
studi
design
doripenem
ventilatorassoci
pneumonia
phase
trial
includ
extend
infus
regimen
g
h
conclus
dose
antibiot
capac
increas
efficaci
resist
infect
infus
extend
period
extend
infus
lower
dose
antibiot
may
produc
efficaci
equival
shorter
higherdos
infus
reduc
toxic
emerg
resist
extend
infus
carbapenem
doripenem
neither
seizur
potenti
high
resist
select
particularli
promis
strategi
seriou
infect
doripenem
investig
carbapenem
complet
phase
multin
trial
complic
urinari
tract
infect
cuti
complic
intraabdomin
infect
ciai
hospitalacquir
pneumonia
hap
ventilatorassoci
pneumonia
vap
doripenem
advantag
carbapenem
includ
enhanc
activ
pseudomona
aeruginosa
low
propens
resist
lowest
potenti
seizur
carbapenem
class
greatest
stabil
reconstitut
two
randomis
doubleblind
phase
ciai
trial
compar
intraven
iv
doripenem
mg
iv
meropenem
mg
option
switch
amoxicillinclavulan
treatment
arm
dose
iv
studi
drug
therapi
result
ciai
trial
show
doripenem
mg
welltoler
noninferior
meropenem
g
doripenem
microbiolog
effect
major
caus
organ
ciai
includ
enterobacteriacea
bacteroid
spp
advers
event
ae
occur
subject
either
treatment
arm
nausea
vomit
seizur
report
randomis
doubleblind
phase
cuti
trial
compar
iv
doripenem
mg
iv
levofloxacin
mg
option
switch
oral
levofloxacin
treatment
arm
result
trial
show
doripenem
welltoler
noninferior
levofloxacin
doripenem
effect
major
caus
organ
cuti
includ
escherichia
coli
proteu
mirabili
klebsiella
pneumonia
doripenem
greater
efficaci
patient
remain
intraven
therapi
patient
levofloxacinresist
e
coli
fewer
pathogen
increas
minimum
inhibitori
concentr
therapi
doripenem
levofloxacin
ae
occur
subject
either
treatment
arm
headach
diarrhoea
phlebiti
seriou
studi
drugrel
ae
report
urin
patient
obtain
evalu
assess
urin
bactericid
titer
serum
urin
drug
concentr
data
collect
phase
studi
also
discuss
doripenem
also
complet
phase
trial
versu
piperacillintazobactam
hap
includ
earlyonset
vap
phase
trial
versu
imipenem
vap
earli
late
onset
doripenem
superior
stabil
allow
vap
trial
utilis
extend
infus
regimen
doripenem
may
maximis
difficult
infect
tuberculosi
major
health
threat
million
new
case
million
death
annual
avail
vaccin
bcg
protect
newborn
miliari
tuberculosi
fail
prevent
preval
form
diseas
pulmonari
tuberculosi
adult
one
third
world
popul
infect
etiolog
agent
mycobacterium
tuberculosi
henc
tuberculosi
control
though
erad
immun
respons
induc
natur
infect
ii
bcg
fail
induc
protect
immun
respons
least
individu
suscept
tuberculosi
current
vaccin
strategi
consid
preexposur
postexposur
vaccin
acquir
immun
tuberculosi
celldepend
phenomenon
cell
system
compris
distinct
popul
cell
undoubtedli
central
import
acquir
resist
tuberculosi
antigen
tuberculosi
also
stimul
cell
probabl
crossprim
addit
unconvent
cell
also
seem
particip
immun
tuberculosi
learn
ration
vaccin
design
novel
vaccin
strategi
either
focu
subunit
vaccin
viabl
attenu
vaccin
subunit
vaccin
strategi
base
assumpt
one
antigen
suffic
effici
immun
respons
henc
identif
protect
antigen
repres
essenti
prerequisit
success
type
vaccin
subunit
vaccin
come
three
form
proteinadjuv
formul
recombin
heterolog
carrier
nake
dna
construct
viabl
attenu
vaccin
base
assumpt
multipl
antigen
requir
efficaci
protect
two
major
strategi
pursu
knockout
mutant
tuberculosi
improv
recombin
r
bcg
vaccin
improv
rbcg
first
endow
higher
immunogen
second
may
need
broader
antigen
repertoir
ration
vaccin
strategi
perform
laboratori
author
focu
improv
bcg
rbcg
strain
express
listeriolysin
induc
better
protect
wildtyp
bcg
tempt
specul
primeboost
scheme
compris
prime
improv
rbcg
boost
efficaci
subunit
vaccin
candid
provid
optim
protect
identif
biosignatur
allow
distinct
infectionprotect
infectiondiseas
tuberculosi
could
speed
efficaci
test
vaccin
clinic
trial
grand
challeng
bill
melinda
gate
foundat
aim
identifi
biosignatur
take
advantag
increas
knowledg
immun
respons
tuberculosi
facilit
ration
design
novel
vaccin
one
frighten
threat
world
tuberculosi
follow
year
wit
transform
vaccin
candid
preclin
clinic
trial
requir
intens
coordin
order
identifi
appropri
candid
one
import
characterist
separ
antimicrobi
drug
use
clinic
medicin
target
receptor
drug
part
microb
men
activ
antimicrobi
therefor
studi
vitro
model
system
anim
model
relationship
exposur
effect
establish
exposur
primarili
determin
pharmacokinet
characterist
drug
effect
determin
concentrationeffect
relationship
antimicrobi
microorgan
howev
clinic
set
potenc
antimicrobi
measur
term
mic
concentrationeffect
relationship
therefor
relationship
need
ascertain
mic
exposur
drug
effect
last
decad
pharmacokineticpharmacodynam
pkpd
relationship
antimicrobi
establish
class
drug
two
major
indic
describ
relationship
time
concentr
antimicrobi
remain
mic
mic
fraction
dose
interv
area
time
concentr
curv
hour
divid
mic
aucmic
ratio
peakmic
ratio
correl
effect
number
drug
mani
case
effect
clearli
distinguish
aucmic
effect
importantli
virtual
antimicrobi
exposur
free
nonprotein
bound
fraction
drug
best
correl
efficaci
particular
signific
drug
compar
within
class
andor
across
speci
includ
men
pkpd
relationship
number
issu
come
forward
importantli
shown
number
clinic
trial
exceed
includ
sever
class
drug
pkpd
relationship
exist
anim
expect
similar
men
moreov
shown
quantit
relationship
remark
similar
word
exposur
infect
anim
result
effect
exposur
infect
human
similar
condit
second
perhap
even
import
topic
relationship
well
establish
use
optimis
therapi
patient
optimis
exposur
drug
rel
simpl
approach
relationship
use
daili
clinic
practic
use
clinic
breakpoint
mic
valu
use
discrimin
high
low
probabl
success
outcom
treatment
r
respect
base
pkpd
relationship
antimicrobi
togeth
clinic
set
instanc
lower
exposur
obtain
effect
need
immunocompet
host
contribut
immun
system
sophist
relationship
use
adjust
dose
regimen
mic
infecti
microorgan
known
thu
provid
integr
approach
individu
patient
final
pkpd
relationship
use
develop
phase
drug
determin
optim
dose
indic
sought
altern
dose
regimen
establish
use
form
opinion
possibl
indic
variou
clinic
treatment
modal
dissemin
microbi
drug
resist
observ
antibiot
era
clearli
relat
select
pressur
gener
use
antibiot
clinic
veterinari
agricultur
practic
notion
univers
acknowledg
support
sever
studi
correl
emerg
dissemin
resist
use
new
antibiot
document
absenc
acquir
resist
clinic
isol
preantibiot
era
howev
presenc
antibioticresist
bacteria
recent
report
also
human
wild
anim
live
remot
area
antibiot
exposur
absent
minim
unexpect
find
rais
question
mechan
respons
spread
mainten
antibiot
resist
similar
set
could
import
implic
design
strategi
address
control
bacteri
resist
base
antibiot
restrict
polici
result
studi
antibiot
resist
set
minim
antibiot
exposur
includ
investig
recent
carri
remot
human
commun
live
bolivian
chaco
alto
amazona
jungl
south
america
among
wild
reptil
land
iguana
remot
protect
island
archipelago
document
sourc
antibiot
exposur
minimum
human
contact
critic
review
present
mechan
potenti
involv
dissemin
resist
strain
resist
gene
unrel
antimicrobi
consumpt
discuss
result
characteris
resist
determin
carri
bacteri
isol
set
point
like
origin
antibioticexpos
area
rather
local
independ
resist
select
process
howev
mechan
respons
flow
resist
gene
mainten
spread
absenc
sustain
antibiot
use
remain
elus
object
object
studi
identifi
chop
contain
protein
characteris
function
virul
p
aeruginosa
method
identifi
chop
contain
protein
bacteri
cell
fraction
separ
fplc
fraction
analys
western
blot
use
specif
monoclon
antichop
antibodi
contain
chop
epitop
purifi
sdspage
protein
contain
chop
epitop
cut
gel
trypsinis
subject
capillari
lcm
msm
chop
epitop
express
whole
cell
extract
genet
unrel
p
aeruginosa
isol
chronic
infect
acut
infect
analys
western
blot
analysi
use
specif
monoclon
antichop
antibodi
chop
epitop
express
also
analys
flow
cytometri
immunofluoresc
microscopi
intact
cell
p
aeruginosa
determin
whether
chop
epitop
involv
interact
p
aeruginosa
isol
respiratori
epitheli
cell
standard
invas
assay
perform
use
cell
either
treat
untreat
pafr
antagonist
chop
contain
protein
shown
elong
factor
tu
eftu
express
chop
epitop
significantli
frequent
p
aeruginosa
strain
isol
chronic
infect
acut
infect
chop
epitop
shown
express
outer
surfac
bacteri
cell
bacteri
invas
significantli
inhibit
treatment
pafr
antagonist
compar
control
demonstr
p
aeruginosa
chop
epitop
associ
eftu
high
percentag
isol
chronic
infect
comparison
acut
infect
express
epitop
epitop
present
cell
surfac
mediat
invas
airway
epitheli
cell
via
pafr
object
aim
develop
novel
therapi
treatment
gramneg
bacteri
infect
isol
monoclon
antibodi
capabl
bind
signal
molecul
involv
bacteri
quorum
sens
signal
blockad
hypothesis
prevent
product
virul
factor
allow
host
immun
system
elimin
infect
method
gramneg
bacteri
signal
molecul
typic
low
molecular
weight
less
da
consid
intract
standard
antibodi
discoveri
methodolog
therefor
use
novel
suit
antibodi
discoveri
process
term
haptom
isol
panel
human
antibodi
capabl
bind
signal
molecul
produc
gramneg
bacteria
result
demonstr
abil
antibodi
bind
bacteri
signal
molecul
use
rang
vitro
experi
also
evalu
antibodi
use
vivo
model
pseudomona
aeruginosa
infect
result
present
demonstr
efficaci
fulli
human
recombin
antibodi
fragment
whole
igg
molecul
treatment
gramneg
bacteri
infect
conclus
approach
offer
excit
prospect
use
power
immunolog
reagent
combat
bacteri
infect
target
signal
molecul
rather
bacteria
believ
resist
consider
less
like
develop
antibodybas
therapeut
current
broaden
approach
develop
antibodi
capabl
disrupt
quorum
sens
gramposit
organ
object
pseudomona
aeruginosa
freeliv
extracellular
common
environment
bacterium
opportunist
nosocomi
pathogen
caus
seriou
health
problem
compet
predat
macrophag
environment
phagocyt
utilis
differ
surviv
strategi
biofilm
format
microcoloni
also
develop
resist
mechan
produc
virul
factor
lipopolysaccharid
algin
well
extracellular
quorum
sens
regul
enzym
toxin
type
iii
secret
system
ttss
aim
studi
examin
interact
p
aeruginosa
acanthamoeba
castellanii
method
bacteria
amoeba
cocultur
interact
examin
p
aeruginosa
castellanii
cocultiv
viabl
count
eosin
stain
electron
microscopi
apoptosi
assay
statist
analysi
result
show
p
aeruginosa
induc
necrosi
apoptosi
kill
castellanii
effect
ttss
protein
exou
exo
exot
exoy
comparison
growth
acanthamoeba
cultur
alon
cocultur
ttss
mutant
strain
affect
result
confirm
natur
p
aeruginosa
strict
extracellular
bacterium
need
ttss
surviv
environ
sinc
system
abl
kill
eukaryot
predat
acanthamoeba
instanc
one
three
method
agre
suscept
test
linezolid
strain
carri
rrna
mutat
show
mic
valu
linezolid
ugml
test
phoenix
etest
vitek
display
mic
ugml
conclus
glycopeptid
resist
enterococci
pose
seriou
therapeut
problem
accur
microbiolog
diagnosi
fundament
treatment
result
evidenc
high
rate
discrep
detect
glycopeptid
resist
three
wide
diffus
suscept
test
method
furthermor
limit
observ
detect
linezolid
resist
prospect
could
reduc
therapeut
option
increas
blactam
resist
e
coli
becom
worri
threat
worldwid
speci
mechan
involv
blactam
resist
link
product
blactamas
includ
clavulanicacid
inhibit
expandedspectrum
blactamas
esbl
carbapenemas
power
enzym
abl
degrad
blactam
besid
common
esbl
circul
enterobacteriacea
tem
shv
ctxmtype
emerg
enzym
mostli
plasmidencod
distribut
larg
varieti
speci
esbl
known
largerli
distribut
southeast
asia
turkey
itali
korea
also
south
america
gesibctyp
enzym
greec
japan
mostli
esbl
known
effici
hydrolyz
expandedspectrum
blactam
variant
ge
famili
also
hydrolys
imipenem
low
level
enzym
kpc
famili
also
report
e
coli
shown
preval
e
coli
israel
reporti
sporad
usa
latter
enzym
consid
esbl
sinc
inhibit
clavulan
acid
hydrolyt
effici
toward
imipenem
high
thu
give
rise
high
level
resist
carbapenem
e
coli
isol
addit
esbl
determin
metalloblactamas
mbl
identifi
e
coli
enzym
inhibit
clavulan
acid
hydrolys
carbapenem
effici
imp
vim
group
e
coli
identifi
japan
greec
worri
observ
relat
spread
greec
inde
determin
identifi
clinic
isol
also
harbour
esbl
encod
gene
thu
lead
panresist
strain
noteworthi
esbl
mbl
encod
gene
encount
e
coli
vehicul
plasmid
locat
class
integron
structur
thu
facilit
occurr
multidrug
resist
via
colocalis
antibiot
resist
gene
particular
attent
need
next
futur
trace
isol
harbour
worri
determin
also
trace
correspond
plasmid
power
tool
dissemin
sever
sepsi
seriou
syndrom
organ
failur
may
affect
larg
proport
patient
admit
intens
care
unit
whose
predict
often
difficult
surviv
sepsi
campaign
ssc
global
programm
reduc
mortal
rate
sever
sepsi
endors
intern
medic
societi
campaign
produc
guidelin
manag
sever
sepsi
septic
shock
recommend
review
annual
meet
societi
critic
care
medicin
held
januari
campaign
taken
action
creat
nation
intern
network
collect
data
monitor
intervent
itali
network
settl
septemb
monitor
therapi
sever
sepsi
concept
tool
idea
attitud
differ
larg
centr
aim
answer
crucial
question
conduct
survey
percept
sever
sepsi
diagnosi
monitor
nation
network
italian
chapter
ssc
twentythre
particip
centr
commun
teach
hospit
respond
survey
total
number
icucrit
care
bed
particip
ask
describ
methodolog
current
use
implement
data
institut
respond
adopt
continu
data
collect
methodolog
event
design
question
whether
educ
tool
use
sensitis
peopl
campaign
respond
declar
specif
tool
use
centr
state
use
differ
educ
mean
mostli
chart
document
depart
confer
ask
data
collect
diagnosi
sepsi
usual
take
place
thirteen
respond
said
collect
occur
within
hour
diagnosi
contemporari
retrospect
question
data
collect
institut
answer
ssc
paper
tool
databas
use
combin
two
system
centr
respons
data
collect
assign
attend
physician
remain
case
resid
nurs
student
collect
data
centr
allow
simultan
collabor
figur
partnership
icu
depart
approach
sepsi
spirit
ssc
unfortun
scarc
respond
form
collabor
unit
effect
mental
interview
hospit
current
appli
screen
sever
sepsi
ward
one
main
concept
illustr
spirit
ssc
idea
earli
intervent
appli
differ
recommend
check
time
present
sepsi
conceiv
emerg
depart
ward
icu
obtain
answer
quit
divers
particip
institut
respond
physician
emerg
depart
identifi
present
time
sever
sepsi
moment
triag
hospit
admiss
remain
sort
posteriori
diagnosi
lose
possibl
earli
approach
thing
much
wors
look
ward
case
moment
sever
sepsi
present
correspond
identif
symptom
posteriori
review
medic
note
arriv
critic
care
consult
icu
admiss
surprisingli
icu
still
case
usual
diagnos
review
medic
report
eucast
subcommitte
antifung
suscept
test
eucastafst
recent
publish
standard
determin
suscept
ferment
yeast
antifung
besid
anoth
standard
relat
suscept
filament
fungi
antifung
publish
soon
eucast
gener
committe
recent
publish
guidelin
harmonis
breakpoint
antimicrobi
therefor
antifung
suscept
test
subcommitte
eucast
adopt
order
prove
breakpoint
antifung
obtain
eucastafst
decid
make
proof
concept
fluconazol
requir
rais
eucast
committe
obtain
break
point
antimicrobi
address
fluconazol
break
point
attain
data
obtain
revis
system
obtain
break
point
fluconazol
discuss
also
discrep
eucast
clsi
break
point
examin
analys
near
futur
intent
eucast
afst
develop
break
point
licens
antifung
object
recent
year
k
pneumonia
shown
increas
resist
due
product
extendedspectrum
blactamas
esbl
metalloblactamas
mbl
aim
studi
record
bacteraemia
due
k
pneumonia
icu
analys
pattern
resist
well
clinic
characterist
ensu
infect
method
prospect
observ
studi
patient
hospitalis
icu
septemb
octob
demograph
characterist
patient
admit
record
well
underli
diseas
diseas
sever
estim
apach
ii
score
possibl
factor
predispos
infect
previou
consumpt
antibiot
suscept
test
cultur
isol
perform
microscan
outcom
bacteraemia
record
statist
analysi
done
espss
result
studi
period
patient
admit
icu
episod
bacteraemia
record
due
k
pneumonia
isol
resist
follow
ampicillin
blactamas
inhibitor
cephalosporin
imipenem
mic
mgl
aztreonam
quinolon
aminoglycosid
isol
suscept
colistin
mic
mgl
carbapenemresist
isol
crkp
also
resist
antibiot
test
except
aztreonam
gentamicin
sensit
respect
bacteria
isol
patient
mean
age
year
male
surgic
mean
apach
ii
score
ten
bacteraemia
primari
secondari
ventilatorassoci
pneumonia
catheterrel
mortal
patient
bacteraemia
due
crkp
sensit
strain
p
outcom
significantli
relat
apach
ii
score
p
patient
bacteraemia
due
crkp
previous
receiv
carbapenem
carbapenemsensit
isol
receiv
carbapenem
p
conclus
infect
due
k
pneumonia
resist
carbapenem
repres
seriou
clinic
problem
icu
associ
high
mortal
rate
seem
previou
use
carbapenem
lead
increas
resist
larger
studi
need
order
obtain
statist
signific
result
object
nosocomi
infect
surveil
perform
italian
icu
order
pretest
helic
protocol
nationwid
implement
evalu
impact
rout
acquisit
three
emerg
multiresist
pathogen
pseudomona
aeruginosa
acinetobact
baumannii
stenotrophomona
maltophilia
determin
occurr
carriag
admiss
ii
microrganismspecif
icuacquir
infect
rate
site
iii
impact
crosstransmiss
use
molecular
type
data
iv
individu
risk
factor
infect
method
sixmonth
surveil
survey
perform
icu
italian
hospit
accord
helic
protocol
exclud
patient
stay
less
three
day
electron
data
form
design
use
spss
data
entri
enterpris
server
spss
inc
clonal
determin
macrorestrict
analysi
use
well
establish
criteria
presenc
two
indistinguish
strain
two
patient
consid
one
episod
crosstransmiss
result
studi
period
patient
enrol
survey
total
day
icuacquir
infect
rate
patient
incid
densiti
patientday
occurr
p
aeruginosa
carriag
admiss
patient
episod
baumannii
maltophilia
carriag
identifi
icuacquir
p
aeruginosa
baumannii
maltophilia
associ
infect
rate
respect
patient
incid
densiti
respect
patientday
icuacquir
pneumonia
confirm
first
infect
type
follow
bloodstream
infect
bsi
local
cvcrelat
infect
urinari
tract
infect
cvcrelat
bsi
surgic
site
infect
eighteen
p
aeruginosa
one
baumannii
four
maltophilia
distinct
clone
identifi
macrorestrict
analysi
total
isol
impact
crosstransmiss
estim
least
thu
defin
prevent
proport
crosstransmiss
episod
two
major
risk
factor
identifi
inappropri
manag
invas
devic
antimicrobi
usag
conclus
studi
confirm
essenti
role
epidemiolog
surveil
provid
advanc
riskadjust
infect
rate
measur
qualiti
care
object
role
multigen
pe
famili
protein
uniqu
mycobacteria
pathogenesi
tuberculosi
still
poorli
understood
tumour
necrosi
factoralpha
tnfa
essenti
success
combat
tuberculosi
object
understand
surfaceexpos
protein
known
undergo
variat
among
strain
influenc
tnfa
releas
macrophag
link
apoptosi
macrophag
method
recombin
test
abil
releas
tnfa
macrophag
cell
line
well
human
monocytederiv
macrophag
bind
cell
surfac
analys
flow
cytometri
role
studi
transfect
cell
dominantneg
prior
analys
tnfa
releas
signal
pathway
activ
studi
assay
mitogenactiv
protein
kinas
mapk
kinas
kinas
downstream
mapk
cell
death
analys
use
histon
elisa
also
assay
surfaceassoci
annexinfitc
result
surfac
expos
protein
elicit
tnfa
releas
macrophag
tolllik
receptor
depend
manner
apoptosi
signalregul
kinas
activ
downstream
activ
mitogenactiv
protein
kinas
mapk
jnk
signal
lead
enhanc
express
tnfa
tnf
receptor
tnfri
gene
mycobacterium
smegmati
express
elicit
effect
purifi
neutralis
tnfa
antibodi
show
releas
tnfa
requir
trigger
apoptosi
macrophag
challeng
death
receptordepend
signal
amplifi
classic
caspas
mitochondri
releas
cytochrom
c
lead
activ
caspas
import
aspect
find
delet
within
pgr
domain
simul
occur
clinic
strain
attenu
tnfainduc
abil
result
provid
first
evid
variat
polymorph
repeat
pgr
domain
modul
innat
immun
respons
object
understand
role
bacteri
surviv
stress
method
evalu
role
mycobacteri
surviv
gene
encod
disrupt
smegmati
homolog
recombin
effect
stress
wild
type
mutant
analys
also
silenc
antisens
tuberculosi
result
strain
smegmati
exhibit
significantli
reduc
intracellular
surviv
murin
raw
macrophag
compar
surviv
wild
type
counterpart
exhibit
extend
lag
phase
growth
shift
low
phosphatecontain
medium
unabl
grow
nitrogendeplet
medium
impair
abil
surviv
anaerob
condit
show
decreas
transcript
stringent
respons
regul
rela
tuberculosi
could
complement
mutant
antisens
gene
tuberculosi
also
show
reduc
level
rela
transcript
mutant
defect
abil
form
biofilm
conclus
like
play
role
mycobacteri
persist
potenti
target
drug
develop
object
object
studi
evalu
cholesterol
oxidas
chod
put
virul
factor
mycobacterium
tuberculosi
method
twostep
recombin
protocol
use
replac
cholesterol
oxidas
gene
nonfunct
copi
pathogen
result
strain
analys
vitro
use
periton
macrophag
vivo
mice
infect
result
cholesterol
oxidas
known
key
enzym
initi
cholesterol
degrad
process
mani
soil
bacteria
includ
fast
grow
mycobacteria
pathogen
mycobacteria
accumul
cholesterol
without
utilis
express
cholesterol
oxidas
extracellular
enzym
homolog
recombin
use
construct
tuberculosi
strain
unmark
delet
within
chod
gene
wild
type
tuberculosi
strain
mtwt
chodmut
mutchod
mutant
complement
chod
gene
control
heat
shock
protein
promot
mutchodphspchod
use
studi
function
cholesterol
oxidas
mycobacteri
pathogenesi
periton
macrophag
well
infect
mtwt
mutchod
mutchodphspchod
tuberculosi
strain
well
incub
four
six
day
number
mtwt
mutchodphspchod
viabl
bacteria
recov
macrophag
least
order
magnitud
higher
compar
mutcho
strain
reveal
cfu
analysi
strain
use
infect
mice
ten
week
post
infect
lung
spleen
isol
euthanis
mice
number
viabl
bacteria
organ
detect
cfu
analys
least
mice
group
strong
attenu
chod
mutant
observ
compar
wild
type
complement
strain
studi
cytokinechemokin
profil
associ
ltbi
tb
order
gain
insight
ongo
immun
activ
event
mtbinfect
method
blood
obtain
patient
cultureconfirm
tb
n
recent
acquir
ltbi
n
healthcar
worker
without
mtb
exposur
n
interferongamma
ifng
releas
sensitis
lymphocyt
upon
ex
vivo
stimul
mtbspecif
antigen
determin
use
quantiferontb
gold
tube
assay
recommend
manufactur
cellesti
ltd
carnegi
australia
microspherebas
multiplex
assay
lincoplex
linco
research
inc
st
charl
usa
use
assess
plasma
concentr
ifng
tnfa
fraktalkin
gmcsf
nil
tbag
ex
vivo
stimul
valu
determin
use
bioplex
manag
biorad
laboratori
hercul
ca
usa
limit
detect
pgml
statist
analysi
perform
use
prism
graphpad
softwar
inc
san
diego
ca
usa
kruskalw
test
use
multipl
group
comparison
mannwhitney
test
group
group
comparison
result
ifng
gmcsf
concentr
significantli
higher
patient
tb
ltbi
compar
control
tabl
conclus
mean
plasma
concentr
higher
ifng
patient
activ
tb
ltbi
assess
might
substanti
increas
sensit
ifng
releas
assay
igra
detect
mtb
infect
ex
vivo
profil
cytokineschemokin
use
igra
combin
flowcytomet
multiplex
assay
identifi
addit
candid
paramet
confirm
mtb
infect
improv
understand
tb
pathogenesi
result
suggest
isol
patient
hospit
ii
ident
transmiss
patient
hospit
hospit
ii
found
vice
versa
indic
preval
one
prevail
c
difficil
strain
local
region
binari
toxin
found
isol
indic
strain
neither
nap
conclus
one
c
difficil
strain
seem
predomin
northern
bavaria
cdad
patient
increas
number
cdad
case
probabl
promot
common
event
eg
increas
antibiot
use
due
respiratori
infect
winter
therefor
infect
control
programm
restrict
spread
c
difficil
restrict
hospit
also
impli
healthcar
facil
nurs
home
hous
doctor
giardia
lamblia
yersinia
enterocolitica
isol
patient
respect
c
difficil
detect
faec
sampl
patient
moderatesever
diarrhoea
suffer
mild
diarrhoea
patient
communityonset
cdad
healthcareassoci
onset
symptom
within
h
follow
admiss
within
week
discharg
communityassoci
mean
age
patient
male
femal
cdad
year
frequent
underli
diseas
cardiovascular
diseas
urogenit
diseas
lung
diseas
diabet
mellitu
malign
recent
antibiot
use
report
patient
cephalosporin
fluoroquinolon
frequent
patient
receiv
ppi
nsaid
preliminari
result
type
strain
reveal
differ
type
type
type
predomin
type
conclus
clostridium
difficil
frequent
caus
diarrhoea
popul
patient
visit
gp
diarrhoea
healthcareassoci
object
clostridium
difficil
infect
implic
case
antibioticassoci
diarrhoea
studi
evalu
risk
factor
develop
c
difficileassoci
diarrhoea
cdad
patient
antibioticassoci
diarrhoea
object
compar
clinic
characterist
hospitalis
patient
receiv
antibiot
develop
cdad
hospitalis
patient
receiv
antibiot
develop
diarrhoea
neg
c
difficil
toxin
assay
stool
method
prospect
cohort
studi
hospitalis
patient
receiv
antibiot
develop
diarrhoea
includ
cdad
patient
defin
patient
diarrhoea
associ
posit
stool
toxin
ab
enzym
immunoassay
test
univari
stepwis
logist
regress
analys
use
predict
c
difficil
toxin
predict
capabl
model
demonstr
receiv
oper
characterist
roc
curv
result
fiftytwo
patient
found
posit
c
difficil
toxin
ab
stool
logist
regress
model
includ
impair
function
capac
wateri
diarrhoea
use
proton
pump
inhibitor
use
histamin
receptor
blocker
leukocytosi
hypoalbuminaemia
area
receiv
oper
characterist
curv
model
predictor
posit
stool
toxin
assay
ci
p
specif
sensit
conclus
result
may
help
clinician
predict
risk
cdad
hospitalis
patient
antibioticassoci
diarrhoea
guid
care
antibiot
prescript
earli
attent
infect
control
issu
inpati
case
receiv
oral
met
vanc
analys
initi
dual
therapi
case
exclud
group
compar
demograph
prior
cdad
admiss
comorbid
proxi
measur
aprdrg
sever
ill
soi
risk
mortal
rom
length
stay
lo
inhospit
mortal
icu
stay
colon
resect
defin
case
outcom
chisquar
ttest
produc
pvalu
result
identifi
cdad
case
treat
first
met
vanc
case
similar
age
mean
year
p
fewer
p
met
vanc
case
femal
vs
princip
cdad
diagnosi
vs
prior
cdad
admiss
vs
prior
acid
suppress
therapi
vs
higher
soi
rom
observ
met
vs
vanc
p
met
vanc
rate
extrem
soi
hospitalis
vanc
case
subsequ
receiv
met
met
receiv
vanc
met
vanc
receiv
iv
met
unknown
specif
cdad
met
vanc
receiv
rifampin
met
vs
vanc
increas
lo
vs
day
p
inhospit
death
vs
p
icu
stay
vs
day
p
differ
colectomi
met
vs
vanc
p
despit
lower
cost
met
vs
vanc
therapi
total
pharmaci
cost
similar
vs
p
total
hospitalis
cost
higher
vs
p
conclus
cdad
patient
receiv
met
modif
initi
therapi
occur
similar
proport
met
vanc
case
compar
initi
vanc
therapi
treat
met
higher
rate
poor
discharg
outcom
greater
resourc
use
howev
comparison
adjust
acut
comorbid
background
sinc
sever
case
clostridium
difficil
cd
associ
diarrhoea
cdad
report
hospit
north
america
europ
caus
hypervirul
strain
cd
ribotyp
toxinotyp
iii
ribotyp
also
detect
netherland
object
descript
studi
incid
cdad
introduct
specif
infect
control
measur
region
outbreak
due
type
method
case
cdad
defin
patient
diarrhoea
posit
toxin
test
faec
sampl
ictab
meridian
strain
isol
posit
faec
sampl
investig
pcr
ribotyp
public
health
laboratori
haarlem
netherland
servic
area
inhabit
includ
nurs
home
three
hospit
b
c
monthli
admiss
rate
latter
respect
overal
admiss
rate
yearli
retrospect
evalu
laboratori
data
show
short
episod
cdad
outbreak
hospit
octob
incid
admiss
june
hospit
c
decemb
april
highest
cdad
increas
found
hospit
b
august
latter
episod
found
start
longterm
increas
cdad
incid
peak
admiss
per
month
hospit
well
one
nurs
home
hospit
patient
transfer
quarter
cd
strain
hospitalis
patient
belong
hypervirul
ribotyp
specif
measur
cdad
introduc
hospit
nurs
home
strict
barrier
precaut
privat
room
glove
use
gown
hand
wash
environment
clean
bleach
restrict
use
fluoroquinolon
also
laboratori
algorithm
introduc
investig
faecal
sampl
hospitalis
patient
diarrhoea
subsequ
part
part
cdad
incid
decreas
mean
rang
admiss
correspond
nation
incid
percentag
type
strain
decreas
period
respect
conclus
specif
hygien
measur
combin
restrict
antibiot
prescript
intensifi
laboratori
surveil
success
overcom
cd
outbreak
wholegenom
multistrain
bacteri
microarray
use
take
rapid
snapshot
gene
presenc
absenc
unsequenc
bacteri
genom
allow
larg
bacteri
popul
interog
genet
marker
phenotyp
clinic
evolutionari
behaviour
design
built
sevenstrain
staphylococcu
aureu
microarray
use
compar
aureu
isol
nasal
carriag
communityand
hospitalacquir
diseas
found
aureu
genom
consist
three
part
core
core
variabl
cv
mobil
genet
element
mge
gene
aureu
genom
common
strain
call
core
surprisingli
gene
cv
presenc
absenc
variab
use
classifi
isol
one
ten
human
lineag
classif
match
well
multilocu
sequenc
type
clonal
complex
mani
cv
gene
regul
virul
gene
known
predict
express
bacteri
surfac
interact
host
nasal
colonis
infect
sinc
lineag
carri
uniqu
combin
cv
gene
scatter
throughout
chromosom
like
common
aureu
ancestor
earli
evolutionari
diverg
lineag
possibl
select
nose
mge
often
carri
key
resist
virul
gene
show
substanti
variat
within
lineag
indic
frequent
horizont
transfer
interestingli
unabl
identifi
marker
differ
carriag
typic
invas
commun
isol
camrsa
suggest
communityacquir
invas
diseas
strongli
depend
host
factor
also
discov
like
mechan
control
independ
evolut
lineag
restrict
modif
pathway
found
aureu
call
block
horizont
transfer
dna
isol
specif
system
vari
accord
lineag
thu
dna
one
lineag
recogn
foreign
digest
lineag
self
isol
lineag
explain
independ
lineag
evolut
import
implic
aureu
continu
evolv
particular
acquir
mge
lead
increasingli
antibiot
resist
virul
strain
baselin
laboratori
facil
remot
site
africa
muchtoo
littl
provis
medic
care
privat
fund
isol
popul
geograph
socioeconom
remot
area
world
pose
challeng
provid
maximum
laboratori
support
medic
paramed
personnel
cost
effect
way
requir
pragmat
approach
base
knowledg
clinic
signific
diseas
area
either
due
high
clinic
signific
incid
high
risk
signific
morbid
mortal
due
diseas
outcom
may
requir
may
benefit
reliabl
afford
readili
avail
laboratori
diagnost
author
provid
perspect
challeng
base
provis
medic
servic
multin
compani
oper
remot
area
africa
limit
budget
ten
year
period
set
rel
small
number
expatri
nation
employe
taken
care
limit
fund
healthcar
provid
need
awar
health
risk
profil
region
servic
render
like
exposur
popul
serv
preval
diseas
avail
laboratori
test
could
would
make
signific
differ
clinic
diseas
manag
avail
main
limit
factor
provis
laboratori
support
medic
servic
fund
laboratori
equip
may
vari
number
simpl
dri
chemistri
base
kit
sophist
spectrophotomet
technolog
base
analys
number
factor
impact
includ
eas
oper
provid
test
sensit
specif
qualiti
assur
sustain
absenc
train
laboratori
personnel
often
signific
determin
decis
make
process
regard
level
sophist
achiev
african
contin
advent
rapid
malaria
antigen
test
kit
major
impact
suspect
malaria
case
manag
absenc
train
miscroscopist
long
stand
main
stay
sideroom
diagnost
blood
urin
test
kit
capabl
detect
number
metabol
diseas
prove
cost
effect
regularli
use
afford
sustain
whilst
sophist
dri
chemistri
analysi
machin
find
limit
applic
remot
site
limit
medic
infrastructur
dri
chemistri
test
may
use
set
superflu
set
patient
requir
eg
regular
kidney
function
monitor
need
evacu
due
overal
limit
beset
area
migrant
mobil
individu
migrant
worker
asylum
seeker
expand
global
popul
grow
social
demograph
polit
import
often
grave
dispar
exist
place
origin
destin
particular
relat
health
determin
effect
dispar
observ
individu
popul
level
migrat
influenc
epidemiolog
mani
diseas
global
nation
receiv
migrant
specif
diseasebas
outcom
may
vari
migrant
group
locat
tradit
migrat
health
activ
design
nation
applic
lack
integr
intern
perspect
present
futur
health
challeng
relat
migrat
may
effect
address
collabor
global
undertak
epidemiolog
relationship
result
health
dispar
migrat
review
grow
role
migrat
popul
mobil
global
diseas
epidemiolog
highlight
implic
nation
intern
health
polici
programm
plan
present
last
decad
southeast
asia
becom
epicentr
number
new
diseas
outbreak
potenti
global
spread
nipah
viru
enceph
first
occur
malaysia
serolog
evid
viru
spread
cambodia
thailand
china
india
bangladesh
nipah
viru
one
close
relat
caus
sever
outbreak
bangladesh
high
mortal
rate
outbreak
sever
acut
respiratori
syndrom
sar
follow
avian
influenza
china
subsequ
spread
led
fear
global
pandem
mani
factor
account
emerg
new
infect
must
place
prior
outbreak
converg
number
factor
southeast
asia
make
region
hotspot
emerg
order
mount
programm
fight
emerg
viral
diseas
import
adequ
fund
polit
commit
key
comprehens
programm
includ
good
surveil
clinic
hospit
manag
prevent
diseas
spread
strong
laboratori
support
research
evalu
welltest
nation
prepared
plan
surveil
complic
case
zoonot
diseas
avian
influenza
hospit
illequip
cater
larg
number
sever
ill
patient
nipah
viru
outbreak
malaysia
prevent
diseas
spread
era
globalis
pose
tremend
challeng
develop
countri
depend
intern
trade
tourism
research
evalu
greatli
hamper
lack
manpow
infrastructur
includ
lack
high
secur
laboratori
although
guidelin
avail
pandem
prepared
case
avian
influenza
nation
plan
total
inadequ
measur
expect
despit
inadequaci
develop
countri
southeast
asia
make
conting
plan
event
unexpect
viral
emerg
doubt
uphil
battl
certain
measur
initi
region
hope
reduc
spread
emerg
viral
diseas
antimicrobi
drug
discoveri
road
long
symposium
arrang
icaac
program
committe
cell
wall
inhibitor
tradit
provid
infecti
diseas
commun
safe
efficaci
agent
treat
seriou
bacteri
infect
addit
metabol
inhibitor
singli
combin
continu
provid
coverag
resist
pathogen
methicillinresist
staphylococcu
aureu
mrsa
cell
wall
inhibitor
pipelin
blactam
major
compon
antibiot
discoveri
programm
lag
develop
multidrugresist
gramposit
bacteria
mrsa
cephalosporinresist
gramneg
organ
emerg
preval
nosocomi
pathogen
compound
late
stage
develop
includ
antimrsa
blactam
ceftobiprol
broadspectrum
cephalosporin
success
complet
two
phase
iii
trial
complic
skin
skin
structur
infect
csssi
follow
two
investig
antimrsa
blactam
antimrsa
cephalosporin
ceftarolin
complet
phase
ii
csssi
trial
carbapenem
vitro
activ
mrsa
cephalosporinresist
enterobacteriacea
also
develop
two
addit
carbapenem
phase
studi
activ
mrsa
well
enterobacteriacea
demonstr
vitro
activ
mani
multidrugresist
gramposit
gramneg
bacteria
preclin
studi
blactam
agent
develop
includ
doripenem
carbapenem
enhanc
activ
pseudomona
aeruginosa
doripenem
recent
complet
clinic
trial
complic
urinari
tract
infect
intraabdomin
infect
unusu
preclin
cephalosporin
promis
vitro
activ
helicobact
pylori
ampchyperproduc
p
aeruginosa
addit
cell
wall
activ
agent
includ
lipoglycopeptid
inhibitor
activ
gramposit
bacteria
telavancin
dalbavancin
latestag
regulatori
review
characteris
long
half
live
human
propos
onceweekli
dose
regimen
dalbavancin
iclaprim
dihydrofol
reductas
inhibitor
advanc
metabol
inhibitor
complet
phase
iii
csssi
clinic
trial
demonstr
vitro
antibacteri
activ
mrsa
penicillinresist
pneumococci
respiratori
pathogen
metabol
inhibitor
describ
earli
develop
includ
peptid
deformylas
inhibitor
inhibitor
fatti
acid
biosynthesi
howev
none
earli
metabol
inhibitor
proceed
proofofconcept
therapeut
studi
time
compound
bank
approach
complement
increas
chanc
success
sinc
public
first
complet
bacteri
genom
genomederiv
target
base
approach
discov
new
class
antibacteri
drug
novel
mechan
action
employ
wide
literatur
show
success
rate
biochem
screen
individu
antibacteri
target
wholecel
antibacteri
screen
disappoint
retrospect
surpris
given
histor
content
chemic
collect
compani
employ
earli
high
throughput
screen
campaign
compani
engag
cleaningup
compound
librari
recent
year
increas
molecular
divers
collect
effort
increas
chanc
success
regardless
therapeut
area
effort
also
made
creat
focuss
chemic
librari
better
suit
find
antibacteri
compound
complement
screen
divers
druglik
infectionfriendli
compound
collect
drugabl
target
earli
applic
structurebas
approach
see
breakthrough
discoveri
antibacteri
drug
novel
mechan
action
natur
product
approach
advanc
last
year
make
attract
approach
urgent
medic
need
discov
develop
new
antibiot
sinc
resist
antibiot
becom
increasingli
frequent
problem
current
develop
pipelin
lack
innov
novel
antibiot
class
past
natur
product
domin
field
antibiot
signific
role
discoveri
develop
commerci
success
drug
class
antibacteri
new
chemic
entiti
nce
introduc
worldwid
base
natur
product
unmatch
chemic
divers
complex
natur
product
one
reason
success
obtain
pure
chemic
synthesi
anoth
reason
superior
explain
fact
synthesi
evolv
natur
respons
need
challeng
natur
environ
gener
compound
preselect
activ
despit
fact
natur
product
research
recent
gone
phase
reduc
interest
big
pharmaceut
compani
particular
downgrad
even
stop
kind
research
reason
develop
may
natur
product
often
produc
low
quantiti
mixtur
similar
compound
rediscoveri
known
compound
challeng
natur
product
derivatis
use
classic
chemic
mean
past
year
wit
major
develop
use
innov
natur
product
relat
technolog
ferment
optimis
separ
structur
elucid
derepl
allow
much
faster
access
suffici
quantiti
pure
natur
compound
applic
modern
medicin
chemistri
adapt
special
need
natur
product
also
effici
way
revisit
recycl
old
antibiot
class
use
modern
genomebas
technolog
establish
past
year
offer
opportun
increas
attract
natur
product
genomebas
screen
technolog
provid
fast
access
enorm
genet
potenti
actinomycet
soil
bacteria
known
repres
one
import
sourc
bioactiv
metabolit
addit
genet
engin
technolog
help
overcom
two
main
hurdl
connect
natur
product
difficulti
derivatis
complex
structur
quantit
improv
product
yield
focuss
exampl
field
genom
base
screen
genet
engin
present
give
overview
major
improv
may
lead
rediscoveri
natur
product
base
drug
meet
urgent
need
new
antibiot
object
recent
describ
discoveri
novel
group
coronaviru
coronaviru
patient
pneumonia
studi
examin
molecular
epidemiolog
genotyp
distribut
recombin
method
collect
nasopharyng
aspir
patient
respiratori
tract
infect
twoyear
period
complet
genom
total
strain
sequenc
compar
genotyp
possibl
site
recombin
determin
result
phylogenet
analysi
put
protein
polypeptid
show
strain
fell
three
cluster
genotyp
strain
genotyp
b
three
strain
genotyp
c
six
strain
howev
differ
phylogenet
relationship
among
three
cluster
observ
differ
region
genom
genotyp
strain
cluster
genotyp
b
strain
genotyp
strain
cluster
genotyp
c
strain
hemagglutinin
esteras
nucleocapsid
n
genotyp
b
strain
cluster
close
genotyp
c
strain
bootscan
analysi
show
possibl
recombin
genotyp
b
c
nucleotid
posit
correspond
junction
give
rise
genotyp
genotyp
b
nucleotid
posit
correspond
junction
give
rise
genotyp
c
multipl
align
narrow
site
crossov
region
nucleotid
posit
region
nucleotid
posit
genom
analysi
also
reveal
variabl
number
tandem
copi
perfect
acid
tandem
repeat
encod
nddedvvtgd
variabl
number
sequenc
imperfect
repeat
ntermin
insid
acid
domain
upstream
papainlik
proteas
among
genom
incomplet
imperfect
repeat
belong
genotyp
conclus
three
genotyp
genotyp
genotyp
b
genotyp
c
exist
analysi
singl
gene
suffici
genotyp
would
requir
amplif
sequenc
least
two
gene
loci
one
eg
pol
helicas
anoth
n
eg
spike
n
influenza
activ
temper
region
australia
typic
occur
may
septemb
wherea
tropic
region
influenza
occur
time
throughout
year
main
purpos
present
outlin
epidemiolog
human
influenza
nsw
second
purpos
report
qualiti
assur
programm
laboratori
diagnosi
influenza
throughout
australia
includ
avian
influenza
epidemiolog
data
nsw
princ
wale
hospit
sydney
show
respiratori
syncyti
viru
rsv
first
respiratori
viru
emerg
winter
season
influenza
infect
typic
last
week
august
septemb
infect
respiratori
virus
parainfluenza
viru
human
metapneumoviru
occur
june
late
novemb
decemb
summari
data
last
year
present
influenza
data
indic
first
one
affect
earli
season
children
young
adult
wherea
peak
season
major
year
age
even
distribut
number
influenza
attack
among
male
femal
respect
total
specimen
test
respiratori
virus
true
influenza
case
rsv
rhinoviru
data
collect
princ
wale
hospit
submit
weekli
basi
new
south
wale
depart
health
part
nsw
influenza
surveil
program
undertaken
qualiti
assur
program
aim
improv
detect
diagnosi
hpai
among
australian
asian
laboratori
collabor
royal
colleg
pathologist
australia
rcpa
elizabeth
macarthur
agricultur
institut
integr
human
veterinari
health
laboratori
project
assess
diagnosi
accuraci
use
serolog
molecular
techniqu
utilis
new
avian
influenza
modul
within
serolog
qualiti
assur
program
sqap
report
first
nucleic
acid
test
panel
alreadi
avail
particip
laboratori
result
suggest
test
laboratori
around
australia
asia
gener
utilis
accur
sensit
method
detect
although
laboratori
test
influenza
current
perform
specif
test
object
influenza
pandem
prepared
plan
current
develop
nation
intern
level
plan
public
health
respons
reli
predict
model
impact
differ
intervent
strategi
evalu
previou
research
rather
focus
produc
predict
certain
local
specif
condit
administr
antivir
drug
effect
intervent
depend
variou
factor
must
explor
sensit
analys
base
mathemat
model
investig
pharmaceut
nonpharmaceut
intervent
mitig
influenza
pandem
examin
intervent
schedul
restrict
stockpil
contact
reduct
social
distanc
measur
partial
isol
case
determin
cours
pandem
wave
success
intervent
method
provid
freeli
avail
plan
tool
influsim
figur
determinist
compart
model
base
system
differenti
equat
design
oper
optim
combin
compet
requir
precis
realism
gener
allow
produc
time
cours
cumul
number
influenza
case
outpati
visit
appli
antivir
treatment
dose
hospitalis
death
work
day
lost
due
sick
may
associ
econom
aspect
result
model
show
time
applic
antivir
drug
combin
quick
implement
contact
reduct
measur
requir
substanti
protract
peak
influenza
epidem
reduc
height
delay
initi
antivir
treatment
eg
parsimoni
use
limit
stockpil
result
much
pessimist
outcom
even
lead
paradox
effect
stockpil
deplet
earlier
compar
earli
distribut
antivir
drug
conclus
influsim
effici
assist
public
health
planner
design
optim
intervent
pandem
influenza
reproduc
infect
dynam
pandem
influenza
like
complex
comput
simul
offer
time
reproduc
higher
comput
perform
better
oper
control
pandem
influenza
pharmaceut
nonpharmaceut
measur
use
exclus
contact
reduct
measur
must
part
mitig
strategi
advantag
limit
per
se
object
although
influenza
flu
old
infecti
diseas
caus
pandem
requir
global
cooper
control
prevent
addit
avoid
exposur
influenza
season
vaccin
effect
modal
prevent
influenza
epidem
howev
due
genet
variabl
influenza
requir
vaccin
everi
year
depart
health
support
free
influenza
vaccin
age
peopl
yearold
year
host
antibodi
respons
evalu
method
total
pair
sera
collect
week
vaccin
one
dose
commerci
trival
influenza
vaccin
pair
sampl
test
influenza
b
antibodi
complement
fixat
cf
quantit
enzymelink
immunosorb
assay
elisa
addit
pair
sera
test
haemagglutin
inhibit
hi
use
anew
strain
male
femal
peopl
older
result
result
indic
cf
respons
rate
defin
titer
increas
pair
sera
influenza
b
low
respect
howev
preimmunis
elisa
titer
influenza
b
much
higher
normal
averag
ruml
flu
ruml
flu
b
normal
ruml
overal
respons
rate
hi
respons
rate
age
yearold
lower
peopl
yearold
howev
rate
preimmunis
sera
protect
hi
titer
hi
conclus
antibodi
respons
induc
influenza
vaccin
low
preimmunis
antibodi
posit
rate
titer
high
phenomenon
might
reflect
qualiti
vaccin
consequ
previou
vaccin
among
nurs
aboveaverag
knowledg
influenza
vaccin
underestim
nonsever
ae
rate
conclus
hp
overestim
sever
ae
rate
underestim
nonsever
ae
rate
influenza
vaccin
apprais
ae
rate
appear
import
decis
hp
get
vaccin
better
mediat
actual
low
rate
sever
advers
effect
may
improv
influenzavaccin
rate
among
hp
object
avian
influenza
virus
could
transmit
human
result
sever
fatal
diseas
aim
studi
evalu
immun
crossreact
human
avian
influenza
strain
healthi
donor
vaccin
season
influenza
method
healthcar
worker
wish
receiv
season
influenza
vaccin
spallanzani
institut
enrol
blood
sampl
assess
humor
cellmedi
respons
obtain
day
vaccin
frequenc
circul
antigenspecif
andor
tcell
healthi
donor
enrol
studi
analys
flow
cytometri
use
intracellular
cytokin
stain
assay
expans
effectorcel
vitro
human
sera
donor
test
hainhibit
activ
vaccin
prepar
neutralis
activ
viru
data
indic
vaccin
may
boost
crosssubtyp
cellular
andor
humor
immun
influenza
specif
tcell
frequenc
significantli
higher
plurivaccin
versu
first
fluvaccin
donor
main
target
crossreact
strain
correl
influenzaspecif
tcell
humor
respons
observ
suggest
respons
mainli
tcellindepend
differ
tcell
may
help
antiinfluenza
tcell
respons
furthermor
human
sera
donor
test
hainhibit
activ
vaccin
prepar
show
signific
rise
vaccin
sera
test
neutralis
activ
subject
abl
show
antibodi
rise
season
influenza
vaccin
show
exist
antibodydepend
crosstyp
immun
correl
influenza
specif
tcell
humor
respons
observ
suggest
type
antibodi
respons
mainli
tcell
independ
studi
demonstr
vaccin
season
influenza
might
induc
cellular
humor
crossreact
immun
avian
influenza
crosstyp
immun
may
repres
import
compon
immun
respons
novel
influenza
infect
consid
local
serotyp
distribut
direct
effect
estim
children
year
assum
vaccin
coverag
effect
reduc
ipd
caus
vaccineserotyp
herd
immun
effect
estim
assum
reduct
ipd
caus
vaccineserotyp
result
incid
total
incid
remain
stabl
throughout
period
popul
wherea
incid
increas
highest
incid
observ
among
adult
year
per
case
present
bacteraemia
approx
case
pneumococc
mening
regist
annual
overal
mortal
method
twentyseven
healthi
adult
immunis
either
pcv
ppv
intramuscularli
sera
obtain
week
immunis
determin
igg
pneumococc
antibodi
titer
enzymelink
immunosorb
assay
opsonis
tier
opsonophagocyt
kill
assay
serotyp
repres
pcv
result
antibodi
titer
opsonis
titer
pneumococc
serotyp
significantli
increas
immunis
pcv
ppv
group
postimmun
antibodi
titer
serotyp
significantli
higher
pcv
group
ppv
group
also
pcv
elicit
significantli
higher
fold
rise
opsonis
titer
compar
ppv
serotyp
antibodi
titer
opsonis
titer
serotyp
good
correl
preimmun
sera
well
postimmuu
sera
group
subject
group
antibodi
titer
mgml
serotyp
immunis
quantit
qualit
antibodi
respons
pcv
ppv
good
korean
adult
pcv
immunogen
ppv
serotyp
studi
includ
isol
year
introduct
vaccin
postreleas
key
demograph
data
serotyp
resist
profil
antimicrobi
class
analys
strain
display
resist
defin
nonsuscept
base
clsi
breakpoint
class
consid
mr
statist
analysi
carri
use
linear
mix
effect
model
repeat
measur
result
adjust
age
invas
statu
region
multivari
logist
regress
model
show
nonvaccin
nv
isol
time
p
like
mr
postvaccin
releas
period
serotyp
divid
group
accord
preval
multipl
resist
propens
expand
ie
becom
preval
introduct
vaccin
found
serotyp
f
time
like
expand
nv
serotyp
p
group
form
serotyp
also
like
increas
preval
p
nv
serotyp
detail
resist
preval
proport
point
time
shown
tabl
conclus
group
vaccin
nonvaccin
serotyp
categoris
accord
propens
expand
acquir
mr
serotyp
slightli
decreas
preval
increas
mr
rate
serotyp
f
increas
preval
acquir
resist
rate
proport
expans
process
half
nv
serotyp
rapidli
increas
preval
resist
vaccin
serotyp
exclud
decreas
preval
resist
bartoloni
object
antr
research
project
aim
describ
antimicrobi
use
resist
lowresourc
countri
latin
america
project
dissemin
microbi
drug
resist
monitor
commens
escherichia
coli
larg
exploit
indic
similar
studi
baselin
studi
carri
observ
high
rate
faecal
carriag
e
coli
acquir
resist
sever
antimicrobi
agent
report
result
second
crosssect
studi
conduct
evalu
evolut
antimicrobi
resist
rate
studi
area
method
rectal
swab
collect
healthi
children
age
month
live
urban
area
bolivia
peru
sampl
process
rapid
screen
method
allow
detect
e
coli
resist
ampicillin
amp
ceftriaxon
cro
tetracyclin
tet
chloramphenicol
chl
kanamycin
kan
gentamicin
gen
amikacin
amk
streptomycin
str
trimethoprimsulphamethoxazol
sxt
nalidix
acid
nal
ciprofloxacin
cip
sampl
strategi
microbiolog
process
baselin
studi
data
survey
confirm
high
resist
rate
amp
vs
sxt
vs
tet
vs
chl
vs
observ
baselin
studi
show
remark
increas
resist
rate
quinolon
vs
nal
vs
cip
cro
vs
signific
increas
trend
also
observ
str
gen
vs
vs
respect
result
studi
confirm
magnitud
problem
antimicrobi
resist
lowresourc
countri
evidenc
alarm
increas
resist
rate
quinolon
expandedspectrum
cephalosporin
result
overal
resist
drug
presenc
resist
one
drug
half
isol
resist
resist
fq
wherea
isol
resist
ag
similarli
almost
isol
resist
ag
also
resist
fq
compar
much
lower
rate
sensit
ag
larg
differ
observ
countri
antimicrobi
resist
rate
wherea
level
associ
resist
among
group
resist
isol
vari
extent
tabl
conclus
level
associ
resist
isol
resist
differ
antimicrobi
group
earss
studi
seem
compar
countri
irrespect
differ
overal
resist
proport
ii
group
isol
resist
one
group
antibiot
like
resist
antimicrobi
group
earss
surveil
compar
suscept
counterpart
observ
resist
associ
type
resist
level
associ
resist
seem
compar
countri
would
suggest
overal
reduct
antibiot
use
probabl
import
societi
whole
target
reduct
singl
drug
analysi
suggest
effort
focus
multi
resist
strain
asia
europ
follow
identif
first
imipenemresist
kpcposit
klebsiella
pneumonia
isol
institut
initi
prospect
studi
august
novemb
consecut
isol
organ
determin
preval
genet
related
kpcposit
strain
method
kpcspecif
polymeras
chain
reaction
perform
total
dna
plasmid
dna
consecut
klebsiella
pneumonia
isol
repetit
sequenc
pcr
perform
kpcposit
isol
determin
genet
related
result
isol
collect
fourmonth
period
shown
harbour
kpc
orf
pcr
six
isol
identifi
three
patient
remain
seven
came
individu
patient
eight
eleven
isol
resist
imipenem
disk
diffus
test
three
isol
fulli
suscept
plasmid
contain
kpc
gene
isol
verifi
pcr
imipenemresist
isol
contrast
unabl
isol
plasmid
imipenemsensit
strain
howev
posit
kpc
orf
use
pcr
total
genom
dna
two
distinct
cluster
klebsiella
pneumonia
seen
follow
repetit
sequenc
pcr
first
cluster
isol
ident
suggest
clonal
expans
isol
unrel
expect
multipl
isol
singl
patient
ident
preval
kpcpossess
klebsiella
pneumonia
institut
risen
month
therebi
compromis
empir
treatment
option
patient
infect
klebsiella
pneumonia
clonal
expans
horizont
plasmid
transfer
appear
involv
kpc
dissemin
addit
data
suggest
kpc
orf
may
resid
chromosom
express
proper
induc
agent
present
kpc
orf
may
resid
transpos
element
express
transfer
plasmid
pseudomona
aeruginosa
resist
rate
associ
level
hospit
care
data
earss
factor
independ
associ
increas
risk
nonsuscept
agent
p
aeruginosa
intens
care
young
age
hour
prior
hospitalis
infect
aris
skinsoft
tissu
line
among
acinetobact
resist
concentr
baumannii
baumannii
nonsuscept
agent
class
agent
overal
acinetobact
nonsuscept
gen
ipm
tzp
cip
caz
respect
number
small
assess
trend
predictor
agreement
min
tgc
larg
overcam
tet
resist
acinetobact
maximum
mic
mgl
respect
dor
mic
close
relat
ipm
averag
dilut
lower
p
aeruginosa
dilut
higher
acinetobact
bpr
mic
averag
dilut
higher
caz
p
aeruginosa
dilut
lower
acinetobact
plasmid
mediat
quinolon
resist
determin
qnrb
qnr
identifi
salmonella
enterica
isol
rais
ciprofloxacin
mic
corval
uncommon
serovar
experi
isol
remark
serovar
repres
high
proport
qnr
posit
isol
detect
evid
epidemiolog
link
corval
isol
orthopaed
trauma
surgeri
implant
specialti
surgic
success
relat
insert
prosthet
joint
eg
knee
hip
shoulder
replac
reconstruct
metalwork
follow
trauma
eg
intramedullari
nail
plate
screw
worst
complic
infect
result
multipl
addit
oper
extend
hospitalis
prolong
morbid
poor
function
outcom
infect
rate
low
ideal
common
infect
organ
staphylococcu
aureu
account
case
methicillinresist
coagulaseneg
staphylococci
grow
import
numer
less
signific
clinic
present
surgic
techniqu
prepost
oper
morbid
chronic
osteomyel
infect
joint
replac
discuss
project
patient
perspect
aureu
emerg
infecti
diseas
major
impact
public
anim
health
economi
environ
scienc
human
mortal
recent
emerg
diseas
vari
rang
less
peopl
thu
far
avian
influenza
million
aid
livestock
product
neg
affect
direct
mortal
anim
emerg
infect
depopul
polici
protect
safeti
intern
trade
control
spread
pathogen
environment
impact
emerg
infect
special
concern
endang
wild
anim
popul
push
brink
extinct
event
anim
particularli
wild
anim
thought
sourc
emerg
infect
august
decemb
also
rise
spring
find
import
understand
influenza
viru
perpetu
natur
concern
presenc
subtyp
prone
chang
highli
pathogen
variant
poultri
mani
strain
isol
studi
prototyp
caus
influenza
outbreak
poultri
europ
recent
year
indic
wild
bird
surveil
influenza
viru
valu
sentinel
system
prevent
outbreak
domest
poultri
result
domest
anim
revolut
never
histori
much
poultri
today
fact
combin
grow
number
human
creat
arena
domest
anim
human
final
zoonot
pathogen
interact
influenza
viru
ultim
actor
play
subtyp
may
chang
highli
pathogen
form
may
transmit
directli
man
anoth
worri
scenario
avian
influenza
viru
reassort
circul
human
influenza
genet
trait
might
readili
go
human
bird
viru
avian
influenza
acquir
capac
pass
person
person
risk
mind
would
advis
consid
method
reduc
probabl
happen
conting
plan
take
account
known
evolutionari
potenti
anim
virus
pathogen
adapt
environ
human
domest
anim
candida
use
fluconazol
suscept
profil
surrog
marker
predict
voriconazol
suscept
also
propos
recent
addit
base
modif
clsi
refer
method
new
guidelin
vitro
suscept
test
antifung
agent
aspergillu
spp
develop
afsteucast
standard
assay
test
antifung
agent
dermatophyt
also
develop
investig
address
applic
method
practic
andor
requir
shorter
incub
period
among
etest
colorimetr
method
flow
cytometri
ergosterol
quantit
util
flow
cytometri
afst
yeast
mould
current
studi
appear
promis
assess
metabol
activ
use
xtt
colorimetr
assay
also
investig
novel
approach
particularli
determin
quantit
endpoint
test
caspofungin
aspergillu
suscept
test
zygomycet
despit
progress
util
afst
direct
antifung
therapi
predict
clinic
outcom
still
limit
vitro
triazol
particularli
fluconazol
suscept
result
candida
appear
optim
correl
clinic
outcom
data
either
limit
investig
fail
demonstr
signific
vitroin
vivo
correl
remain
fungusantifung
drug
combin
importantli
conclus
result
obtain
afst
constitut
one
sever
factor
influenc
clinic
outcom
optimis
test
methodolog
paramet
routin
use
expand
vitroin
vivo
correl
studi
may
enhanc
role
afst
adjunct
direct
antifung
therapi
recent
year
import
progress
knowledg
bacteri
resist
antibiot
avail
larg
number
antibiot
allow
precis
individualis
resist
phenotyp
enzym
inhibitor
provid
clue
concern
certain
mechan
resist
detail
analysi
bacteriostat
bactericid
activ
antibiot
alon
combin
indic
limit
vitro
antimicrobi
suscept
test
detect
resist
result
clinic
failur
goal
combin
molecular
therapeut
interpret
suscept
test
provid
improv
logic
basi
decisionmak
antibiot
therapi
take
account
recent
progress
understand
bacteri
resist
molecular
analysi
therapeut
interpret
design
interpret
read
vitro
antibiot
suscept
test
consist
three
step
characteris
resist
phenotyp
judici
assort
antibiot
belong
class
deduct
observ
phenotyp
correspond
biochem
mechan
resist
infer
deduc
mechan
predict
resist
phenotyp
vitro
antibiot
suscept
test
like
test
biolog
provid
object
quantit
data
eg
mic
variou
histor
reason
also
provid
subject
interpret
data
clinic
categori
interpret
read
antimicrobi
suscept
test
attempt
reconcil
two
notion
base
interpret
recent
knowledg
field
antibiot
studi
particular
mechan
resist
best
one
ask
antibiot
suscept
test
detect
resist
particular
lowlevel
resist
achiev
improv
interpret
result
vitro
sensit
test
design
certain
genotyp
approach
goal
propos
approach
provid
clinician
necessari
result
judici
decisionmak
antibiot
therapi
utilis
avail
inform
draw
attent
combin
bacterium
antibiot
therapeut
risk
resist
aminoglycosid
mostli
relat
product
modifi
enzym
phosphorylas
nucleotidyltransferas
acetyltransferas
enzym
vari
substrat
rang
often
broad
enzym
characteris
particular
profil
resist
allow
put
identif
confer
phenotyp
enzym
gramposit
cocci
gener
differ
enzym
detect
gramneg
bacteria
gener
presenc
enzym
confer
host
frank
resist
antibiot
modifi
vitro
howev
except
gramneg
gramposit
bacteria
instanc
resist
gramposit
organ
kanamycinneomycin
group
antibiot
due
synthesi
aph
iii
enzym
enzym
catalyz
effici
phosphoryl
amikacin
cellfre
extract
alway
determin
resist
antibiot
howev
bactericid
synerg
amikacin
blactam
vancomycin
alway
abolish
therefor
test
kanamycin
better
predict
activ
amikacin
gramposit
organ
case
sever
other
interpret
read
suscept
test
base
identif
resist
phenotyp
may
help
identifi
impair
activ
aminoglycosid
interpret
read
may
also
allow
identifi
pitfal
detect
resist
macrolid
lincosamid
antibiot
staphylococci
may
resist
macrolid
product
ribosom
methylas
encod
erm
gene
confer
mlsb
phenotyp
product
efflux
pump
encod
msr
gene
case
induc
mlsb
resist
clindamycin
induc
remain
activ
howev
constitut
resist
mutant
select
clindamycin
clinic
failur
treatment
clindamycin
report
occas
use
clindamycin
probabl
best
avoid
sever
infect
infect
heavi
bacteri
inocula
case
resist
efflux
clindamycin
substrat
pump
risk
select
resist
mutant
greater
erythromycinsuscept
isol
disk
diffus
test
induc
mlsb
phenotyp
identifi
flatten
clindamycin
zone
face
erythromycin
disk
rel
import
contamin
inanim
environ
discuss
controversi
wherea
outbreak
due
environment
sourc
describ
repeatedli
role
sourc
endem
colonis
consequ
infect
intens
care
patient
firmli
establish
recent
data
show
icu
high
figur
case
p
aeruginosa
acquisit
may
origin
contamin
tap
water
clonal
relationship
isol
retrograd
contamin
faucet
patient
may
occur
howev
surveil
intestin
colonis
play
relev
role
epidemiolog
p
aeruginosa
undertaken
major
colonis
patient
alreadi
colonis
admiss
preced
antibiot
exposur
respons
major
case
acquir
respiratori
tract
colonis
regard
infect
control
adequ
hand
hygien
essenti
wherea
sterilis
sink
routin
use
water
filter
seem
impract
alcoholbas
handrub
via
dispens
near
bedsid
coat
pocket
prefer
situat
hand
wash
soap
water
open
water
sourc
includ
sink
may
potenti
habitat
pathogen
like
p
aeruginosa
use
tap
water
critic
ill
immunocompromis
patient
must
restrict
second
pathogen
report
patient
candida
sp
seen
signific
region
variat
distribut
pathogen
number
cultur
test
taken
cultur
per
patient
admiss
princip
pathogen
resist
commonli
use
antibiot
case
preval
asymptomat
bacteriuria
region
preval
urosepsi
vari
region
studi
conclus
urolog
section
encourag
monitor
suscept
pathogen
caus
nauti
order
tailor
better
empir
antibiot
treatment
urologist
need
work
guidelin
take
blood
cultur
urolog
surgeri
obtain
uniform
report
urosepsi
region
high
preval
urosepsi
urolog
surgeri
caus
concern
escherichia
coli
account
organ
uncompl
uti
contrast
complic
uti
mani
kind
enterobacteriacea
isol
staphylococci
enterococci
pseudomona
aeruginosa
glucosenonferment
gramneg
rod
nfgnr
isol
almost
nosocomi
uti
nuti
complic
uti
gpiu
studi
formerli
pep
studi
nuti
preval
rate
gpiu
studi
e
coli
frequent
pathogen
account
pathogen
isol
pseudomona
klebsiella
enterococcu
proteu
isol
frequent
hospit
enterococcu
faecali
frequent
isol
organ
account
enterococci
marcescen
p
aeruginosa
nfgnr
e
coli
staphylococcu
epidermidi
isol
frequent
consid
differ
occur
differ
patient
background
fluoroquinoloneand
cephemresist
enterobacteriacea
isol
patient
nuti
increas
cephemresist
isol
e
coli
k
pneumonia
p
mirabili
produc
extendedspectrum
blactamas
esbl
esbl
plasmidmedi
broadspectrum
blactamas
ratio
esbl
produc
e
coli
k
pneumonia
quit
differ
countri
less
nosocomi
esbl
produc
acquir
resist
nonblactam
fluoroquinolon
phosphomycin
cotrimoxazol
multidrug
resist
isol
effect
oral
antibiot
accord
gisp
studi
ratio
fluoroquinolon
resist
e
coli
k
pneumonia
account
respect
enterococci
account
mechan
resist
quinolon
mainli
target
mutat
especi
gyra
parc
qnr
plasmid
encod
quinolon
resist
report
emerg
qnr
also
alert
us
potenti
rapid
dissemin
quinoloneresist
determin
qnr
show
quinolon
specif
resist
qnrplasmid
report
integronassoci
carri
multipl
resist
determin
provid
resist
sever
class
antimicrobi
includ
blactam
aminoglycosid
multidrug
resist
isol
caus
nosocomi
spread
easili
mani
report
nosocomi
spread
multidrug
resist
esbl
produc
prevent
preval
antimicrobialresist
isol
appropri
antimicrobi
select
need
geograph
variat
pathogen
occurr
suscept
profil
requir
monitor
continu
import
updat
treatment
guidelin
base
suscept
profil
result
clinic
trial
urosepsi
account
approxim
sepsi
case
may
develop
commun
nosocomi
acquir
urinari
tract
infect
uti
underli
uti
almost
exclus
complic
one
involv
parenchymat
urogenit
organ
eg
kidney
prostat
mostli
associ
kind
obstruct
uropathi
urosepsi
origin
nosocomi
infect
broad
spectrum
gramneg
gramposit
pathogen
expect
often
multiresist
urosepsi
type
sepsi
sever
sepsi
depend
mostli
upon
host
respons
treatment
urosepsi
follow
gener
accept
rule
surviv
sepsi
campaign
guidelin
earli
normalis
blood
pressur
earli
adequ
empir
antibiot
therapi
optimis
dose
equal
import
meet
requir
earli
goal
direct
therapi
case
urosepsi
earli
control
infecti
focu
possibl
import
optim
support
measur
need
follow
earli
phase
resuscit
although
antibiot
achiev
high
urinari
concentr
sever
uniqu
properti
complic
uti
thu
urosepsi
influenc
activ
antibiot
substanc
renal
pharmacokinet
unilater
bilater
renal
impair
unilater
bilater
renal
obstruct
differ
ii
varat
ph
may
influenc
activ
certain
antibiot
iii
biofilm
infect
frequent
found
condit
may
increas
minim
inhibitori
concentr
mic
antimicrobi
site
infect
sever
order
assess
antibiot
pharmacodynam
properti
situat
mic
determin
vitro
plasma
concentr
free
unbound
drug
guid
principl
mani
infect
also
actual
renal
excret
urinari
bactericid
activ
antibiot
substanc
taken
account
treatment
urosepsi
import
achiev
optim
exposur
antimicrobi
plasma
urinari
tract
role
drug
low
renal
excret
rate
therefor
limit
sinc
urosepsi
origin
quit
often
cathet
associ
uti
urolog
intervent
optim
cathet
care
optim
strategi
prevent
nosocomi
uti
may
abl
reduc
frequenc
urosepsi
p
commonli
classifi
pneumonia
sever
index
highrisk
class
group
v
vs
p
also
receiv
frequent
prior
corticosteroid
vs
p
antibiot
vs
p
therapi
multivari
analysi
identifi
copd
prior
corticosteroid
therapi
independ
risk
factor
patient
cap
due
p
aeruginosa
present
frequent
septic
shock
entri
vs
p
multilobar
pneumonia
vs
p
remain
patient
also
given
frequent
inappropri
initi
empir
antibiot
therapi
vs
p
earli
vs
p
overal
vs
p
casefat
rate
higher
among
patient
cap
due
p
aeruginosa
conclus
cap
caus
p
aeruginosa
uncommon
occur
mainli
patient
copd
treat
corticosteroid
frequent
present
shock
caus
high
casefat
rate
risk
factor
delin
studi
consid
select
initi
empir
antibiot
therapi
patient
cap
object
prospect
aetiolog
studi
microbi
caus
found
subject
communityacquir
pneumonia
cap
object
analysi
identifi
predictor
microbiolog
document
larg
cap
trial
persist
deterior
cxr
abnorm
correl
poor
prognosi
therefor
routin
followup
cxr
seem
appropri
patient
respond
therapi
cxr
followup
exclud
noninfecti
caus
perform
within
week
initi
diagnosi
empir
broadspectrum
therapi
alway
necessari
sever
communityacquir
pneumonia
g
barlow
nathwani
p
davey
hull
dunde
uk
object
uk
guidelin
recommend
coamoxiclavmacrolid
secondthirdgener
cephalosporinmacrolid
sever
communityacquir
pneumonia
cap
observ
studi
suggest
adher
guidelin
atyp
pathogen
cover
result
better
outcom
concern
ecolog
impact
howev
broadspectrum
agent
studi
compar
mortal
hospitalis
patient
receiv
amoxicillinmacrolid
narrow
spectrum
ns
receiv
either
coamoxiclavmacrolid
second
thirdgener
cephalosporinmacrolid
broad
spectrum
bs
object
bacteraemia
import
caus
mortal
hospitalis
patient
valid
predictor
mortal
communityacquir
pneumonia
cap
lim
et
al
thorax
caus
sepsi
aim
studi
assess
perform
patient
bacteraemia
method
retrospect
cohort
studi
perform
use
data
routin
collect
deliveri
hull
bacteraemia
servic
part
servic
patient
confirm
bacteraemia
seen
bedsid
infecti
diseas
physician
type
report
includ
physiolog
data
sent
patient
physician
patient
includ
criteria
record
point
bacteraemia
mortal
establish
hospit
databas
stratifi
score
receiv
oper
curv
roc
produc
area
curv
confid
interv
ci
calcul
result
patient
report
patient
male
full
set
criteria
patient
year
old
manag
renal
ward
common
bacteria
mssa
patient
mrsa
variou
gramneg
thought
signific
coagulaseneg
staphylococci
group
streptococci
enterococci
common
sourc
bacteraemia
central
venou
line
patient
intraven
drug
use
urinari
tract
contamin
skinsoft
tissu
patient
receiv
discord
therapi
prior
review
overal
mortal
recrudesc
within
day
occur
patient
tabl
show
mortal
stratifi
score
area
roc
ci
conclus
first
studi
assess
perform
nonrespiratori
infect
although
preliminari
appear
stratifi
mortal
patient
bacteraemia
cutoff
sever
ill
may
need
lower
howev
cap
potenti
therefor
identifi
lowrisk
cohort
patient
ie
may
appropri
earli
switch
oral
therapi
discharg
hospit
likewis
patient
high
risk
ie
like
need
aggress
therapi
accord
princip
surviv
sepsi
campaign
larg
prospect
studi
warrant
mortal
occur
rapidli
onset
symptom
median
day
rang
day
seven
patient
nonmenstru
stss
deceas
patient
aggress
treat
comparison
survivor
never
receiv
clindamycin
linezolid
intraven
immunoglobulin
ivig
observ
nonmenstru
stss
sever
diseas
expect
compar
menstrual
stss
nonmenstru
stss
patient
high
posit
blood
cultur
mortal
rate
respect
could
reflect
evolut
aureu
isol
toward
higher
virul
express
variou
superantigen
toxin
bacteraemia
could
partial
explain
sever
nonmenstru
case
may
composit
form
shock
frontier
septic
shock
stss
potenti
sever
stss
specif
therapeut
intervent
implement
patient
nonmenstru
stss
propos
follow
strategi
rapid
wound
debrid
whatev
import
local
inflamm
rapid
addit
antitoxin
antibiot
clindamycin
linezolid
prescript
ivig
determin
best
model
model
select
criterion
msc
coeffici
determin
taken
account
well
visual
inspect
good
fit
result
two
suscept
stage
defin
mrsastag
selfrepl
suscept
linezolid
stage
unsuscept
metabol
inact
loggrowth
phase
suscept
bacteria
grow
growth
rate
constant
k
greater
natur
death
rate
constant
k
certain
ratio
converg
stationari
phase
ratio
chang
nonlinear
manner
describ
addit
n
max
term
presenc
linezolid
concentr
c
depend
kill
taken
account
certain
drug
specif
concentr
maximum
effect
reach
describ
maximum
kill
rate
constant
k
max
howev
onset
growth
kill
delay
model
exponenti
term
characteris
time
dg
dk
respect
final
shape
curv
smooth
hill
factorshap
factor
h
modifi
sigmoid
emaxmodel
shown
describ
data
best
result
msc
valu
conclus
propos
model
incorpor
five
addit
term
could
account
much
better
vitro
situat
simpl
emaxmodel
simultan
fit
describ
actual
timekil
curv
data
suffici
well
recent
evalu
number
antistaphylococc
drug
vivo
murin
model
periton
respect
intracellular
antistaphylococc
activ
object
pk
descript
azithromycin
azm
cefuroxim
cxm
dicloxacillin
dcx
gentamicin
gen
rifampicin
rif
plasma
periton
exud
follow
sc
inject
descript
intracellular
accumul
antibiot
periton
exud
method
femal
nmri
mice
inocul
ip
staphylococcu
aureu
mucin
two
hour
later
mice
treat
sc
one
five
antibiot
individu
mous
aliquot
periton
exud
save
differenti
somat
cell
count
measur
antibiot
concentr
pellet
cell
g
min
rest
periton
exud
lyse
small
volum
dh
antibiot
concentr
measur
bioassay
intracellular
accumul
calcul
divid
intracellular
extracellular
concentr
concentr
found
cxm
dcx
higher
concentr
found
azm
gen
rif
correspond
well
higher
dose
inject
rel
high
antistaphylococc
activ
observ
pd
studi
intracellular
accumul
azm
rif
found
correspond
well
previous
report
intracellular
accumul
cxm
dcx
gen
found
surprisingli
high
sinc
blactam
notori
consid
accumul
intracellularli
fold
intracellular
accumul
aminoglycosid
take
sever
day
influx
correl
well
good
effect
seen
vivo
model
inflammatori
reaction
venou
vessel
common
clinic
problem
observ
intraven
applic
antibiot
drug
local
irrit
endothelium
site
infus
lead
inflammatori
respons
increas
express
variou
cell
surfac
antigen
among
cd
eselectin
cd
cd
cd
studi
effect
three
close
relat
antibiot
human
endotheli
cell
vitro
use
endotheli
cell
line
eahi
analys
reaction
mean
flow
cytometri
facscan
becton
dickinson
cell
incub
clarithromycin
azithromycin
concentr
rang
mgl
mgl
concentr
rang
mgl
mgl
erythromycin
concentr
occur
therapeut
condit
site
infus
subsequ
stain
fluoresceinisothiocyanateor
phycoerythrinconjug
monoclon
igg
mouseantibodi
four
antigen
mention
cell
incub
drug
h
analysi
carri
addit
time
period
h
control
cell
found
posit
stain
cell
follow
level
cd
eselectin
pronounc
chang
observ
mgl
erythromycin
mgl
azithroymcin
mgl
clarithromycin
erythromycin
mgl
caus
significantli
increas
express
epitop
cd
eselectin
mgl
azalid
azithromycin
provok
stronger
upregul
proinflammatori
antigen
cd
eselectin
clarithromycin
concentr
mgl
caus
similar
effect
erythromycin
twice
concentr
cd
eselectin
analysi
cell
surfac
marker
involv
cellcellinteract
prove
use
approach
studi
mechan
infus
phlebiti
compar
proinflammatori
effect
relat
compound
vitro
conclus
studi
first
report
integronassoci
imp
resist
high
preval
coexist
among
multipl
clone
multiresist
clinic
isol
baumannii
romania
take
account
narrow
antibiotherapi
choic
infect
horizont
transfer
gene
also
increas
resist
colistin
possibl
spread
carbapenemhydrolyz
oxacillinas
consider
concern
antimicrobi
chemotherapi
strain
investig
presenc
metalloblactamas
gene
integron
pcr
follow
digest
restrict
enzym
southern
hybridis
probe
blavim
probe
posit
isol
investig
pcr
sequenc
primer
design
integron
blavim
gene
transposas
gene
result
isol
posit
hybridis
radiolabel
probe
digest
integron
pcr
product
hincii
produc
ten
differ
integron
rflp
type
type
type
found
six
psa
ppu
one
pst
strain
consist
integron
harbour
gene
cassett
type
b
found
psa
strain
individu
ec
strain
harbour
integron
gene
cassett
insert
sequenc
eight
strain
harbour
gene
cassett
sever
differ
gene
array
one
strain
psa
harbour
gene
cassett
integron
common
form
includ
conserv
sequenc
integron
found
cs
found
sever
recent
isol
divers
geograph
region
object
sought
evalu
bactericid
effect
human
bdefensin
metalloblactamas
mbl
produc
p
aeruginosa
clinic
isol
materi
method
total
uniqu
multidrugresist
p
aeruginosa
strain
test
origin
relev
specimen
patient
hospitalis
hospit
bacteri
identif
antimicrobi
suscept
test
perform
vitek
autom
system
accord
drug
suscept
clinic
isol
categoris
distinct
resist
phenotyp
metalloblactamas
mbl
product
detect
use
etest
mbl
strip
accord
manufactur
instruct
determin
mbl
type
isol
subject
pcr
analysi
confirm
presenc
blavim
blaimp
gene
bactericid
activ
recombin
assess
liquid
microdilut
assay
presenc
sodium
phosphat
buffer
previous
describ
briefli
exponenti
grow
bacteria
inoculum
densiti
cfuml
expos
differ
concentr
ugml
ugml
follow
incub
min
ml
sampl
plate
onto
mcconkey
agar
plate
bactericid
effect
express
percentag
reduct
number
viabl
bacteria
hr
incub
ambient
air
result
concentr
ugml
peptid
produc
reduct
rate
rang
wherea
use
ugml
result
kill
signific
variabl
bactericid
effect
observ
appear
independ
isol
resist
phenotyp
conclus
despit
rel
low
concentr
use
exhibit
bactericid
activ
mblproduc
pseudomona
aeruginosa
nosocomi
strain
therefor
would
attract
altern
current
theurapeut
agent
system
biolog
fast
develop
research
area
life
scienc
combin
experiment
theoret
disciplin
investig
compon
complex
biolog
system
exampl
protein
cell
collect
larg
biolog
dataset
novel
highthroughputbas
technolog
develop
comput
tool
bioinformat
analysi
thu
allow
holist
view
complex
biolog
system
set
improv
biolog
model
particularli
sever
differ
experiment
paramet
integr
exampl
protein
interact
express
profil
data
although
system
biolog
usual
base
screen
assay
thu
start
without
bia
contrast
hypothesisdriven
research
case
eventu
lead
multitud
novel
work
hypothes
particularli
interest
hypothes
deriv
bioinformat
concept
like
network
emerg
robust
modular
sinc
current
complet
unclear
translat
biolog
system
biologybas
approach
infecti
diseas
even
complex
investig
interact
compon
two
distinct
biolog
system
pathogen
host
host
side
cellular
compon
directli
deal
control
infect
ie
innat
adapt
immun
system
particular
interest
understand
pathogenesi
pathogen
product
counteract
cellular
compon
similarli
import
integr
compon
immun
system
system
biologybas
approach
might
abl
gener
better
diseas
model
previou
reductionist
approach
focus
one
pathogen
aspect
exampl
herpesvirus
caus
persist
latent
infect
innat
well
adapt
immun
system
compon
play
role
differ
time
point
infect
thu
consid
fulli
understand
pathogenesi
recent
develop
technolog
molecular
biolog
allow
genomewid
analys
one
prerequisit
system
biologybas
approach
exampl
novel
sequenc
technolog
power
enough
evalu
whole
genom
within
short
time
abl
detect
interindividu
polymorph
grow
evid
genet
variat
host
pathogen
side
often
crucial
outcom
infecti
diseas
varieti
experiment
system
develop
last
decad
meanwhil
suffici
potent
allow
genomewid
analys
includ
microarray
transcript
protein
express
profil
genet
screen
system
like
yeasttwohybrid
system
use
identifi
pairwis
protein
interact
novel
mass
spectrometri
approach
use
proteom
metabolom
medicin
system
biolog
current
still
larg
consid
basic
research
area
littl
practic
relev
howev
lead
substanti
chang
medicin
within
year
system
biologybas
diseas
model
considerabley
improv
understand
pathogenesi
acceler
rationalis
drug
discoveri
also
sinc
abil
determin
individu
genet
trait
avail
multiparamet
diagnost
eventu
lead
much
personalis
medicin
therapeut
intervent
tailor
singl
individu
human
immunodefici
viru
repres
best
model
evolut
earth
due
high
rate
replic
cycl
errorpron
polymeras
abl
make
error
nucleotid
entir
genom
hiv
chang
everi
day
base
factor
calcul
hiv
genom
vari
one
day
variabl
influenza
viru
anoth
highli
variabl
viru
year
variabl
human
genom
whole
histori
mankind
despit
immens
potenti
mutat
randomli
produc
daili
replic
cycl
fix
within
viral
genom
bottleneck
phenomenon
relat
constraint
target
cell
unabl
support
replic
vira
strain
daili
gener
larg
major
mutat
gener
variant
whose
replic
capac
low
absent
case
lower
one
characteris
wild
type
strain
reason
number
quasispeci
limit
environ
immun
pharmacolog
pressur
chang
cours
situat
chang
unpo
environ
chang
case
therapeut
pressur
abil
viru
rapidli
deselect
wildtyp
strain
favour
resist
mutant
function
strength
drug
regimen
case
fulli
suppress
therapi
viru
unabl
gener
andor
select
new
variant
wildtyp
strain
remain
preval
therapi
highli
success
contrast
therapeut
pressur
inconsist
errat
suffici
potent
viru
continu
replic
cycl
drug
presenc
repres
best
environ
select
mutantresist
strain
rapid
select
occur
function
genet
barrier
drug
turn
relat
number
mutat
occur
gener
new
variant
fulli
resist
drug
low
genet
barrier
mean
mutat
requir
gener
resist
variant
occur
rapidli
high
genet
barrier
mutat
occur
sequenc
make
difficult
slower
process
select
resist
strain
data
strong
clinic
implic
view
imposs
least
today
erad
viru
infect
bodi
thu
antihiv
therapi
start
damag
immun
system
advanc
must
strong
consist
reason
today
least
three
drug
ration
combin
need
achiev
result
great
effort
dedic
physician
nurs
achiev
high
level
adher
repres
key
factor
maintain
longlast
protect
hivdiseas
progress
good
qualiti
life
object
novel
antimicrobi
mechan
action
target
fatti
acid
biosynthesi
current
develop
new
class
oral
intraven
antistaphylococc
agent
studi
compar
singledos
respons
experi
perform
linezolid
assess
quantit
oral
efficaci
hospitalacquir
ha
mrsa
communityacquir
ca
mrsa
method
mic
determin
clsi
guidelin
singl
dose
pk
studi
conduct
thigh
neutropaen
mice
inocul
singl
isol
hamrsa
camrsa
linezolid
administ
oral
singl
dose
rang
mgkg
cfu
determin
infect
thigh
hour
postdos
efficaci
determin
chang
cfuthigh
hour
versu
hour
control
result
mic
linezolid
isol
mgl
respect
hamrsa
cfu
reduct
seen
dose
mgkg
mgkg
dose
display
variabl
effect
camrsa
dose
mgkg
result
sustain
antibacteri
activ
linezolid
dose
mgkg
requir
maintain
sustain
antibacteri
activ
hour
exposur
period
isol
mrsa
isol
maxim
effect
dose
mgkg
lower
compar
linezolid
pharmacodynam
index
correl
show
faucmic
best
predictor
efficaci
mrsa
strain
faucmic
rang
result
respect
ed
valu
similar
observ
mssa
icaac
abstract
conclus
data
demonstr
superior
doserespons
compar
linezolid
hamrsa
camrsa
mous
thigh
model
faucmic
appear
best
characteris
pd
profil
novel
agent
low
efficaci
faucmic
valu
support
develop
novel
oral
intraven
agent
challeng
staphylococc
infect
emerg
multidrugresist
pathogen
includ
methicillinresist
staphylococcu
aureu
mrsa
combin
absenc
new
antibiot
pharmaceut
sector
demand
altern
antimrsa
agent
scientif
evalu
develop
matter
urgenc
recent
studi
shown
enorm
potenti
use
phage
endolysin
potenti
therapeut
object
characteris
staphylococc
phage
kderiv
protein
lysk
bifunct
endolysin
antimicrobi
activ
mrsa
view
identifi
domain
domain
respons
lytic
activ
method
lysk
gene
pcramplifi
phage
k
cdna
clone
ptopo
invitrogen
vector
domain
architectur
lysk
studi
perform
delet
analysi
intact
lysk
protein
use
pcr
andor
slice
overlap
extens
soe
pcr
ptopo
clone
assess
activ
lysk
delet
deriv
construct
recreat
qiagen
express
system
sdspage
zymogram
assay
use
visualis
activ
lysk
delet
deriv
assess
domain
lytic
activ
lysk
could
ascrib
result
bioinformat
analysi
lysk
amino
acid
suggest
modular
structur
contain
two
peptidoglycan
hydrolas
domain
chap
endopeptidas
activ
nacetylmuramoyllalanin
amidas
activ
nterminu
cellwal
bind
domain
cterminu
analysi
delet
deriv
lysk
confirm
domain
signific
activ
alon
chap
domain
activ
intact
lysk
display
ident
lytic
spectra
examin
zymograph
assay
attempt
defin
smallest
possibl
function
chap
domain
antimicrobi
activ
found
endopeptidas
activ
associ
chap
domain
contain
within
first
amino
acid
lysk
delet
result
complet
loss
antimicrobi
activ
amino
acid
truncat
chap
found
activ
main
mrsa
strain
emerg
hospit
local
area
conclus
retain
activ
highli
fqr
sa
exhibit
rang
qrdr
mutat
cfx
efflux
must
target
topoisomeras
manner
distinct
fq
har
host
respons
antiinfect
therapi
control
pathogen
bacteria
phage
lytic
enzym
bacteriophag
lytic
enzym
highli
evolv
molecul
use
phage
quickli
destroy
bacteri
cell
wall
releas
phage
progeni
exploit
rapid
lethal
action
enzym
destroy
pathogen
biolog
warfar
bacteria
mucou
membran
blood
enzym
gener
specif
speci
strain
produc
thu
avoid
destruct
surround
normal
commens
organ
found
mucos
surfac
enzym
specif
streptococcu
pyogen
pneumonia
bacillu
anthraci
staphylococcu
aureu
enterobact
faecalis
faecium
group
b
streptococci
result
show
vitro
bacteria
reduc
steril
second
enzym
contact
anim
model
experi
abl
colonis
mice
either
streptococc
pneumococc
speci
oral
nasal
remov
complet
phage
enzym
deliv
site
use
singl
enzym
dose
septicaemia
model
pneumonia
bacteria
reduc
blood
infect
anim
singl
intraven
dose
enzym
lytic
enzym
call
plyg
gammaphag
b
anthraci
specif
worldwid
isol
b
anthraci
enzym
specif
kill
b
anthraci
effect
bacilli
organ
b
anthraci
bacilli
deliv
iv
mice
observ
progress
symptom
lead
surviv
anim
follow
day
plyg
inject
iv
min
infect
signific
therapeut
effect
observ
mice
recov
fulli
resist
enzym
found
antibodi
neutralis
activ
furthermor
combin
antibiot
enzym
shown
work
synergist
result
effici
lethal
activ
case
antibiot
resist
bacteria
thu
phage
lytic
enzym
new
reagent
may
use
hospit
nurs
home
gener
popul
control
antibiot
resist
pathogen
bacteria
blood
mucos
surfac
offer
capabl
previous
unavail
twocompon
signal
transduct
system
ubiquit
bacteria
woven
within
fabric
regulatori
process
use
sens
environment
chang
respond
accordingli
system
allow
bacteri
cell
continu
reprogramm
pattern
gene
express
rapidli
defin
way
bring
cellular
adapt
direct
consequ
specif
environment
signal
achiev
function
twocompon
system
compos
signal
ligandrespons
sensor
histidin
kinas
usual
integr
membran
protein
respons
regul
often
transcript
regul
signal
ligand
sens
sensor
histidin
kinas
result
atpdepend
autophosphoryl
subsequ
transfer
phosphoryl
moieti
cognat
respons
regul
influenc
dna
bind
transcript
activ
therefor
gene
express
bacteri
pathogen
signal
transduct
pathway
frequent
key
element
regul
myriad
virul
respons
facilit
colonis
surviv
persist
within
host
environ
specif
host
site
exampl
type
virul
attribut
modul
twocompon
system
includ
biofilm
format
quorum
sens
resist
host
defenc
peptid
secret
toxin
product
addit
twocompon
system
essenti
bacteri
viabil
known
exist
reason
twocompon
signal
system
variant
recogn
target
develop
antiinfect
drug
present
featur
twocompon
system
make
potenti
attract
target
develop
novel
antiinfect
discuss
mechan
action
limit
class
previous
develop
twocompon
system
inhibitor
also
discuss
current
futur
perspect
develop
select
inhibitor
bacteri
signal
system
global
increas
methicillinresist
staphylococcu
aureu
mrsa
gener
much
attent
last
decad
public
link
socal
superbug
experi
dirti
hospit
precis
role
clean
control
organ
unknown
support
link
poor
hygien
hospit
mrsa
sinc
epidemiolog
characterist
permit
surviv
clinic
environ
well
make
potenti
vulner
clean
process
unfortun
assess
risk
acquir
mrsa
clinic
environ
way
measur
effect
clean
perhap
time
introduc
microbiolog
standard
surfac
level
hospit
would
allay
concern
grade
hygien
visual
assess
would
provid
mean
wherebi
remov
dirt
becom
evidencebas
scienc
without
evid
import
clean
hospit
continu
remain
specul
even
benefit
clean
well
establish
buf
floor
shine
reduc
number
patient
acquir
mrsa
floor
may
form
repositori
varieti
organ
play
major
role
hai
pathogen
deliv
patient
hand
like
contamin
handtouch
site
greater
risk
mrsa
acquisit
area
prioritis
manag
clean
schedul
sinc
target
approach
hospit
clean
might
use
control
factor
mrsa
never
abl
guarante
consist
hand
hygien
sustain
reduct
antibiot
consumpt
improv
clean
howev
insurmount
research
associ
mrsa
environment
hygien
urgent
requir
basic
clean
could
deliv
signific
cost
benefit
mrsa
control
could
ultim
defenc
organ
carriag
mrsa
often
transient
persist
patient
carriag
associ
increas
risk
develop
infect
healthcar
worker
carri
mrsa
may
transmit
microorgan
patient
control
transmiss
prevent
develop
infect
erad
carriag
may
indic
decis
start
decolonis
therapi
care
balanc
risk
develop
resist
factor
associ
increas
failur
rate
presenc
wound
skin
lesion
presenc
indwel
devic
multisit
carriag
presenc
reservoir
home
individu
without
risk
factor
treatment
mupirocin
nasal
ointment
succesful
major
subject
often
combin
applic
antisept
shower
individu
fail
topic
treatment
presenc
risk
factor
failur
system
antimicrobi
treatment
indic
welldesign
trial
avail
present
evidencebas
recommend
made
exist
data
indic
combin
two
agent
includ
rifampicin
prefer
choic
agent
base
suscept
test
result
treatment
failur
may
base
recolonis
persist
reservoir
home
therefor
patient
repeatedli
fail
decolonis
therapi
sourc
sought
european
food
safeti
author
efsa
set
follow
decad
food
scare
loss
confid
european
public
led
complet
overhaul
european
union
food
safeti
system
polici
efsa
mission
provid
risk
assess
matter
relat
food
feed
safeti
commun
risk
twentyfour
member
state
iceland
norway
switzerland
submit
inform
occurr
zoonos
zoonot
agent
antimicrobi
resist
foodborn
outbreak
european
commiss
efsa
campylobacteriosi
found
frequent
report
zoonot
diseas
human
within
eu
report
campylobact
case
increas
compar
previou
year
rise
incid
rate
case
per
peopl
total
record
case
salmonellosi
remain
second
frequent
zoonosi
report
human
case
despit
fall
incid
rate
compar
salmonella
often
report
fresh
poultri
pig
meat
proport
posit
sampl
detect
tabl
egg
find
posit
sampl
rang
past
year
overal
decreas
trend
occurr
salmonella
egg
observ
anim
popul
salmonella
frequent
detect
poultri
flock
salmonella
campylobact
virus
import
caus
report
foodborn
outbreak
egg
bakeri
product
common
report
sourc
salmonella
outbreak
wherea
broiler
meat
import
sourc
salmonella
campylobact
outbreak
foodborn
viru
outbreak
often
caus
drink
water
fruit
veget
rel
high
proport
campylobact
salmonella
isol
anim
food
resist
antimicrobi
commonli
use
treatment
human
diseas
especi
case
resist
fluoroquinolon
campylobact
isol
poultri
foodborn
infect
caus
resist
bacteria
pose
particular
risk
human
due
possibl
treatment
failur
result
routin
monitor
layinghen
flock
compar
result
euwid
fulli
harmonis
salmonella
baselin
studi
layinghen
hold
preval
baselin
studi
remark
higher
routin
monitor
reflect
differ
sensit
sampl
scheme
sampl
type
use
demonstr
harmonis
protocol
use
compar
situat
one
member
state
anoth
yersinia
enterocolitica
pseudotuberculosi
infect
yersiniosi
occur
predominantli
northern
hemispher
clinic
manifest
rang
acut
gastroenter
diver
postinfecti
sequela
notabl
reactiv
arthriti
pathogen
gramneg
bacteria
studi
intens
last
decad
result
identif
molecular
characteris
set
chromosom
extrachromosom
plasmid
pyv
encod
pathogen
factor
pf
function
pf
context
cell
cultur
anim
infect
model
discuss
intrigu
pf
yersinia
outer
protein
yop
microinject
host
cell
via
type
secret
system
function
tranquillis
toward
innat
host
defenc
sever
pf
yersinia
becom
prototyp
member
grow
famili
pf
invasin
trimer
autotransport
tata
yersinia
adhesin
yada
siderophor
yersiniabactin
encod
high
pathogen
island
hpi
yersinia
invasin
inv
close
relat
intimin
eaea
enteropathogen
epec
enterohaemorrhag
escherichia
coli
ehec
yersinia
adhesin
yada
trimer
autotransport
member
oligom
coiledcoil
adhesin
oca
famili
compris
adhesin
haemophilu
influenza
hia
moraxella
catarrhali
uspa
speci
yersiniabactin
biosynthet
gene
cluster
hpi
wide
spread
among
member
famili
enterobacteriacea
becom
marker
extraintestin
pathogen
particular
e
coli
molecular
analysi
pathogen
yersinia
improv
understand
bacteri
mechan
invas
persist
also
provid
us
new
tool
laboratori
diagnosi
prevent
sever
pf
turn
use
antigen
differenti
virul
avirul
enterocolitica
ii
detect
classspecif
serum
antibodi
respons
serolog
diagnosi
iii
vaccin
moreov
yersinia
suitabl
deliveri
antigen
antigen
present
cell
thu
open
new
strategi
design
oral
live
vaccin
carrier
strain
heesemann
j
sing
k
yersinia
stratagem
target
innat
adapt
immun
defenc
curr
opin
microbiol
diarrhoeacaus
escherichia
coli
pathotyp
gene
target
identif
past
decad
variou
group
escherichia
coli
associ
diarrhoeal
diseas
man
recogn
current
frequent
identifi
pathotyp
enteropathogen
epec
enterotoxigen
etec
enteroinvas
eiec
enterohaemorrhag
ehec
enteroaggreg
eaec
diffus
adher
daec
e
coli
strain
individu
class
defin
basi
less
characteris
interact
bacteri
cell
host
induc
diarrhoea
sever
problem
associ
recognit
strain
laboratori
easili
detect
phenotyp
marker
suffici
specif
sensit
distinguish
strain
nonpathogen
counterpart
known
although
certain
virul
factor
toxin
adhesin
invasin
alway
often
present
particular
group
detect
express
frequent
goe
beyond
capabl
diagnost
laboratori
use
molecular
method
specif
gene
factor
often
multiplex
pcr
system
current
straightforward
diagnost
approach
detect
gene
eg
shiga
toxin
stx
intimin
eae
serv
screen
purpos
identif
may
prove
actual
virul
isol
virul
factor
share
member
differ
pathotyp
present
isol
recov
healthi
individu
nonpathogen
strain
class
still
clear
particular
combin
gene
necessari
caus
diseas
eg
eaec
other
exist
subgroup
variou
pathogen
potenti
alreadi
known
exist
eg
epec
shiga
toxin
produc
strain
current
lack
straightforward
diagnost
algorithm
limit
knowledg
epidemiolog
diarrhoeacaus
e
coli
furthermor
data
incid
pathotyp
help
understand
role
individu
host
suscept
outcom
encount
strain
sinc
discoveri
antimicrobi
extens
use
livestock
poultri
signific
benefici
effect
food
anim
health
product
effici
class
antimicrobi
use
anim
includ
fluoroquinolon
human
analogu
fluoroquinolon
fq
use
anim
product
primarili
therapi
prophylaxi
infect
control
metaphylaxi
growth
promot
healthi
anim
contrast
human
medicin
treatment
customarili
direct
patient
entir
group
anim
may
treat
use
medic
feed
andor
water
moreov
growthpromot
dosag
usual
low
concentr
extend
time
period
therefor
practic
potenti
signific
drive
forc
acceler
emerg
resist
bacteria
anim
transfer
contact
food
infect
human
acquisit
quinolon
resist
gramneg
bacteria
mainli
due
chromosom
mutat
either
topoisomeras
gene
mainli
gyra
parc
gene
associ
decreas
uptak
increas
efflux
quinolon
addit
plasmid
confer
low
level
quinolon
resist
link
presenc
qnr
gene
encod
protein
protect
dna
gyras
topoisomeras
iv
quinolon
report
mention
mechan
describ
escherichia
coli
salmonella
spp
gener
increas
level
fq
resist
stepwis
model
first
mutat
found
either
gyra
gene
gene
involv
efflux
pump
produc
overexpress
acrab
howev
campylobact
spp
easili
acquir
high
level
fq
resist
associ
mutat
gyra
gene
like
microorgan
topoisomeras
iv
sever
studi
demonstr
associ
fq
use
anim
subsequ
isol
fqresist
bacteria
anim
antimicrobialresist
enter
pathogen
reach
human
direct
anim
contact
commonli
ingest
contamin
water
food
three
scenario
may
propos
use
fq
food
anim
could
affect
treatment
diseas
human
fqresist
bacteri
pathogen
select
food
contamin
slaughter
andor
prepar
consumpt
food
pathogen
caus
infect
requir
antibiot
treatment
therapi
compromis
fqresist
bacteria
nonpathogen
human
select
anim
contamin
food
ingest
bacteria
transfer
fqresist
determin
plasmid
carri
qnr
gene
bacteria
human
gut
commens
potenti
pathogen
fq
remain
residu
food
product
allow
select
antibioticresist
bacteria
food
consum
conclus
ongo
surveil
antimicrobi
suscept
profil
foodborn
pathogen
need
identifi
emerg
antimicrobialresist
phenotyp
within
food
product
continuum
moreov
barrier
stop
dissemin
fq
antimicrobialresist
bacteria
anim
human
improv
object
suggest
tuberculosi
tb
elderli
often
atyp
difficult
diagnos
lack
inform
tb
peopl
year
age
aim
studi
examin
current
clinic
manifest
time
diagnosi
outcom
old
year
old
year
patient
tb
diagnosi
tb
infect
base
anamnesi
tb
risk
two
step
tuberculin
skin
test
tst
chest
xray
patient
follow
throughout
period
chemoprophylaxi
adher
monitor
determin
isoniazid
metabolit
urin
urin
colour
appropri
posit
tst
defin
indur
mm
result
patient
women
mean
age
year
evalu
baselin
ill
rheumatoid
arthriti
cutan
psoriasi
psoriat
arthriti
ankylos
spondyl
crohn
diseas
thirtyeight
patient
immunosuppress
treatment
thirtyon
patient
bcgvaccin
treat
tb
prior
posit
tst
patient
underw
tst
result
posit
first
second
test
respect
result
neg
chemoprophylaxi
given
patient
isoniazid
month
rifampin
month
three
patient
experienc
increas
transaminas
level
uln
patientyear
follow
one
patient
final
receiv
antitnf
treatment
develop
tb
ci
twostep
tst
result
neg
began
adalimumab
five
month
later
tb
develop
conclus
systemat
protocolis
assess
tb
infect
treatment
indic
reliabl
use
method
prevent
antitnfassoci
tb
data
show
twostep
tst
help
detect
tb
infect
signific
number
patient
prolong
treatment
isoniazid
seem
safe
antitnf
treat
patient
object
interferongamma
releas
assay
igra
quantiferon
tb
gold
intub
qftgit
cellesti
ltd
carnegi
australia
increasingli
use
diagnosi
tuberculosi
tb
test
exploit
immunolog
mechan
normal
contain
mycobacterium
tuberculosi
mtb
infect
human
host
fail
contain
result
clinic
tb
associ
prolifer
mtb
thu
wonder
situat
indetermin
neg
qftgit
result
associ
posit
microscopi
thu
serv
surrog
bacteri
burden
method
novemb
octob
consecut
patient
cultureconfirm
tb
prospect
enrol
patient
receiv
less
day
antitubercul
therapi
n
recruit
within
two
month
sinc
begin
treatment
n
sever
immunosuppress
condit
present
qftgit
perform
accord
manufactur
instruct
laboratori
investig
includ
fluoresc
microscopi
acidfast
bacilli
cultur
liquid
solid
media
univari
multivari
analysi
done
statview
version
sa
institut
inc
cari
nc
result
overal
patient
pulmonari
extrapulmonari
combin
pulmonari
extrapulmonari
tb
respect
one
patient
microscopi
result
avail
mtb
detect
blood
cultur
microscopi
posit
patient
ci
respiratori
extrapulmonari
specimen
smearposit
tb
patient
respect
overal
qftgit
posit
ci
tb
patient
indetermin
neg
qftgit
result
occur
tb
patient
respect
age
gender
influenc
qftgit
test
result
howev
likelihood
neg
indetermin
qftgit
test
result
significantli
independ
associ
posit
microscopi
odd
ratio
ci
p
immunesuppress
ci
p
conclus
knowledg
first
studi
demonstr
signific
associ
smearposit
tb
neg
indetermin
qftgit
result
associ
independ
stronger
effect
concomit
immunesuppress
find
implic
use
qftgit
clinic
practic
object
durat
exposur
tuberculosi
tb
major
risk
factor
transmiss
diseas
current
guidelin
base
transmiss
tb
aeroplan
flight
recommend
hour
period
cut
screen
howev
routin
use
ifng
assay
compar
mantoux
skin
test
quantiferontb
gold
qfn
hospit
associ
outbreak
stratifi
patient
durat
contact
method
hospit
contact
index
case
screen
sequenti
manner
close
contact
share
room
hour
contact
ward
hour
contact
ward
hour
object
nationwid
surveil
transmiss
resist
mycobacterium
tuberculosi
netherland
function
sinc
presum
due
lower
transmiss
wellorganis
tuberculosi
control
transmiss
multidrug
resist
tuberculosi
mdrtb
far
limit
singl
secondari
case
howev
mdr
strain
unusu
low
level
rifampicin
resist
mic
mgl
transmit
singl
sourc
nine
person
three
develop
activ
diseas
far
current
studi
assess
molecular
basi
inh
rifampicin
resist
outbreak
strain
implic
transmiss
therapi
method
katg
rpob
gene
mdr
strain
sequenc
minimum
inhibit
concentr
mic
inh
rifampicin
determin
dna
fingerprint
tuberculosi
isol
convent
contact
trace
perform
investig
spread
mdr
strain
result
respect
outbreak
strain
mutat
katg
gene
inh
resist
strain
mutat
previous
found
maintain
higher
transmiss
inh
resist
strain
mutat
found
rpob
gene
phenotyp
outbreak
isol
interpret
resist
part
isol
read
suscept
confus
therapi
guidanc
surveil
mdrtb
conclus
rel
high
rate
transmiss
variant
may
relat
evolutionari
develop
tuberculosi
maintain
transmiss
despit
adapt
withstand
therapi
import
antimycobacteri
drug
inh
rifampicin
studi
need
investig
contribut
mdr
strain
transmiss
mdrtb
consequ
unusu
low
level
rifampicin
resist
therapi
guidanc
surveil
determin
consid
introduc
term
intermedi
suscept
indic
level
rifampicin
resist
object
real
time
tb
assay
rttb
new
multiplex
real
time
pcr
assay
allow
rapid
detect
differenti
tuberculosi
complex
mycobacteria
assay
target
element
specif
region
differenti
tuberculosi
posit
posit
mycobacteri
speci
includ
tuberculosi
complex
posit
neg
recent
evalu
first
version
rttb
kit
demonstr
assay
sensit
particularli
smear
negativecultur
posit
clinic
sampl
report
evalu
new
version
rttb
assay
label
probe
modifi
order
improv
stabil
detect
level
new
rttb
biorad
kit
includ
probe
instead
previou
version
increas
sensit
detect
amplicon
fiftytwo
clinic
sampl
collect
routin
sputa
bronchoalveolar
gastric
lavag
includ
dna
prepar
rt
pcr
reaction
carri
accord
manufactur
instruct
new
specif
softwar
develop
manufactur
use
autom
analysi
rttb
amplif
result
result
present
studi
sampl
found
contain
inhibitor
indic
neg
amplif
signal
correspond
intern
control
smear
posit
sampl
includ
studi
found
interestingli
show
acid
fast
bacilli
per
field
microscop
examin
good
sensit
test
confirm
smear
neg
sampl
found
rttb
assay
two
sampl
confirm
posit
tuberculosi
roch
amplicor
assay
final
remain
smearneg
sampl
found
neg
suggest
increas
sensit
new
probe
impair
specif
test
result
obtain
first
evalu
new
version
rttb
kit
suggest
assay
sensit
specif
may
promis
detect
tuberculosi
clinic
sampl
contain
bacilli
experi
progress
confirm
preliminari
data
object
dotblot
hybridis
assay
detect
mutat
occur
tuberculosi
rpob
hotspot
region
develop
assay
use
five
probe
capabl
bind
differ
target
segment
within
rpob
hotspot
region
wildtyp
tuberculosi
genom
present
studi
preliminari
investig
assess
suitabl
assay
detect
resist
mutat
rpob
clinic
isol
tuberculosi
delhi
india
method
suscept
test
isol
tuberculosi
carri
proport
method
confirm
bactec
system
dotblot
assay
perform
isol
two
probe
hybridis
wildtyp
sequenc
tuberculosi
codon
probe
probe
e
absenc
hybridis
probe
assay
mutat
present
indic
rifampicin
resist
surrog
marker
multidrugresist
tuberculosi
result
suscept
test
isol
reveal
isoniazid
resist
rifampicin
resist
streptomycin
resist
ethambutol
resist
strain
fortyf
strain
multidrug
resist
analysi
data
show
rifampicinresist
strain
ethambutolresist
strain
co
resist
one
antitubercul
drug
also
interest
note
rifampicinresist
strain
multidrug
resist
correspond
figur
ethambutolresist
strain
dotblot
hybridis
assay
probe
e
carri
isol
tuberculosi
resist
rifampicin
rifampicinresist
isol
test
hybridis
probe
e
indic
mutat
site
result
strain
confirm
sequenc
mutat
detect
strain
codon
one
codon
remain
rifampicinresist
strain
hybridis
probe
e
may
mutat
site
complimentari
probe
e
hybridis
probe
indic
mutat
site
complimentari
probe
codon
rifampicinsuscept
isol
hybridis
probe
e
indic
wildtyp
sequenc
dotblot
assay
found
sensit
specif
assay
methicillinsuscept
aureu
mssa
respect
malditof
correct
identif
rate
comparison
identifi
phenotyp
method
agreement
rate
determin
api
staph
con
isol
identifi
speci
level
malditof
seven
pvlposit
mrsa
isol
correctli
recogn
malditof
accord
result
determin
realtim
pcr
whole
process
sampl
prepar
result
analysi
complet
hour
greatli
shorten
time
usual
need
current
phenotyp
identif
conclus
malditof
mass
spectrometri
provid
rapid
relev
system
clinic
identif
staphylococci
detect
pvl
protein
directli
clinic
isol
provid
bacteri
identif
system
desir
clinic
diagnost
servic
object
bacteroid
fragili
gramneg
anaerob
isol
often
human
infect
b
fragili
strain
produc
kda
enterotoxin
bft
enterotoxigen
b
fragili
etbf
isol
variou
diarrhoeic
anim
speci
epidemiolog
studi
worldwid
note
signific
correl
etbf
human
diarrhoeal
diseas
especi
children
preval
etbf
gastrointestin
diseas
uk
howev
investig
partli
due
lack
simpl
identif
test
use
diagnost
laboratori
aim
studi
develop
sensit
specif
multiplex
pcr
assay
detect
etbf
directli
faec
investig
etbf
associ
case
communityacquir
diarrhoea
uk
method
primer
design
publish
enterotoxin
sequenc
amplifi
bp
bft
multiplex
primer
amplifi
bp
nanh
control
presenc
b
fragili
assay
valid
strain
speci
dna
extract
stool
use
qiaamp
dna
stool
mini
kit
qiagen
spike
experi
use
determin
sensit
assay
stool
obtain
case
communityacquir
diarrhoea
select
basi
bacteri
pathogen
identifi
bft
detect
dna
extract
second
novel
multiplex
pcr
assay
use
determin
bft
isoform
present
result
pcr
assay
etbf
found
specif
detect
limit
cfug
stool
diarrhoea
sampl
gave
posit
result
bft
nanh
predomin
isoform
etbf
sampl
n
three
sampl
diarrhoeal
sampl
old
male
yield
pcr
amplim
suggest
carriag
least
differ
etbf
strain
conclus
multiplex
pcr
assay
highli
specif
etbf
allow
detect
without
need
cultur
first
report
etbf
communityacquir
diarrhoea
uk
distribut
isoform
clinic
sampl
similar
earlier
report
europ
occurr
differ
bft
isoform
faecal
sampl
describ
find
etbf
high
proport
sampl
bacteri
explan
diarrhoea
merit
investig
pathogen
